<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004930.pub3" GROUP_ID="COLOCA" ID="997603122912152438" MERGED_FROM="" MODIFIED="2009-08-10 13:15:22 +0200" MODIFIED_BY="Susse Wegeberg" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;&lt;p&gt;Old title: Procinetic pharmacologic treatment for postoperative adynamic ileus after abdominal surgery in adults&lt;/p&gt;" NOTES_MODIFIED="2009-08-10 13:02:48 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="079" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-08-10 13:15:22 +0200" MODIFIED_BY="Susse Wegeberg">
<TITLE>Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults</TITLE>
<CONTACT MODIFIED="2009-08-10 13:15:22 +0200" MODIFIED_BY="Susse Wegeberg"><PERSON ID="18210" ROLE="AUTHOR"><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>T.</MIDDLE_INITIALS><LAST_NAME>Koller</LAST_NAME><POSITION>MD MSc Research associate</POSITION><EMAIL_1>MKoller@uhbs.ch</EMAIL_1><ADDRESS><DEPARTMENT>Institute for Clinical Epidemiology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><ADDRESS_1>Hebelstrasse 10, 3rd floor</ADDRESS_1><CITY>Basel</CITY><ZIP>CH 4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-10 13:15:22 +0200" MODIFIED_BY="Susse Wegeberg"><PERSON ID="900DCFB482E26AA201AA8B4252BAC28C" ROLE="AUTHOR"><FIRST_NAME>Ulrike</FIRST_NAME><LAST_NAME>Traut</LAST_NAME><POSITION>Assistenzärztin-Doktorandin</POSITION><EMAIL_1>ulrike.traut@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Clinical Epidemiology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><ADDRESS_1>Hebelstrasse 10</ADDRESS_1><CITY>Basel</CITY><ZIP>4031</ZIP><REGION>BS</REGION><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+49-176-22641248</PHONE_1></ADDRESS></PERSON><PERSON ID="900DCDFE82E26AA201AA8B42B98B76C3" ROLE="AUTHOR"><FIRST_NAME>Lukas</FIRST_NAME><LAST_NAME>Brügger</LAST_NAME><POSITION>MD, Oberarzt</POSITION><EMAIL_1>lukas.bruegger@insel.ch</EMAIL_1><ADDRESS><DEPARTMENT>Department of Visceral and Transplantation Surgery</DEPARTMENT><ORGANISATION>Inselspital, University of Bern</ORGANISATION><ADDRESS_1>Ludw. Pav. 5, Inselspital</ADDRESS_1><CITY>Bern</CITY><ZIP>3010</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>0041 31 632 97 32</PHONE_1></ADDRESS></PERSON><PERSON ID="5889" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>Kunz</LAST_NAME><EMAIL_1>RKunz@uhbs.ch</EMAIL_1><ADDRESS><ORGANISATION>Basler Institute for Clinical Epidemiology</ORGANISATION><ADDRESS_1>Gemeinsamer Bundesausschuss</ADDRESS_1><ADDRESS_2>Auf dem Seidenberg 3A</ADDRESS_2><CITY>Siegburg</CITY><ZIP>53707</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 02 241 938 848</PHONE_1><FAX_1>+49 02 241 938 835</FAX_1></ADDRESS></PERSON><PERSON ID="398BFBB582E26AA201071537E880EBF1" ROLE="AUTHOR"><PREFIX>PD</PREFIX><FIRST_NAME>Christiane</FIRST_NAME><LAST_NAME>Pauli-Magnus</LAST_NAME><POSITION>Head</POSITION><ADDRESS><DEPARTMENT>Clinical Trail Unit</DEPARTMENT><ORGANISATION>University Hospital Basel, Switzerland</ORGANISATION><ADDRESS_1>Hebelstrasse 2</ADDRESS_1><CITY>Basel</CITY><ZIP>4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 61 265 3106</PHONE_1><FAX_1>+41 61 265 3109</FAX_1></ADDRESS></PERSON><PERSON ID="398BFE4682E26AA2010715374095E0B8" ROLE="AUTHOR"><FIRST_NAME>Klaus</FIRST_NAME><LAST_NAME>Haug</LAST_NAME><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>Kantonsspital Luzern</ORGANISATION><CITY>Zürich</CITY><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></PERSON><PERSON ID="18834" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Heiner</FIRST_NAME><LAST_NAME>Bucher</LAST_NAME><SUFFIX>MD MPH</SUFFIX><EMAIL_1>hbucher@uhbs.ch</EMAIL_1><ADDRESS><DEPARTMENT>Basel Institute for Clinical Epidemiology</DEPARTMENT><ORGANISATION>University Hospital Basel (USB)</ORGANISATION><ADDRESS_1>Petersgraben 4</ADDRESS_1><CITY>Basel</CITY><ZIP>CH-4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 61 265 2525</PHONE_1><FAX_1>+41 61 265 4300</FAX_1></ADDRESS></PERSON><PERSON ID="18210" ROLE="AUTHOR"><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>T.</MIDDLE_INITIALS><LAST_NAME>Koller</LAST_NAME><POSITION>MD MSc Research associate</POSITION><EMAIL_1>MKoller@uhbs.ch</EMAIL_1><ADDRESS><DEPARTMENT>Institute for Clinical Epidemiology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><ADDRESS_1>Hebelstrasse 10, 3rd floor</ADDRESS_1><CITY>Basel</CITY><ZIP>CH 4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-05 15:23:15 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Minor update: 12/11/07&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 15:23:15 +0200" NOTES_MODIFIED_BY="Henning Keinke Andersen">
<UP_TO_DATE>
<DATE DAY="23" MONTH="9" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="9" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="10" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2009-08-10 13:02:48 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-08-10 13:02:48 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Comments</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Most prokinetic drugs routinely used to support bowel recovery after major abdominal surgery are not supported by current research evidence</TITLE>
<SUMMARY_BODY>
<P>Postoperative ileus (POI) refers to the delayed recovery of bowel function following abdominal surgery. POI may cause major patient discomfort and delayed recovery. Several drugs are commonly used to treat POI but it is unclear which drugs are supported by patient-oriented research. <BR/>Many of the 39 studies assessed in this review enrolled only a small number of patients and date back to before 1990. The novel drug alvimopan shortened bowel recovery, but many studies failed to report methodology according to current guidelines. Erythromycin, cholecystokinin, cisapride, dopamine-antagonists, propranolol or vasopressin are not supported due to lack of evidence or absence of effect. Intravenous lidocaine and neostigmine might show to be beneficial, but more evidence is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Postoperative adynamic bowel atony interferes with recovery following abdominal surgery. Prokinetic pharmacologic drugs are widely used to accelerate postoperative recovery. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the benefits and harms of systemic acting prokinetic drugs to treat postoperative adynamic ileus in patients undergoing abdominal surgery. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Trials were identified by computerised searches of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and the Cochrane Colorectal Cancer Group specialised register. The reference lists of included trials and review articles were tracked and authors contacted. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled parallel-group trials (RCT) comparing the effect of systemically acting prokinetic drugs against placebo or no intervention.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Four reviewers independently extracted the data and assessed trial quality. Trial authors were contacted for additional information if needed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty-nine RCTs met the inclusion criteria contributing a total of 4615 participants. Most trials enrolled a small number of patients and showed moderate to poor (reporting of) methodological quality, in particular regarding allocation concealment and intention-to-treat analysis. Fifteen systemic acting prokinetic drugs were investigated and ten comparisons could be summarized. Six RCTs support the effect of Alvimopan, a novel peripheral mu receptor antagonist. However, the trials do not meet reporting guidelines and the drug is still in an investigational stage. Erythromycin showed homogenous and consistent absence of effect across all included trials and outcomes. The evidence is insufficient to recommend the use of cholecystokinin-like drugs, cisapride, dopamine-antagonists, propranolol or vasopressin. Effects are either inconsistent across outcomes, or trials are too small and often of poor methodological quality. Cisapride has been withdrawn from the market due to adverse cardiac events in many countries. Intravenous lidocaine and neostigmine might show a potential effect, but more evidence on clinically relevant outcomes is needed. Heterogeneity among included trials was seen in 10 comparisons. No major adverse drug effects were evident.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Alvimopan may prove to be beneficial but proper judgement needs adherence to reporting standards. Further trials are needed on intravenous lidocaine and neostigmine. The remaining drugs can not be recommended due to lack of evidence or absence of effect. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Delayed return of normal gastrointestinal function due to 'postoperative ileus' (POI) following major abdominal surgery is the main cause for prolonged convalescence leading to extended hospital stay and additional health care costs. In 2002 for instance, total hospital costs attributable to POI has been estimated to be as large as 1.46 billion dollars in the United States in 2002 (<LINK REF="REF-Goldstein-2007" TYPE="REFERENCE">Goldstein 2007</LINK>).<BR/>The term 'postoperative ileus' refers to the atony of the bowel which frequently follows abdominal surgery. Delayed recovery of normal peristalsis causes variable clinical symptoms ranging from minor complaints to significant discomfort with painful abdominal distension, cramps, nausea and vomiting. Furthermore, delay in oral food intake affects the immune defence with an increased risk of localised or generalised infections (<LINK REF="REF-Moore-1992" TYPE="REFERENCE">Moore 1992</LINK>, <LINK REF="REF-Moore-1989" TYPE="REFERENCE">Moore 1989</LINK>).<BR/>The pathogenesis of postoperative ileus is multifactorial and not yet completely understood. Activation of the sympathetic nervous system by manipulation of the gut seems to play a major role (<LINK REF="REF-Dubois-1974" TYPE="REFERENCE">Dubois 1974</LINK>, <LINK REF="REF-Resnick-1997_x0028_1_x0029_" TYPE="REFERENCE">Resnick 1997(1)</LINK>, <LINK REF="REF-Resnick-1997_x0028_2_x0029_" TYPE="REFERENCE">Resnick 1997(2)</LINK>). Release of inflammatory mediators as well as the immigration of leucocytes into the intestinal wall has been shown to correlate with the intestinal trauma and paralysis of intestinal smooth muscles tissue (<LINK REF="REF-Kalff-1998" TYPE="REFERENCE">Kalff 1998</LINK>, <LINK REF="REF-Kalff-1999" TYPE="REFERENCE">Kalff 1999</LINK>). Stimulation of opioid receptors by exogenous and endogenous opioids significantly accounts for a delay in postoperative recovery of colonic motility (<LINK REF="REF-Frantzides-1992" TYPE="REFERENCE">Frantzides 1992</LINK>) and prolonged postoperative ileus ( <LINK REF="REF-Cali-2000" TYPE="REFERENCE">Cali 2000</LINK>). Moreover, perioperative fluid excess can impair bowel motility due to oedema of the intestinal wall (<LINK REF="REF-Lobo-2002" TYPE="REFERENCE">Lobo 2002</LINK>).<BR/>Impaired bowel motility is most extensive after major abdominal procedures such as colonic segmental resections ( <LINK REF="REF-Kehlet-2001" TYPE="REFERENCE">Kehlet 2001</LINK>). Other procedures without bowel resection like cystectomy (<LINK REF="REF-Chang-2002" TYPE="REFERENCE">Chang 2002</LINK>), nephrectomy (<LINK REF="REF-Kerbl-1994" TYPE="REFERENCE">Kerbl 1994</LINK>), transabdominal hysterectomy (<LINK REF="REF-Wattwil-1989" TYPE="REFERENCE">Wattwil 1989</LINK>) or abdominal aortic aneurysm surgery (<LINK REF="REF-Buckley-2000" TYPE="REFERENCE">Buckley 2000</LINK>) may also cause postoperative ileus of on average more than three days. Despite the widespread use of epidural anaesthetics and laparoscopic procedures, POI is still a problem in daily postoperative care (<LINK REF="REF-Mann-2000" TYPE="REFERENCE">Mann 2000</LINK>). Therefore, prokinetic drugs are widely administered in surgical wards and Intensive Care Units (ICU's). <BR/>Comprehensive systematic reviews in the field of POI exist for epidural local anaesthetics (<LINK REF="REF-Jorgensen-2000" TYPE="REFERENCE">Jorgensen 2000</LINK>), homeopathy (<LINK REF="REF-Barnes-1997" TYPE="REFERENCE">Barnes 1997</LINK>) or selective opioid receptor antagonists (<LINK REF="REF-Tan-2007" TYPE="REFERENCE">Tan 2007</LINK>) but not for the widely used and systemically applied prokinetic drugs.<BR/>The aim of this systematic review was therefore to assess the efficacy of systemic prokinetic pharmacologic treatment to shorten the duration of POI and to assess the effectiveness to reduce length of hospital stay in patients undergoing major abdominal surgery.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the benefits and harms of different systemically acting prokinetic drugs in the treatment of POI, in patients undergoing abdominal surgery with or without peri - or postoperative epidural anaesthesia or analgesia.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included all randomised and quasi randomised controlled parallel-group trials, published or unpublished, which compared any systemically acting prokinetic drug to placebo or no intervention. Trials with multiple comparison arms were included if subjects were randomly allocated to each treatment arm separately and if the distinction between each treatment arm and the control arm was unambiguous. Unpublished trials were considered when we were able to obtain full-text manuscripts from the author(s). We considered subjective outcomes as time to first flatus only if a trial was carried out in a double blind manner (i.e. patients and outcome assessors were blinded to treatment allocation). </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Adult patients undergoing open or laparoscopic abdominal surgery with or without peri- and postoperative epidural analgesia.</P>
<P>Exclusion criteria:<BR/>
</P>
<UL>
<LI> Trials with patients on postoperative obstructive or mechanical ileus </LI>
<LI> Trials with patients on caesarean section or sole inguinal hernia repair.</LI>
<LI> Trials with paediatric patients (i.e. age less than 16 years).</LI>
<LI> Trials with patients undergoing total or subtotal colectomy or enterostomy *.</LI>
<LI> Trials with an observation period of 24 hours or less.</LI>
</UL>
<P>* Assessment of time to passage of first stool is not reliable and POI affects the large bowel in the first place (<LINK REF="REF-Clin.-Consensus-2006" TYPE="REFERENCE">Clin. Consensus 2006</LINK>)</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We considered systemically acting prokinetic drugs of any type, duration or dose compared to placebo or no intervention. Combinations of prokinetic drugs against placebo or no intervention were considered as well. Trials where treatment of POI was indirect via a reduction of the consumption opioid-based analgesics were not considered for this review. Furthermore, we did not consider drugs with a local mechanism of action (e.g. enemas or local anaesthetic treatment); interventions which primarily alter the perioperative anabolic or catabolic state of the patient (e.g. carbohydrate supplementation or early enteral nutrition); herbal medicine treatments or gum chewing.<BR/>The most recent development concerns the drug alvimopan, a peripheral opioid mu-receptor antagonist. Due to its greater affinity for the mu- than the kappa- or sigma-opioid receptors, alvimopan acts as an antagonist of the inhibitory effects of endogenous and exogenous opioids. Cerulein/ceruletide and cholecystokinin were resumed under 'cholecystokinin-like acting drugs' because of their related pharmacodynamic action. Cholecystokinin (CCK) seems to be important in the regulation of gastrointestinal motility (<LINK REF="REF-Herbert-2002" TYPE="REFERENCE">Herbert 2002</LINK>). The synthetic decapeptid ceruletide from cerulein is suggested to act similar to CCK. Cisapride is a 5 HT4- agonist that facilitates acetylcholine release from the intrinsic plexus and therefore increases gut motility (<LINK REF="REF-Tonini-1999" TYPE="REFERENCE">Tonini 1999</LINK>). Dihydroergotamine is a alpha-adrenergic blocking agent that increases postoperative bowel motility (<LINK REF="STD-Thorup-1983" TYPE="STUDY">Thorup 1983</LINK>). Metoclopramide and bromopride both act as cholinergic agonists and dopamine-antagonists (<LINK REF="REF-Luckey-2003" TYPE="REFERENCE">Luckey 2003</LINK>). The macrolide antibiotic erythromycin has been suggested to act as a motilin agonist and directly stimulates enteral smooth muscle by inducing the migrating motor complex (MMC) (<LINK REF="REF-Weber-1993" TYPE="REFERENCE">Weber 1993</LINK>, <LINK REF="REF-Peeters-1993" TYPE="REFERENCE">Peeters 1993</LINK>). The exact mechanism of lidocaine as prokinetic drug is still unknown. Lidocaine may decrease postoperative pain or act directly by inhibition of sympathetic nerve stimulation (<LINK REF="REF-Liu-1995" TYPE="REFERENCE">Liu 1995</LINK>, <LINK REF="REF-Carpenter-1996" TYPE="REFERENCE">Carpenter 1996</LINK>, <LINK REF="REF-Groudine-1994" TYPE="REFERENCE">Groudine 1994</LINK>). Neostigmine acts as a reversible acetycholinesterase inhibitor which results in an activation of colonic motility (<LINK REF="REF-Luckey-2003" TYPE="REFERENCE">Luckey 2003</LINK>). The beta-blocking agent propranolol is suggested to act as inhibitor of sympathoadrenergic neurones in the intestinal wall. </P>
<P>The drugs were classified as follows:<BR/>
</P>
<UL>
<LI> Cholinergic agonists: bethanechol, neostigmine</LI>
<LI> Benzamides: cisapride*, metoclopramide, bromopride</LI>
<LI> Dopamine antagonists: domperidone*</LI>
<LI> Peptide hormones: cholecystokinin, ceruletide, vasopressin</LI>
<LI> Adrenergic antagonists: propranolol</LI>
<LI> Macrolide antibiotic: erythromycin</LI>
<LI> Ergotamine derivates: dihydroergotamine</LI>
<LI> Systemic application of local anaesthetics</LI>
<LI> Prostaglandins</LI>
<LI> Vitamines: pantothenic acid, dexpanthenol</LI>
<LI> Selective gastrointestinal opioid antagonists</LI>
</UL>
<P>
<BR/>* Withdrawn from the market in the United States (<LINK REF="REF-FDA-2006" TYPE="REFERENCE">FDA 2006</LINK>) and most European countries</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>We considered the following outcome measures according to decreasing order of clinical relevance.</P>
<P>1. Composite endpoint of maximum time to either tolerance of solid food or passage of first stool* (GI-2)<BR/>2. Composite endpoint of maximum time to either tolerance of solid food or the latest of time to first flatus or time to passage of first stool* (GI-3)<BR/>3. Time to passage of first stool*<BR/>4. Time to tolerance of regular diet<BR/>5. Length of hospital stay<BR/>6. Time to passage of first flatus. Trials using as outcome time to a combination of passage of first flatus or stool were treated as time to passage of first flatus.<BR/>7. Adverse drug effects</P>
<P>* if not indicated otherwise, the term bowel movement refers to the passage of stool.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We used the Cochrane Colorectal Cancer Group search strategy as outlined in detail for each searched database below. </P>
<P>The following bibliographic databases were searched to identify relevant trials:<BR/>The Cochrane Central Register of Controlled Trials (CENTRAL), from the Cochrane Library 2007 issue 2. MEDLINE from 1966 to June, 18, 2007 and EMBASE from 1980 to June, 18, 2007. The Cochrane Colorectal Cancer Group specialised register SR-COLOCA and SCISEARCH.<BR/>Searches were carried out using medical subject headings (MeSH) and free text words in combination. The highly sensitive search strategy for identifying reports of randomised controlled trials as contained in the Cochrane Reviewer's Handbook ( <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>, <LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK> ) was used. No language restriction was applied. <BR/>The reference lists of relevant trials and review articles in the field were reviewed. Additionally, authors of relevant articles and known international experts in the field of POI were contacted to obtain information on any past, ongoing, or planned future trials. Authors of abstracts were asked to provide full reports.</P>
<P>The following search strategies were used for each database:</P>
<P>EMBASE</P>
<P>#23 ((laparo*) or (digestive surgery) or (abdom* surgery) or (aortic aneurysm) or (aortic surgery) or (urologic surgical procedures) or (colorectal surgery) or (gynecologic surgical procedures) or (digestive system surgical procedures) or (obsteric surgical procedures) or (post-operative) or (postoperative) or (postoperative complications) or (postoperative care) or (postoperative period)) and ((colon*) or (gut) or (intestin*) or (bowel)) and ((paralysis) or (gastrointestinal motility) or (paresis) or (ileus) or (aton*) or (peristalsis) or (motility) or (adynam*) or (paralytic)) and ((intestines)or (alvimopan) or (purgative*) or (laxative*) or (dexpanthenol) or (ceruletide) or (procinetic) or (prokinetic) or (selective gastrointestinal opioid antagonists) or (cathartics) or (pantothenic acid) or (prostaglandins) or (anaesthetics) or (dihydroergotamine) or(erythromycin) or (adrenergic antagonists) or (postoperative complications) or (peristalsis) or (defecation) or (intestinal drug therapy) or (digestive system) or (gastrointestinal motility) or (gastrointestinal agents) or (therapeutics) or (drug evaluation) or (drug therapy) or (metoclopramide) or (cisapride) or (benzamides) or (neostigmine) or (cholinergic agents)) and (#12 not #16) and (PY:EMBV = 2006-2007) 71 <BR/> #22 ((laparo*) or (digestive surgery) or (abdom* surgery) or (aortic aneurysm) or (aortic surgery) or (urologic surgical procedures) or (colorectal surgery) or (gynecologic surgical procedures) or (digestive system surgical procedures) or (obsteric surgical procedures) or (post-operative) or (postoperative) or (postoperative complications) or (postoperative care) or (postoperative period)) and ((colon*) or (gut) or (intestin*) or (bowel)) and ((paralysis) or (gastrointestinal motility) or (paresis) or (ileus) or (aton*) or (peristalsis) or (motility) or (adynam*) or (paralytic)) and ((intestines)or (alvimopan) or (purgative*) or (laxative*) or (dexpanthenol) or (ceruletide) or (procinetic) or (prokinetic) or (selective gastrointestinal opioid antagonists) or (cathartics) or (pantothenic acid) or (prostaglandins) or (anaesthetics) or (dihydroergotamine) or(erythromycin) or (adrenergic antagonists) or (postoperative complications) or (peristalsis) or (defecation) or (intestinal drug therapy) or (digestive system) or (gastrointestinal motility) or (gastrointestinal agents) or (therapeutics) or (drug evaluation) or (drug therapy) or (metoclopramide) or (cisapride) or (benzamides) or (neostigmine) or (cholinergic agents)) and (#12 not #16) 373 <BR/> #21 (laparo*) or (digestive surgery) or (abdom* surgery) or (aortic aneurysm) or (aortic surgery) or (urologic surgical procedures) or (colorectal surgery) or (gynecologic surgical procedures) or (digestive system surgical procedures) or (obsteric surgical procedures) or (post-operative) or (postoperative) or (postoperative complications) or (postoperative care) or (postoperative period) 348023 <BR/> #20 (colon*) or (gut) or (intestin*) or (bowel) 468052 <BR/> #19 (paralysis) or (gastrointestinal motility) or (paresis) or (ileus) or (aton*) or (peristalsis) or (motility) or (adynam*) or (paralytic) 100669 <BR/> #18 (intestines)or (alvimopan) or (purgative*) or (laxative*) or (dexpanthenol) or (ceruletide) or (procinetic) or (prokinetic) or (selective gastrointestinal opioid antagonists) or (cathartics) or (pantothenic acid) or (prostaglandins) or (anaesthetics) or (dihydroergotamine) or(erythromycin) or (adrenergic antagonists) or (postoperative complications) or (peristalsis) or (defecation) or (intestinal drug therapy) or (digestive system) or (gastrointestinal motility) or (gastrointestinal agents) or (therapeutics) or (drug evaluation) or (drug therapy) or (metoclopramide) or (cisapride) or (benzamides) or (neostigmine) or (cholinergic agents) 1698255 <BR/> <BR/>Searches and results below from saved search history from EMBASE SS for RCT/CCT are listed below</P>
<P> #17 #12 not #16 1665210 <BR/> #16 #14 not #15 2675100 <BR/> #15 #13 and #14 476674 <BR/> #14 (ANIMAL or NONHUMAN) in DER 3151774 <BR/> #13 HUMAN in DER 5823446 <BR/> #12 #9 or #10 or #11 2665088 <BR/> #11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near ((BLIND* or MASK*) in TI,AB) 86449 <BR/> #10 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI,AB 471851 <BR/> #9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 2452728 <BR/> #8 "SINGLE-BLIND-PROCEDURE"/ all subheadings 6660 <BR/> #7 "DOUBLE-BLIND-PROCEDURE"/ all subheadings 64218 <BR/> #6 "PHASE-4-CLINICAL-TRIAL"/ all subheadings 596 <BR/> #5 "PHASE-3-CLINICAL-TRIAL"/ all subheadings 7423 <BR/> #4 "MULTICENTER-STUDY"/ all subheadings 38817 <BR/> #3 "CONTROLLED-STUDY"/ all subheadings 2422081 <BR/> #2 "RANDOMIZATION"/ all subheadings 22563 <BR/> #1 "RANDOMIZED-CONTROLLED-TRIAL"/ all subheadings 119188 </P>
<P>MEDLINE<BR/>Searches and results from saved search history from Medline for RCT/CCT are listed below</P>
<P>#42 #36 and #37 and #38 and #39 and #40 and (PY:MEDS = 2006-2007) 58 <BR/> Searches and results below from saved search history MKO 079 Medline 11.08.06 <BR/> #41 #36 and #37 and #38 and #39 and #40 738 <BR/> #40 (laparo*) or (digestive surgery) or (abdom* surgery) or (aortic aneurysm/surgery ) or (urologic surgical procedures) or (colorectal surgery) or (gynecologic surgical procedures) or (digestive system surgical procedures) or (obsteric surgical procedures) or (post-operative) or (postoperative) or (postoperative complications) or (postoperative care) or (postoperative period) 499842 <BR/> #39 (colon*) or (gut) or (intestin*) or (bowel) 579621 <BR/> #38 (paralysis) or (gastrointestinal motility) or (paresis) or (ileus) or (aton*) or (peristalsis)or (motility) or (adynam*) or (paralytic) 121965 <BR/> #37 (intestines) or (alvimopan) or (purgative*) or (laxative*) or (dexpanthenol) or (ceruletide) or (procinetic) or (prokinetic) or (selective gastrointestinal opioid antagonists) or (cathartics) or (pantothenic acid) or (prostaglandins) or (anaesthetics) or (dihydroergotamine) or (erythromycin) or (adrenergic antagonists) or (cholecystokinin) or (vasopressins) or (caerulein) or (dopamine antagonists) or (postoperative complications) or (peristalsis) or (defecation) or (intestinal drug therapy) or (digestive system) or (gastrointestinal motility) or (gastrointestinal agents) or (therapeutics) or (drug evaluation) or (drug therapy) or (metoclopramide) or (cisapride) or (benzamides) or (neostigmine) or (cholinergic agents) 1746855 <BR/> #36 #9 or #25 or #35 2255636 <BR/> #35 #34 not (#9 or #25) 1495005 <BR/> #34 #32 not #33 1963230 <BR/> #33 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS)) 3981295 <BR/> #32 #26 or #27 or #28 or #29 or #31 2636042 <BR/> #31 (#30 in TI) or (#30 in AB) 1808238 <BR/> #30 control* or prospectiv* or volunteer* 2549375 <BR/> #29 PROSPECTIVE-STUDIES 219643 <BR/> #28 FOLLOW-UP-STUDIES 336173 <BR/> #27 explode EVALUATION-STUDIES/ all subheadings 655695 <BR/> #26 TG=COMPARATIVE-STUDY 0 <BR/> #25 #24 not #9 404115 <BR/> #24 #22 not #23 743777 <BR/> #23 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS)) 3981295 <BR/> #22 #10 or #11 or #12 or #13 or #15 or #16 or #17 or #18 or #19 or #20 or #21 844148 <BR/> #21 RESEARCH-DESIGN 39763 <BR/> #20 random* in AB 371259 <BR/> #19 random* in TI 55674 <BR/> #18 placebo* in AB 100158 <BR/> #17 placebo* in TI 15711 <BR/> #16 PLACEBOS 26294 <BR/> #15 (#14 in TI) or (#14 in AB) 90239 <BR/> #14 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*) 123962 <BR/> #13 (clin* near trial*) in AB 107191 <BR/> #12 (clin* near trial*) in TI 27408 <BR/> #11 explode CLINICAL-TRIALS/ all subheadings 187759 <BR/> #10 CLINICAL-TRIAL in PT 431820 <BR/> #9 #7 not #8 356516 <BR/> #8 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS)) 3981295 <BR/> #7 #1 or #2 or #3 or #4 or #5 or #6 389405 <BR/> #6 SINGLE-BLIND-METHOD 10819 <BR/> #5 DOUBLE-BLIND-METHOD 90364 <BR/> #4 RANDOM-ALLOCATION 57287 <BR/> #3 RANDOMIZED-CONTROLLED-TRIALS 41633 <BR/> #2 CONTROLLED-CLINICAL-TRIAL in PT 74414 <BR/> #1 RANDOMIZED-CONTROLLED-TRIAL in PT 232881 </P>
<P>The Cochrane Central Register of Controlled Trials (CENTRAL):</P>
<P>Searches and results from saved search history from the Cochrane Central of Clinical Trials database for RCT/CCT are listed below</P>
<P>#1 (intestines) or (alvimopan) or (purgative*) or (laxative*) or (dexpanthenol) or (ceruletide) or (procinetic) or (prokinetic) or (selective gastrointestinal opioid antagonists) or (cathartics) or (pantothenic acid) or (prostaglandins) or (anaesthetics) or (dihydroergotamine) or (erythromycin) or (adrenergic antagonists) or (cholecystokinin) or (vasopressins) or (caerulein) or (dopamine antagonists) or (postoperative complications) or (peristalsis) or (defecation) or (intestinal drug therapy) or (digestive system) or (gastrointestinal motility) or (gastrointestinal agents) or (therapeutics) or (drug evaluation) or (drug therapy) or (metoclopramide) or (cisapride) or (benzamides) or (neostigmine) or (cholinergic agents) in All Fields in all products 205562 edit delete <BR/>#2 (paralysis) or (gastrointestinal motility) or (paresis) or (ileus) or (aton*) or (peristalsis)or (motility) or (adynam*) or (paralytic) in All Fields in all products 2672 edit delete <BR/>#3 (laparo*) or (digestive surgery) or (abdom* surgery) or (aortic aneurysm/surgery) or (urologic surgical procedures) or (colorectal surgery) or (gynecologic surgical procedures) or (digestive system surgical procedures) or (obsteric surgical procedures) or (post-operative) or (postoperative) or (postoperative complications) or (postoperative care) or (postoperative period) in All Fields in all products 41563 edit delete <BR/>#4 (colon*) or (gut) or (intestin*) or (bowel) in All Fields in all products 21181 edit delete <BR/>#5 (#1 AND #2 AND #3 AND #4), </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Study selection</P>
<P>Two reviewers (UT and MKO) scanned the titles and the abstract sections of all citations retrieved by the search procedure. Full text articles were obtained of all titles and abstracts suggestive of being eligible for inclusion if one reviewer considered the citation as potentially relevant. Both reviewers independently assessed the full text reports against the inclusion criteria. Discrepancies for inclusion of trials were resolved by consensus following consultation of a third reviewer.</P>
<P>Data collection</P>
<P>Details on the number of retrieved references, the number of obtained full-text reports and the number of included and excluded articles were recorded and reported ('Characteristics of included/excluded studies' and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) The lists of included and excluded studies are provided in 'Table of included studies' and 'Table of excluded studies', respectively. All data were managed and stored in Review Manager software version 4.2; the reason for excluding trials from this review is stated in ´Table of excluded studies`.</P>
<P>Data extraction</P>
<P>Four reviewers (UT, LB, RK, MKO) independently performed appraisal of the methodological quality and extracted the data of all included trials in duplicate. Differences in the assessment of quality or data extraction between two reviewers were resolved by consensus. If necessary and possible, additional information was sought from the authors of the trials. Prespecified data extraction forms were used to record all data. </P>
<P>Quality assessment (<LINK REF="REF-NHS-CRD-2001" TYPE="REFERENCE">NHS CRD 2001</LINK>)</P>
<P>We rated the quality of included trials using the Cochrane approach to assess the quality of eligible trials. The quality items were as follows: random sequence generation, concealment of random allocation, blinding of patients and/or care givers and/or outcome assessors and intention-to-treat analysis. Description was rated as follows: A: adequate, B: unclear, C: clearly inadequate, D: not used. We described trial quality as good if all above-mentioned criteria were adequately reported. If at least two but not all criteria were reported, we assigned 'moderate' quality and if less than two were reported we used the attribute 'poor'. Beyond these criteria, we recorded whether information on the distribution of baseline characteristics was reported according to treatment allocation. </P>
<P>Statistical analysis</P>
<P>The endpoint of primary interest in the evaluation of post-operative ileus was time from treatment initiation until resolution of ileus (i.e. signs of restoration of intestinal motility according to outcome measures 1 to 4 and 6). The measurement unit to summarise and compare treatment effects was therefore time measured in hours or days. We assumed that the resolution times follow a log-normal normal distribution due to the generally short duration until resolution of POI and due to accumulation of resolution times in the early post-operative period. We further assumed that treatment effects for postoperative ileus are multiplicative for the time to resolution of ileus (i.e. subjects with short and subjects with long-lasting ileus were expected to have the same relative benefit). The accelerated failure time (AFT) model allows modelling a multiplicative treatment effect and the acceleration factor equals the ratio of the means as well as the ratio of the medians (<LINK REF="REF-Keene-2002" TYPE="REFERENCE">Keene 2002</LINK>) of the intervention group relative to the control group. Therefore we used for the summary effect the ratio of means or the ratio of medians - whatever available - of the intervention and control group, and aggregated the natural logarithm-transformed ratios across trials using the generalized inverse variance method. Similarly, if hazard ratios (HR) were used as in more recent trials of selective opioid receptor antagonists, we aggregated the natural logarithm-transformed HRs using the same method.<BR/>If the median and interquartile range was reported, we estimated the standard deviation of the log data per treatment arm with the following formula: (log(quartile3)-log(quartile1))/1.349. We calculated the standard error of the log ratio of the medians by taking the square root of the sum of each standard deviation divided by the number of subjects randomized to the treatment and the control arm, respectively. If the mean and standard deviation was reported, we estimated the standard error of the logarithm of the ratio of the means using the delta method (<LINK REF="REF-Friedrich-2005" TYPE="REFERENCE">Friedrich 2005</LINK>). If trials reported response rates at different time points, response times were extracted per subject and treatment arm and the log ratio of the medians with the corresponding standard error were estimated using an accelerated failure time model as mentioned above. If standard deviations were not reported or only the range was given, we imputed standard deviations with the method by Furukuwa et al (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).<BR/>Statistical heterogeneity of summary estimates was assessed both by calculating a test of heterogeneity (standard chi-squared test) and by using I2 statistic. I2 is an estimate of the amount of variance due to between-trial heterogeneity rather than chance (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>, <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). It is based on the traditional measure of variance, the Cochran Q statistic (<LINK REF="REF-Cochrane-1954" TYPE="REFERENCE">Cochrane 1954</LINK>). Substantial heterogeneity exists when I2 exceeds 50%. For each hypothesis, we tested the difference in estimates of treatment effect between the two groups using a Z-test (<LINK REF="REF-Deeks--2001" TYPE="REFERENCE">Deeks 2001</LINK>) and we considered a p-value of 0.05 or less to be statistically significant. All pooled effect estimates are presented with 95% confidence intervals (CI). Funnel plot analysis was not considered since none of the drug categories contained more than five trials. In the case of significant heterogeneity, we used random effect models and compare these to fixed effect models to test the robustness of the findings. Two possible reasons for heterogeneity were pre-specified: (i) Difference of responses according to difference in the quality of the trials; (ii) difference of responses according to clinical heterogeneity (e.g. bowel resection, applied drug doses). The limited number of studies per drug precluded to explore between-trial heterogeneity according to these criteria. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>'Table of included studies'</P>
<P>A total of 1189 titles and abstracts were retrieved through searching databases and reference tracking. We obtained the full text of 75 articles whereof 34 trials were ineligible. Hence the final trial sample consisted of 39 randomized trials meeting the inclusion criteria for this review (see also <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The details of included trials are reported in 'Characteristics of included studies´. The reasons for excluding trials are stated in ´Characteristics of excluded studies´.</P>
<P>Study design</P>
<P>All trials compared active treatment against placebo or no intervention in a parallel-group randomized manner. Thirty-four trials were described as double blind, one trial was declared as single blinded and five trials did not report on blinding. </P>
<P>Participants</P>
<P>A total of 4615 participants with major abdominal surgery were recruited across all trials. The surgical procedures included major abdominal surgery, major abdominal-vascular surgery, and major abdominal urological and gynaecological surgery ('Characterististics of included studies´). Reporting of inclusion and exclusion criteria was similar across trials. Patients with advanced diseases, e.g. chronic inflammatory bowel disease, cardiac impairment, renal, pulmonary or liver diseases or insulin dependent diabetes were excluded in twenty-one trials.</P>
<P>Interventions and co-interventions</P>
<P>Of the 39 included trials, six trials compared opioid receptor antagonists (alvimopan) to placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>), four trials compared cholecystokinin (CCK)-like acting drugs to placebo or no treatment (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>), seven trials compared cisapride to placebo (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1991" TYPE="STUDY">Hallerbäck 1991</LINK>,<LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK>, <LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>, <LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK>), two trials compared dihydroergotamine to no treatment (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>, Thorup 1983), four trials compared dopamine-antagonists (metoclopramide and bromopride) to placebo or no treatment (<LINK REF="STD-Cheape-1991" TYPE="STUDY">Cheape 1991</LINK>, <LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>, <LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>, <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> ), four trials compared erythromycin to placebo (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>), three trials compared systemically applied lidocaine to placebo (<LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>), two trials compared neostigmine to placebo ( <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TYPE="STUDY">Hallerbäck 1987(1)</LINK>, <LINK REF="STD-Orlando-1994" TYPE="STUDY">Orlando 1994</LINK>), two trials compared propranolol to placebo or no treatment (<LINK REF="STD-Ferraz-2001" TYPE="STUDY">Ferraz 2001</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK>) and two trials compared the combined administration of propranolol and neostigmine to placebo ( <LINK REF="STD-Garcia-1993" TYPE="STUDY">Garcia 1993</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TYPE="STUDY">Hallerbäck 1987(1)</LINK> ). Twenty-two trials initiated the test drug on the day of surgery and sixteen trials initiated the drug regimen on the first postoperative day (POD). Two trials did not specify the time point of drug treatment initiation (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>). Duration of drug treatment varied between a single dose regimen (<LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>) to permanent application until hospital discharge (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). One trial did not specify the duration of drug administration ( <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK> ). Follow-up durations ranged from 33 hours (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>) until hospital discharge or 30 days post surgery (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>). <BR/>Physicians were allowed to administer co-medication to treat POI in five trials (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>). Type of anaesthesia and analgesia used was properly reported in twenty-four trials. In twelve trials anaesthetic techniques and use of analgesia remains unclear. One trial did not allow the administration of morphine, morphine-like, anticholinesterase or sympatholytic drugs during the course of the study (<LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>). In seven trials analgesic treatment consisted of opioid-based patient controlled analgesia (PCA) (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Intra- and postoperative epidural analgesia reduces GI recovery times (<LINK REF="REF-Jorgensen-2000" TYPE="REFERENCE">Jorgensen 2000</LINK>). Six trials reported to allow for intra- or postoperative epidural analgesia with opioids (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>, <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>) and one trial with local anaesthetics (<LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>). The remaining trials use intramuscular or subcutaneous analgesic application or did not report further details.</P>
<P>Outcomes</P>
<P>In addition to the outcomes of this review, various additional outcomes were measured, e.g. electromyographic analysis with either continuous manometric recording or radio opaque marker to study transit times. (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>, <LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> , <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> ) ('Characteristics of included studies').<BR/>Wolff et al (<LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) used GI-2 and GI-3 as novel outcomes of POI recovery for the first time. GI-3 was defined as the later of either time to tolerance of solid food or time to passage of the first of flatus or stool. Because of the subjectiveness and large variability of the component flatus (<LINK REF="REF-Bungard-1999" TYPE="REFERENCE">Bungard 1999</LINK>), the GI-2 composite end point was introduced. GI-2 was defined as the later of time to either tolerance of solid food or first stool. Four trials reported GI-2 and GI-3 outcomes (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Ludwig et al. (<LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>) used solely GI-3 as outcome.<BR/>Twenty-three trials reported on time to passage of first stool, thirteen trials on time to tolerance of regular diet, twenty-four trials on time to passage of first flatus and nineteen trials on length of hospital stay. Thirty-one trials reported adverse drug reactions in different levels of detail. The majority of the included trials did not specify surgical complications and the rate of surgical re-interventions ('Characteristics of included studies'). Twenty trials reported resolution or incidence of nausea or vomiting. <BR/>Nine trials reported outcomes directly for individual patients (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>, <LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>, <LINK REF="STD-Ferraz-2001" TYPE="STUDY">Ferraz 2001</LINK>, <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK> , <LINK REF="STD-Orlando-1994" TYPE="STUDY">Orlando 1994</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>, <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK> ). In this case the AFT model was used to compute summary estimates and standard errors (see 'Methods of the review'). For five trials, the summary POI restoration times had to be read off from figures according to treatment allocation (<LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>; <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK>; <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK>). Five trials reported the mean or median restoration time according to treatment allocation but did not report dispersion parameters (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Garcia-1993" TYPE="STUDY">Garcia 1993</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>, <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>). In these cases we used the imputation method to estimate the standard errors of the log ratio of the means (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>'Characteristics of included studies'</P>
<P>Seventy-five percent of the trials were performed before the year 2000 and 68% before the year 1990. The number of patients per trial was small and ranged between 14 for the smallest (<LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>) and 666 patients for the largest trial (<LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>). Only eight trials enrolled more than 100 patients (<LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>; <LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). The reporting of methodological quality of the included trials was variable but often poor. In the majority of the trials the method of randomisation was not specified. Three trials used inadequate methods ( <LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK> and <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK> used quasi-randomisation; <LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK> used random number tables). Allocation was concealed in 7 of 40 trials (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>, <LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>, <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>). The remaining trials did not state or use concealment of random allocation. The intention-to-treat principle (ITT) was applied in only three trials (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>). Nine trials did not report the use of the ITT principle but the reported number of patients available for data analyses was in agreement with the number of initially randomized patients (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>, <LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>, <LINK REF="STD-Hakansson-1985" TYPE="STUDY">Hakansson 1985</LINK>, <LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> , <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> , <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK>). Five trials (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) reported effect estimates based on a 'modified-intention-to-treat population', which does not correspond to an intention to treat analysis. Withdrawals were excluded from the analysis in twenty-one trials and eleven trials did not report on the occurrence of withdrawals. Twelve trials described blinding procedures in detail, while five did not provide information on blinding at all (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>; <LINK REF="STD-Ferraz-2001" TYPE="STUDY">Ferraz 2001</LINK>; <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>; <LINK REF="STD-Thorup-1983" TYPE="STUDY">Thorup 1983</LINK>; <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>). Twenty-two trials declared to be double-blind, but did not provide any details about the used blinding methods. Only eight trials included information on sample size calculations (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>; <LINK REF="STD-Cheape-1991" TYPE="STUDY">Cheape 1991</LINK>; <LINK REF="STD-Hallerb_x00e4_ck-1991" TYPE="STUDY">Hallerbäck 1991</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>; <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>In 'Characteristics of included studies' we provide a summary of each included trial. Results of pooled analyses are shown in the section 'Analysis' and adverse drug reactions are reported in 'Additional Tables'. </P>
<P>
<B>Selective opioid antagonists (alvimopan) versus placebo</B>
</P>
<P>Six trials reported on the effect of alvimopan (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Methodological quality was good in only one trial where the method of random sequence generation, concealment of random allocation, double blinding, number of withdrawals and the use of the intention-to-treat principle was properly reported (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>). All remaining trials showed methodological or reporting deficiencies. Except reporting of attrition, none of the trials properly described the randomization method used, only one trial detailed on blinding (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>) and none of the trials properly applied the intention to treat principle (modified intention-to-treat principle). Of note, authors of alvimopan trials used Cox models to analyze the effect of treatment against placebo on time to recovery. Acceleration of time to recovery in e.g. the treatment arm compared to the control arm corresponds to a larger hazard in the treatment arm compared to the control arm what appears as a hazard ratio larger than unity. </P>
<P>
<I>Recovery of gastrointestinal function: composite endpoints GI-2 and GI-3<BR/>(Comparison 01, outcome 01, outcome 02)</I>
</P>
<P>Five trials used the composite endpoint GI-2 (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) and four trials the composite endpoint GI-3 (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) as primary efficacy endpoint. Subjects in the intervention groups received either alvimopan 12mg or 6mg on the day of operation or on the first postoperative day (POD). The trials by Herzog et al and Ludwig et al used alvimopan 12mg as single active treatment group.<BR/>The alvimopan 12 mg against placebo comparison contained a total of 2181 patients (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>), the alvimopan 6 mg against placebo comparison a total of 1034 patients (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>).<BR/>The pooled hazard ratio for recovery of gastrointestinal function according to the GI-2 outcome for alvimopan 12 mg compared to placebo was 1.59 (95% CI 1.33, 1.90). A large effect seen with the trial by Herzog et al (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>) lead to between-trial heterogeneity (I²=67%) within this comparison. The pooled hazard ratio of alvimopan 6 mg compared to placebo was 1.41 (95% CI 1.22, 1.63) for the same outcome (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). <BR/>The pooled hazard ratio of GI-3 recovery for 12mg alvimopan against placebo was 1.30 (95% CI 1.16, 1.46), and 1.31 (95% CI 1.15, 1.50) for 6 mg alvimopan against placebo (test for heterogeneity I²=0% for both comparisons). </P>
<P>
<I>Time to passage of first stool <BR/>(Comparison 01, outcome 03)</I>
</P>
<P>Four trials assessed the outcome time to passage of first stool. Three trials compared 12mg alvimopan to placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>) and three trials compared 6mg alvimopan to placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>).<BR/>The pooled analyses of the outcome time to first stool included a total of 1238 patients in the 12 mg alvimopan against placebo comparison and a total of 782 patients in the 6 mg alvimopan against placebo comparison.<BR/>The pooled hazard ratio for passage of first stool for alvimopan 12mg compared to placebo was 1.74 (95% CI 1.29, 2.34). The pooled hazard ratio for alvimopan 6mg compared to placebo was 1.60 (95% CI 1.32, 1.92) for the same outcome.</P>
<P>
<I>Time to tolerance of regular diet <BR/>(Comparison 01, outcome 04)</I>
</P>
<P>Four trials reported on tolerance of regular diet. Three trials compared 12mg alvimopan against placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>) and three trials compared 6mg alvimopan against placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>). <BR/>The pooled results for 12 mg alvimopan compared to placebo included a total of 1238 patients and a total of. 782 patients were assigned to the 6mg alvimopan against placebo comparison. The pooled hazard ratio for the 12mg alvimopan against placebo comparison was 1.14 (95% CI 1.00, 1.29) and 1.57 (95% CI 1.04, 2.37) for the 6mg alvimopan against placebo comparison. The trial from Taguchi et al contributed to heterogeneity of the treatment effect estimates of the 6mg against placebo comparison (I² = 81.7%).</P>
<P>
<I>Length of hospital stay <BR/>(Comparison 01, outcome 05)</I>
</P>
<P>Five trials reported length of hospital stay. Five trials (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) studied 12mg alvimopan against placebo and four trials investigated 6mg alvimopan against placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). <BR/>The pooled analysis included a total of 2181 patients into the 12mg alvimopan against placebo comparison and 1086 patients contributed to the 6mg alvimopan against placebo comparison. The pooled hazard for length of hospital stay was larger for both the 12mg alvimopan against placebo comparison and the 6mg alvimopan against placebo comparison (HR 1.31 (95% CI 1.20, 1.43) and HR 1.38 (95% CI 1.22, 1.57), respectively). </P>
<P>
<I>Time to passage of first flatus <BR/>(Comparison 01, outcome 06)</I>
</P>
<P>Two trials reported the time to passage of first flatus (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>). The pooled analysis included a total of 562 patients into both the alvimopan and placebo groups. The treatment effect was heterogeneous across trials and showed a non-significant trend towards reduction of time to passage of first flatus (HR 1.67 (95% CI 0.86, 3.23), I² = 77.0%).</P>
<P>Taguchi et al. also studied the effect alvimopan 1mg against placebo (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>). The analysis included a total of 52 patients and did not show a significant reduction of time to resolution of POI (the HR for time to tolerance of regular diet was 1.30 (95% CI 0.69, 2.46) and the HR for length of hospital stay was 1.40 (95% CI 0.78, 2.60)). We did not incorporate the data from the 1mg alvimopan against placebo comparison into pooled analyses.</P>
<P>
<I>Summary of effect and dose-response considerations </I>
</P>
<P>The effect of alvimopan was consistent across all endpoints, except for time to first flatus which was only reported in two trials who showed heterogeneous effects. There was no clear dose-response relationship. Alvimopan 12mg against placebo did not show a larger effect which was consistent across different endpoints than alvimopan 6mg against placebo. None of the trials reported whether the proportional hazards assumption was fulfilled or violated. Except the trial from Taguchi (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>), the (reporting of) methodological quality of the trials was moderate.</P>
<P>
<B>Cholecystokinin-like acting drugs (cerulein and ceruletide) versus placebo or no treatmen</B>
<B>
<U>t<BR/>
</U>
</B>
<BR/>Four trials assessed the effect of cholecystokinin-like drugs (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>) on several endpoints. Methodological quality was moderate in one trial where the method of random sequence generation, concealment of random allocation, double blinding and number of withdrawals was properly reported (<LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>). None of the remaining trials properly reported on the randomization process and only two trials detailed on attrition (<LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>). None of the trials on cholecystokinin-like acting drugs properly applied an intention to treat analysis.</P>
<P>
<I>Time to passage of first stool <BR/>(Comparison 02, outcome 03)</I>
</P>
<P>Four trials reported the effect on passage of first stool (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>, <LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>). Pooled analysis of cholecystokinin-like drugs included a total of 257 patients in both the intervention and control arm. The pooled ratio of the mean time to passage of first stool showed a small and non-significant advantage of cholecystokinin-like drugs compared to placebo (0.86 (95% CI 0.71, 1.04)). The effect was heterogeneous (I² = 84.8%) due to a large effect of the trial by Ferreira et al (<LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>). </P>
<P>
<I>Time to tolerance of regular diet and length of hospital stay<BR/>(Comparison 02, outcome 04 and outcome 05)</I>
</P>
<P>Two trials assessed tolerance of regular diet and length of hospital stay (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>). The pooled analyses included a total of 141 patients within both comparison groups. The analysis showed a small but significant acceleration of the time to tolerance of regular diet (pooled ratio of means of 0.93 (95% CI 0.90, 0.97)) and similarly significant acceleration of length of hospital stay (pooled ratio of the mean of 0.81 (95% CI 0.68, 0.97) for cholecystokinin-like drugs compared to control. </P>
<P>
<I>Time to passage of first flatus *<BR/>(Comparison 02, outcome 06)</I>
</P>
<P>Two trials assessed the outcome time to passage of first flatus (<LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>, <LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>). The pooled analysis of this comparison included a total of 148 patients. The analysis showed a non-significant reduction of time to passage of first flatus in treated subjects compared to control subjects with a pooled ratio of the means of 0.77 (95% CI 0.55, 1.08). Two trials were excluded from the analysis of time to first flatus (<LINK REF="STD-Alvarez-1979" TYPE="STUDY">Alvarez 1979</LINK>, <LINK REF="STD-Ferreira-1980" TYPE="STUDY">Ferreira 1980</LINK>) since no information on blinding was available (see 'Criteria for considering studies for this review').<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<I>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>There is inconsistent evidence of a reduction of recovery times for the group of cholecystokinin-like drugs. The effect did not reach significance for time to passage of first stool and time to passage of flatus, but for the outcomes tolerance of regular diet and length of hospital stay. These inconsistent results are based on small trials of moderate to poor methodological quality. .</P>
<P>
<B>Cisapride versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Seven trials investigated the effect of cisapride to shorten POI (<LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>, <LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>, <LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1991" TYPE="STUDY">Hallerbäck 1991</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> , <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK>). Methodological quality was acceptable in only one trial where all quality criteria but attrition were properly reported (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>). Of the remaining trials, no information on the randomization process was given and only two trials properly applied the intention to treat principle <BR/>(<LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>). Withdrawal of patients was stated, but often not in detail specified.</P>
<P>
<I>Time to passage of first stool <BR/>(Comparison 03, outcome 03)</I>
</P>
<P>Four trials reported on the effect of cisapride to reduce time to the passage of first stool (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1991" TYPE="STUDY">Hallerbäck 1991</LINK>, <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> , <LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>). The pooled analysis encompassed a total of 181 patients allocated to cisapride or placebo. The mean time to passage of first stool was smaller in the cisapride group compared to the placebo group (pooled ratio of means 0.72 (95% CI 0.54, 0.97). Effect estimates across trials were heterogeneous and therefore the random effects model was used (I² = 86.5%). There was variation regarding duration of drug administration and the surgical interventions between the analysed trials. In two trials, the duration of drug administration was restricted to either 48 hours (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>) or 56 hours (<LINK REF="STD-Hallerb_x00e4_ck-1991" TYPE="STUDY">Hallerbäck 1991</LINK>). These two trials did not show an effect on reduction of time to passage of first stool. Two other trials used longer durations of drug administration, namely 72 hours ( <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> ) and until hospital discharge (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>). These two trials showed a significant effect of cisapride on time to passage of first stool (<LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>, <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> ).</P>
<P>
<I>Time to tolerance of regular diet and length of hospital stay <BR/>(Comparison 03, outcome 04 and outcome 05)</I>
</P>
<P>Two trials reported on time to tolerance of regular diet and on length of hospital stay (<LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Brown-1999" TYPE="STUDY">Brown 1999</LINK>). The pooled analysis included a total of 72 patients in the cisapride and control group for both outcomes. Only the more recent trial of Brown et al showed a small effect on both outcomes. The random effects model showed a non-significant reduction in time to tolerance of regular diet with a pooled ratio of the means of 0.89 (95% CI 0.71, 1.10) in patients treated with cisapride compared to placebo. Similarly, the pooled ratio of the means of the fixed effects model for length of hospital stay was 0.86 (95% CI 0.72, 1.01) for cisapride compared to placebo.</P>
<P>
<I>Time to passage of first flatus* <BR/>(Comparison 03, outcome 06)</I>
</P>
<P>Five trials investigated time to passage of first flatus or the combination of time to first flatus or first stool (<LINK REF="STD-Benson-1994" TYPE="STUDY">Benson 1994</LINK>, <LINK REF="STD-Clevers-1991" TYPE="STUDY">Clevers 1991</LINK>, <LINK REF="STD-Roberts-1995" TYPE="STUDY">Roberts 1995</LINK>, <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK> , <LINK REF="STD-Von-Ritter-1987" TYPE="STUDY">Von Ritter 1987</LINK>). The pooled analysis of this comparison enrolled a total of 146 patients into the treatment and control groups. The effect was homogenous across all trials and showed a non-significant effect with a pooled ratio of the mean of time to passage of first flatus of 0.89 (95% CI 0.79, 1.01) in favour of cisapride compared to control.<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<I>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>Cisapride showed a significant acceleration of the time to passage of first stool in a heterogeneous random effects model. The effect was not consistent across endpoints; in particular the effect did neither significantly replicate in a homogenous fixed-effects model for the outcome time to first flatus nor for other endpoints. All cisapride trials were of moderate to poor quality.</P>
<P>
<B>Dihydroergotamine versus no treatment</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Two trials studied the effect of dihydroergotamine compared to no treatment (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>; <LINK REF="STD-Thorup-1983" TYPE="STUDY">Thorup 1983</LINK>). Methodological quality was poor in both trials with no information available on the process of randomization. One trial properly applied the intention to treat principle (<LINK REF="STD-Thorup-1983" TYPE="STUDY">Thorup 1983</LINK>), the other (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>) stated patient withdrawals.</P>
<P>
<I>Time to passage of first stool<BR/>(Comparison 04, outcome 03)</I>
</P>
<P>Both trials reported time to passage of first stool (<LINK REF="STD-Altaparmakov-1984" TYPE="STUDY">Altaparmakov 1984</LINK>; <LINK REF="STD-Thorup-1983" TYPE="STUDY">Thorup 1983</LINK>). The analysis of this comparison included a total of 123 patients allocated to dihydroergotamine or no treatment. The pooled ratio of the mean time to passage of first stool was lower in subjects treated with dihydroergotamine but the reduction was far from being significant (ratio of the means 0.71 (95% CI 0.43, 1.18)). Effect estimates across the two trials were heterogeneous and therefore the random effects model was used (I² = 88.2%).</P>
<P>
<I>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>The two low quality trials did not show a significant reduction of time to passage of first stool in favour of dihydroergotamine compared to no treatment.</P>
<P>
<B>Dopamine-antagonists (metoclopramide and bromopride) versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Four trials studied the effect of dopamine-antagonists (<LINK REF="STD-Cheape-1991" TYPE="STUDY">Cheape 1991</LINK>, <LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>, <LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>, <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> ). Methodological quality was poor in all included trials and all quality criteria but attrition were poorly reported. No information on the randomization process was reported and only one trial applied the intention-to-treat principle ( <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> ). Withdrawals were stated and excluded (<LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>, <LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>).</P>
<P>
<I>Time to passage of first stool and time to tolerance of regular diet<BR/>
</I>
<BR/>One small trail reported time to passage of first stool ( <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> ), with in total 20 patients assigned to either metoclopramide or placebo. Time to passage of stool was similar in patients treated with metoclopramide compared to control (ratio of the means 0.96 (95% CI 0.68, 1.37).<BR/>One trail reported on time to tolerance of regular diet (<LINK REF="STD-Cheape-1991" TYPE="STUDY">Cheape 1991</LINK>). Ninety-three patients were in total allocated to treatment or control. The effect in favour of metoclopramide compared to control was small and not significant (ratio of the means 0.90 (95% CI 0.80, 1.02)).</P>
<P>
<I>Time to passage of first flatus*<BR/>(Comparison 05, outcome 06)</I>
</P>
<P>Three trials investigated the effect on time to passage of first flatus (<LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>, <LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>, <LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK> ) with a total of 239 patients assigned to the treatment or control group. The results were heterogeneous across trials due to a significant effect of the largest trial (<LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>) (I² = 64.3%). Conte et al included patients undergoing abdominal surgery with and without bowel resection (<LINK REF="STD-Conte-1983" TYPE="STUDY">Conte 1983</LINK>), Jepsen included patients with surgery of the aorta and iliac arteries (<LINK REF="STD-Jepsen-1986" TYPE="STUDY">Jepsen 1986</LINK>) and Tollesson enrolled elective cholecystectomy patients (<LINK REF="STD-Tollesson-1991_x0028_1_x0029_" TYPE="STUDY">Tollesson 1991(1)</LINK>). The pooled analysis did not reveal a significant reduction of the time to passage of first flatus in patients treated with dopamine-antagonists compared to placebo (pooled ratio of the means of 0.94 (95% CI 0.66, 1.33)).<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<I>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>We did not find evidence of an effect of dopamine-antagonists on the resolution of POI. The absence of significant effects was consistent across endpoints, however, the evidence for the 'harder endpoints' time to stool or tolerance of regular diet is based on only one trial each. The quality of all trials was poor. <BR/>
<B>
<U>
<BR/>
</U>
</B>
<B>Erythromycin versus placebo<BR/>
</B>
<BR/>Four trials studied the effect of erythromycin (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>). Methodological quality was moderate in three trials where the randomization process and the number of withdrawals was properly reported (<LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>). Only one trial applied an intention-to-treat analysis (<LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>).</P>
<P>
<I>Time to passage of first stool<BR/>(Comparison 06, outcome 03)</I>
</P>
<P>Three trials reported on the passage of first stool (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) including a total of 233 patients enrolled into erythromycin or placebo. There was a homogenous lack of effect across all trials with a pooled ratio of the mean time to passage of first stool 0.99 (95% CI 0.90, 1.08) for erythromycin compared to placebo.</P>
<P>
<I>Time to tolerance of regular diet, length of hospital stay and time to passage of first flatus*<BR/>(Comparison 06, outcome 04, 05 and 06)</I>
</P>
<P>Three trials assessed tolerance of regular diet (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>) and four trials length of hospital stay (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>). For the outcome time to tolerance of regular diet, a total of 233 patients were available in the erythromycin and placebo groups and a total of 254 patients for the length of hospital stay comparison. There was neither evidence of effect of erythromycin against placebo on time to tolerance of regular diet (pooled ratio of the means of 1.04 (95% CI 0.93, 1.15)) nor on length of hospital stay (pooled ratio of the means of 1.00 (95% CI 0.90, 1.11)).<BR/>Four trials assessed time to passage of first flatus (<LINK REF="STD-Bonacini-1993" TYPE="STUDY">Bonacini 1993</LINK>, <LINK REF="STD-Lightfoot-2007" TYPE="STUDY">Lightfoot 2007</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Wilkinson-2002" TYPE="STUDY">Wilkinson 2002</LINK>) in a total of 254 patients. Similar to other endpoints, the analysis showed no reduction of erythromycin compared to control for time to passage of first flatus (pooled ratio of the means of 0.95 (95% CI 0.88, 1.03)).<BR/>* includes the combination of time to first flatus or stool<BR/>
<I>
<BR/>Summary of effect</I>
<I>
<U>
<BR/>
</U>
</I>
<BR/>There is evidence of absence of a treatment effect of erythromycin on time to recovery of post-operative bowel function. The absence of effect was homogenous and consistent across all endpoints. The overall quality of included trials was moderate. </P>
<P>
<B>Systemic administration of lidocaine versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Three trials analysed the effect of systemic lidocaine compared to placebo (<LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>). Methodological quality varied across included trials. Information on the randomization process was detailed in two trials (<LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>), but one (<LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>) used a quasi randomization scheme. Two trials properly applied the intention to treat principle (<LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>). <BR/>
<I>
<BR/>Time to passage of first stool and time to passage of first flatus*<BR/>(Comparison 07, outcome 03 and 06)</I>
</P>
<P>Two small trials reported on time to passage of first stool (<LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>) with a total of 68 patients allocated to lidocaine or placebo. The analysis showed a significant reduction of the mean time to passage of first stool in treated subjects compared to control (pooled ratio of the means 0.83 (95% CI 0.73, 0.95)). Similarly, three trials assessed time to passage of first flatus (<LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>, <LINK REF="STD-Rimb_x00e4_ck-1990" TYPE="STUDY">Rimbäck 1990</LINK>) in 108 patients. Consistent with time to first stool, time to passage of first flatus was reduced in favour of the active group compared to control (pooled ratio of the means 0.82 (95% CI 0.73, 0.92)).<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<I>Length of hospital stay<BR/>(Comparison 07, outcome 05)</I>
</P>
<P>Two small trials investigated length of hospital stay (<LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>, <LINK REF="STD-Groudine-1998" TYPE="STUDY">Groudine 1998</LINK>) in 38 patients receiving lidocaine or placebo. Random effects meta-analysis of the two heterogeneous trials (I² = 73.6%) did not show a significant effect on length of hospital stay in favour of active treatment (pooled ratio of the means of 0.89 (95% CI 0.73, 1.10)).<BR/>
<I>
<BR/>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>Systemic treatment with lidocaine might eventually be effective to support restoration of POI. The evidence is based on small trials, but the treatment effect is consistent for time to passage of first stool and time to passage of first flatus. However, the evidence is insufficient to judge the effect on length of hospital stay and data of randomized comparisons on tolerance of regular diet are not available. All included trials were of moderate quality. Sensitivity analysis excluding the study with quasi-randomisation did not change the conclusions drawn for lidocaine.</P>
<P>
<B>Neostigmine versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Two trials assessed the effect of neostigmine against placebo ( <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TYPE="STUDY">Hallerbäck 1987(1)</LINK>; <LINK REF="STD-Orlando-1994" TYPE="STUDY">Orlando 1994</LINK>). The trials showed methodological or reporting deficiencies. Except reporting of attrition, none of the trials properly reported the randomization process and none of the trials properly applied the intention to treat principle.</P>
<P>
<I>Time to passage of first stool and time to passage of first flatus*</I>
</P>
<P>One trial reported on time to passage of first stool (<LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TYPE="STUDY">Hallerbäck 1987(1)</LINK> ) in 35 patients. The median time to first stool was 75 hours in neostigmine treated subjects compared to 93 hours in control group subjects. The reduction was statistically significant yielding a ratio of the medians of 0.81 (95% CI 0.65, 0.99) for neostigmine to control. One trial reported on time to passage of first flatus (<LINK REF="STD-Orlando-1994" TYPE="STUDY">Orlando 1994</LINK>). The comparison included a total of 39 patients. Orlando et al assessed the endonasal application of neostigmine for a period of 4 days and found a borderline significant reduction in time to passage of first flatus (ratio of the means 0.57 (95% CI 0.33, 1.01)).<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<B>Propranolol versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Two trials assessed the effect of propranolol against placebo (<LINK REF="STD-Ferraz-2001" TYPE="STUDY">Ferraz 2001</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK> ). The two trials were of poor methodological quality. Except reporting of attrition, none of the trials properly reported the requested quality criteria.</P>
<P>
<I>Time to passage of first stool or time to passage of first flatus* <BR/>(Comparison 09, outcome 06)</I>
</P>
<P>One trial reported time to passage of first stool (<LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK>) and two trials reported on time to passage of first flatus (<LINK REF="STD-Ferraz-2001" TYPE="STUDY">Ferraz 2001</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TYPE="STUDY">Hallerbäck 1987(2)</LINK> ). The comparison regarding the outcome time to passage of first stool enrolled a total of 39 patients to propranolol or placebo. The median time to evacuation of stool was reported as 74.5 hours in treated patients and 120 hours in control patients (ratio of the medians 0.37 (95% CI 0.29, 0.46). The effect of the drug was not consistent over the two trials including a total of 66 patients for the outcome time to passage of first flatus. The results were homogenous over both trials and failed to show a significant on acceleration of time to passage of first flatus in the treatment group compared to the control group (pooled ratio of the means 0.91 (95% CI 0.74, 1.11)).<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<B>Propranolol combined with neostigmine versus placebo</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Two trials were carried out to assess the combination of propranolol and neostigmine compared to placebo(<LINK REF="STD-Garcia-1993" TYPE="STUDY">Garcia 1993</LINK>, <LINK REF="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TYPE="STUDY">Hallerbäck 1987(1)</LINK> ). Both trials showed methodological and reporting deficiencies. Except reporting of withdrawals, no further details on the requested methodological quality criteria were given.</P>
<P>
<I>Time to passage of first stool and time to passage of first flatus*<BR/>(Comparison 08, outcome 03 and outcome 06)</I>
</P>
<P>Both trials enrolled a total of 70 patients into the propranolol/neostigmine or placebo group. The pooled analysis showed heterogeneity of effects (I² = 71.0%) and failed to show a significant association of the drug combination against placebo with time to passage of first stool (pooled ratio of the means of 0.85 (95% CI 0.62, 1.16)). Similarly, Garcia-Caballero et al. (<LINK REF="STD-Garcia-1993" TYPE="STUDY">Garcia 1993</LINK>) compared time to passage of first flatus in 37 patients receiving the same drug combination or placebo. The median time to flatus was 48 hours in the treatment arm and 60 hours in the control arm and failed to show a significant effect (ratio of the means of 0.80 (95% CI 0.61, 1.05)).<BR/>* includes the combination of time to first flatus or stool</P>
<P>
<I>Summary of effect</I>
<B>
<BR/>
</B>
<BR/>There is insufficient evidence for any of neostigmine, propranolol or the combination of neostigmine and propranolol. The effect of neostigmine is based on two small trials, both of low methodological quality. The effect of propranolol in contrast was inconsistent with an effect on time to stool but no replication on time to flatus. Similarly, the combination of both drugs did not enhance recovery times beyond chance, based on two low-quality trials.</P>
<P>
<B>Other drugs</B>
<B>
<U>
<BR/>
</U>
</B>
<BR/>Four trials (<LINK REF="STD-Hakansson-1985" TYPE="STUDY">Hakansson 1985</LINK>, <LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>, <LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>, <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>) could not be assigned to any of the drug classes mentioned in the methods section. Methodological quality was moderate in one trial where the method of random sequence generation, concealment of random allocation, double blinding and number of withdrawals was reported (<LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>). All remaining trials showed methodological or reporting deficiencies. None properly described the randomization process; only one trial detailed on blinding (<LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>) but two trials, however, applied an intention to treat analysis (<LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>, <LINK REF="STD-Hakansson-1985" TYPE="STUDY">Hakansson 1985</LINK>). Mieny et al and Woods et al used quasi randomization (<LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>, <LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>).<BR/>One trial analysed the effect of postoperative albumin replacement (<LINK REF="STD-Woods-1993" TYPE="STUDY">Woods 1993</LINK>). The comparison enrolled 69 patients. Albumin replacement was administrated according to serum albumin levels in the treatment group. The approach used in the control group, which had no albumin replacement, was unclear. Time to regular diet and time to hospital discharge was similar in both groups (220 hours for albumin versus 202 hours for no treatment and 9 days versus 8 days, respectively). Blinding was not reported, therefore time to passage of first flatus was not considered according to the protocol.<BR/>Manani et al (<LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>) investigated systemic administration of fructose-1,6-diphosphate. They compared 100 patients. Fructose-1, 6-diphosphate reduced the time to first flatus (ratio of the means 0.84 (95% CI 0.72, 0.98)). However, the control group received fructose which is chemically similar to Fructose-1, 6-diphosphate. <BR/>Pantothen Acid was studied by Mieny et al (<LINK REF="STD-Mieny-1972" TYPE="STUDY">Mieny 1972</LINK>). Eighty-nine patients undergoing cholecystectomy were included. There was no difference in time to first flatus between pantothen acid treated patients and control group patients (ratio of means 1.00 (95% CI 0.85, 1.17)).<BR/>Another trail investigated vasopressin (<LINK REF="STD-Hakansson-1985" TYPE="STUDY">Hakansson 1985</LINK>). They enrolled 60 patients undergoing major abdominal surgery. Time to hospital discharge and time to passage of first flatus was not significantly different in the treatment group compared to the control group (ratio of means 1.14(95% CI 0.86, 1.52) and 0.72 (95% CI0.45, 1.14), respectively).</P>
<P>
<I>Summary of effect of 'other drugs'</I>
<B>
<BR/>
</B>
<BR/>There is insufficient evidence for a conclusive judgement of the effect of albumin, pantothen acid, fructose 1,6 diphosphate or vasopressin. All single trials were of small size. Except the trial of Manani on Fructose-1, 6-diphosphate which was of adequate methodological quality, the quality of the remaining trials was poor. </P>
<P>
<B>Summary of adverse drug reactions</B>
<I>
<BR/>
</I>
<BR/>There was large variability in the degree of reporting of adverse drug reactions, especially in older trials. Also, some trials did not report adverse drug reactions according to treatment allocation (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Moreover, adverse events associated with cisapride occurred in the post-marketing period and lead to withdrawal of the drug from the market. For alvimopan, we only found a small and non-significantly increased risk of headache in treated patients. Frisell (<LINK REF="STD-Frisell-1985" TYPE="STUDY">Frisell 1985</LINK>) and Sadek (<LINK REF="STD-Sadek-1988" TYPE="STUDY">Sadek 1988</LINK>) reported increased adverse drug reactions (nausea and vomiting) for cholecystokinin-like drugs and Orlando (<LINK REF="STD-Orlando-1994" TYPE="STUDY">Orlando 1994</LINK>) reported mild side effects associated with neostigmine. The remaining trials reported, if any, balanced risk of adverse drug reactions between active and control arms.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Prokinetic acting drugs are often prescribed for patients with symptoms of postoperative ileus (POI) or to step up recovery on a regular basis following abdominal surgery. We reviewed efficacy and effectiveness outcomes of 15 systemically acting prokinetic drugs used in patients with POI. More than half of all trials were published before the year 1990 and such older trials can therefore not satisfy current methodological and reporting criteria which were mainly introduced after the year 2000 (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). <BR/>Six RCTs reported on alvimopan and the summary estimate indicate a shortened recovery period of gastrointestinal (GI) function and time to hospital discharge of alvimopan when compared to placebo. Alvimopan is still an investigational drug which has not yet passed the regulatory affairs. Moreover safety concerns have been issued recently with alvimoan in patients taking opioids for chronic non-cancer pain (<LINK REF="REF-www.biospace.com" TYPE="REFERENCE">www.biospace.com</LINK>). The quality of reporting of the alvimopan trials does not, except the study from Taguchi et al. (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>) comply with current reporting standards (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Although these are recent trials, we judged the methodological quality as only moderate. Cholecystokinin-like prokinetic drugs like cerulein/ceruletide and cholecystokinin showed inconsistent evidence to reduce recovery time of post-operative bowel function and trials were of poor quality. Three trials of intravenous lidocaine and two trials of neostigmine showed a small effect of GI recovery with reduced time to passage of first flatus and passage of first stool. The, evidence for both drugs, however, is insufficient for other patient relevant outcomes and sufficiently powered trials of high-quality are needed to confirm these preliminary data. There is insufficient evidence of generally low to moderate quality for the use of propranolol, propranolol and neostigmine and cisapride. None of the drugs showed a consistent effect over several clinically relevant outcomes. Moreover, cisapride has been withdrawn form the market in many countries since 2000 due to serious cardiac events (<LINK REF="REF-Tonini-1999" TYPE="REFERENCE">Tonini 1999</LINK>). We found clear evidence for the absence of effects of erythromycin on postoperative bowel recovery in four trials of moderate quality. These findings were consistent across trials and different outcomes. RCTs of different drugs like dopamine-antagonists, dihydroergotamine, albumin replacement, vasopressin and pantothen acid were most of poor methodological quality and failed to demonstrate any effect on restoration of postoperative ileus. Only Manani (<LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>) showed that fructose 1, 6 diphosphate reduced time to passage of first flatus in a trial of moderate methodological quality. But the drug did not receive attention in later randomised trials. <BR/>Alvimopan selectively blocks opioid effects throughout the gastrointestinal tract without affecting the analgesic effects of opioid medications (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="REF-Greenwood_x002d_Van-2004" TYPE="REFERENCE">Greenwood-Van 2004</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Although the most promising drug to accelerate recovery of bowel function following abdominal surgery, it is currently unclear whether and to which extent the found effect estimates suffer from bias. All trials compute effect estimates based on 'modified intention to treat populations', a subset of the ITT population that received the protocol-specified surgery and had at least one on- treatment primary efficacy evaluation (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Subjects who did not receive the protocol specified surgery were excluded after randomization, what is debatable. The exclusions add an arbitrary element to the trials (<LINK REF="REF-Senn-1997" TYPE="REFERENCE">Senn 1997</LINK>). Effect estimates based on ITT could have been provided at least as sensitivity analysis (<LINK REF="REF-Fowler-2006" TYPE="REFERENCE">Fowler 2006</LINK>, <LINK REF="REF-Heritier-2003" TYPE="REFERENCE">Heritier 2003</LINK>). Further, the Cox proportional hazard model was used for statistical analysis. Since recovery times are thought to be shortened, the hazard ratio of a beneficial effect is above unity what makes the clinical interpretation not wrong but unusual. No trial reported in the statistical analysis whether the proportional hazard assumption was fulfilled. If not, the length of follow-up employed becomes critical because the hazard will accordingly increase or decrease. As a result, the hazard ratios tend to be more discrepant from unity in trials with short follow-up compared to trials with longer follow-up (<LINK REF="REF-Keene-2002" TYPE="REFERENCE">Keene 2002</LINK>). Two of the included studies (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) received funding of pharmaceutical companies, which were involved in the development of the compound, and some co-authors were employees of the sponsors (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). <BR/>N-methylnaltrexone (MNTX) is another mu opioid antagonist with effects restricted to the periphery. We identified one ongoing trial that currently evaluates the efficacy of MNTX in the treatment of postoperative ileus. Asimadoline, a peripherally acting kappa opioid agonist is currently tested regarding POI in one phase II trial in patients with segmental colonic resection (see ' Characteristics of ongoing studies' ).<BR/>Cerulein or ceruletide are dekapeptides with similar pharmacodynamic properties as cholecystokinin. The evidence for an effect of this class of drugs was inconsistent. The treatment effects were heterogeneous and did not show a significant effect on the outcome time to stool or time to flatus. Based on only two trials and in contradiction with the first outcome, cerulein or ceruletide reduced time to tolerance of regular diet and length of hospital stay. The quality of all included trials was poor and complicates the interpretation of the inconsistent results.<BR/>Cisapride did not show a consistent prokinetic effect across endpoints and the results are based on work with overall poor reporting quality. In 2000 cisapride was withdrawn from the market in the USA and in many other countries because of reports of serious, and in many cases fatal, cardiac events (<LINK REF="REF-Layton-2003" TYPE="REFERENCE">Layton 2003</LINK>, <LINK REF="REF-Barbey-2000" TYPE="REFERENCE">Barbey 2000</LINK>). The drug is included in this review since it is still approved in some countries (Greece, Serbia, Poland, South Africa).<BR/>Although dopamine-antagonists are widely used to positively influence postoperative bowel motility, the trial evidence is of poor methodological quality and pooled analyses did not demonstrate a significant effect of the drug. <BR/>Erythromycin showed no effect on time to recovery of bowel function in four trials, irrespective of the endpoint considered. We found preliminary evidence of intravenously applied lidocaine and neostigmine on time to first flatus or stool, but the effect on other patient relevant outcomes is unclear and needs further attention. The trials were very small and only of poor to moderate quality. We suppose the currently ongoing trials to be of adequate power and methodological quality to provide further evidence of these drugs in patients undergoing major abdominal surgery (<LINK REF="STD-Asimadoline" TYPE="STUDY">Asimadoline</LINK>, <LINK REF="STD-Lidocaine" TYPE="STUDY">Lidocaine</LINK>, <LINK REF="STD-Lidocaine_x002f_Ketamin" TYPE="STUDY">Lidocaine/Ketamin</LINK>, <LINK REF="STD-Methylnaltrexone" TYPE="STUDY">Methylnaltrexone</LINK>).<BR/>Single trial evidence was available for albumin, pantothen acid, fructose 1,6 diphosphate and vasopressin. However, the small study sizes, the poor reporting quality (except the trial of Manani (<LINK REF="STD-Manani-1982" TYPE="STUDY">Manani 1982</LINK>)) and the outdated information makes recommendation of any of these drugs impossible. <BR/>Many important aspects of drug treatment for POI can not be addressed with the current evidence. It would be interesting, for example, to know whether differential drug effects exist in patients with or without epidural analgesia (<LINK REF="REF-Jorgensen-2000" TYPE="REFERENCE">Jorgensen 2000</LINK>) or in patients who had open or laparoscopic surgery (<LINK REF="REF-Schwenk-2005" TYPE="REFERENCE">Schwenk 2005</LINK>). Such subgroup analyses, however, need adequate power or specific research questions and are not possible to address currently. Similarly, the influence of postoperative opioid consumption, either as an effect modifier or if unbalanced as confounder, can not be addressed. Only alvimopan trials reported, that the effect was apparently not influenced by the amount of opioids given (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Ludwig-2006" TYPE="STUDY">Ludwig 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Tollesson-1991_x0028_2_x0029_" TYPE="STUDY">Tollesson 1991(2)</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>).</P>
<P>Limitations of this review<BR/>Most included trials are of small size and therefore prone to effect overestimation due to publication bias. Since the number of trials per comparison was usually very limited, formal assessment of publication bias was impossible.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Pharmacological agents to decrease POI are commonly used in post-surgical management. Evidence for the majority of these agents is based on small trials of limited methodological quality compromising the interpretation of study findings. Adequately powered trials of high methodological quality are required to prove beneficial effects of any compound currently used for POI or under investigation for POI. <BR/>Limited evidence from few small trials of moderate to poor quality indicates that intravenous use of lidocaine and neostigmine may show effects on time to recovery from POI, but more evidence on patient-relevant outcomes is needed from trials with rigorous design. For cholecystokinin-like acting drugs, cisapride, dopamine-antagonists, pantothen acid, propranolol or vasopressin the evidence is insufficient to recommend their use for the treatment of POI. For all these compounds effects are either inconsistent across different outcomes, study sample sizes are too small to be conclusive, or the methodological quality of eligible trials is too poor. Cisapride has been withdrawn from the market due to adverse cardiac events in most countries worldwide. Erythromycin has no effect on GI recovery following abdominal surgery. Alvimopan may be likely to reduce time to recovery of bowel function following major abdominal surgery. However, current evidence is based on 6 trials of reasonable size but most studies do not follow current reporting standards what makes judgement of potential bias or the influence of potential conflicts of interests impossible. The compound is not yet approved for the treatment of POI. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Trial protocols should use an explicit rational when to start therapy for POI, should provide sufficiently long intervention and follow-up duration (<LINK REF="REF-Kehlet-2006" TYPE="REFERENCE">Kehlet 2006</LINK>) and use uniform endpoint reporting according to time to GI-2 and GI-3 criteria. In addition, such protocols should prohibit the use of other prokinetic drugs and use standardized protocols for pain medication with an appropriate stratified randomisation scheme for patients with epidural analgesia and laparoscopic operation techniques. <BR/>Pharmacologic treatment of POI, if proven to be effective, should furthermore be contrasted against the multimodal or proactive POI management (<LINK REF="REF-Kehlet-2001" TYPE="REFERENCE">Kehlet 2001</LINK>).<BR/>Applied methodological work should elicit statistical time-to-event models most suited and clinically meaningful to report drug effects of POI data.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Mette Agervist of the Danish Cochrane Colorectal Cancer group for giving assistance with electronic database searches.<BR/>Toshi A Furukawa of the Department of Psychiatry and Cognitive-Behavioural Medicine, Nagoya City University, Japan for giving assistance with translating Japanese articles and applying the imputation method.<BR/>Marcel Wolbers of the Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland, for providing statistical support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Four reviewers (UT, LB, RK, MKO) independently performed appraisal of the methodological quality and extracted the data of all included trials in duplicate. Differences in the assessment of quality or data extraction between two reviewers were resolved by consensus. If necessary and possible, additional information was sought from the authors of the trials. Prespecified data extraction forms were used to record all data. <BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Altaparmakov-1984" NAME="Altaparmakov 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altaparmakov I, Erckenbrecht JF, Wienbeck M</AU>
<TI>Modulation of the adrenergic system in the treatment of postoperative bowel atonia</TI>
<SO>Scandinavian journal of gastroenterology.</SO>
<YR>1984</YR>
<VL>19</VL>
<NO>8</NO>
<PG>1104-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-1979" NAME="Alvarez 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez Cordero R</AU>
<TI>Valoracion del uso de la ceruleina (ceruletide) en el postoperatorio de la cirugia abdominal. [Evaluation of the use of caerulein (ceruletide) in the postoperative of abdominal surgery]</TI>
<SO>Rev Gastroenterol Mex</SO>
<YR>1979</YR>
<VL>44</VL>
<NO>3</NO>
<PG>135-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benson-1994" NAME="Benson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benson MJ, Roberts JP, Wingate DL, Rogers J, Deeks JJ, Castillo FD, Williams NS</AU>
<TI>Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride</TI>
<SO>Gastroenterology.</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>4</NO>
<PG>924-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonacini-1993" NAME="Bonacini 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonacini M, Quiason S, Reynolds M, Gaddis M, Pemberton B, Smith O</AU>
<TI>Effect of intravenous erythromycin on postoperative ileus</TI>
<SO>The American journal of gastroenterology.</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>2</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1999" NAME="Brown 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown TA, McDonald J, Williard W</AU>
<TI>A prospective, randomized, double-blinded, placebo-controlled trial of cisapride after colorectal surgery</TI>
<SO>American journal of surgery.</SO>
<YR>1999</YR>
<VL>177</VL>
<NO>5</NO>
<PG>399-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheape-1991" NAME="Cheape 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheape JD, Wexner SD, James K, Jagelman DG</AU>
<TI>Does metoclopramide reduce the length of ileus after colorectal surgery? A prospective randomized trial</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1991</YR>
<VL>34</VL>
<NO>6</NO>
<PG>437-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clevers-1991" NAME="Clevers 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clevers GJ, Hendriks AV, Smouth AJPM, Akkermans LMA, Van Vroonhoven TJMV</AU>
<TI>Prospective double-blind placebo-controlled study on the effect of cisapride on early postoperative nausea and vomiting</TI>
<SO>Surgical Research Communications</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conte-1983" NAME="Conte 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conte R, Laringe M, Leone C, De Rosa A</AU>
<TI>Evaluation of the effects of bromopride on the post-surgical ileus</TI>
<SO>Giornale di Chirurgia</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>5</NO>
<PG>548-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delaney-2005" NAME="Delaney 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delaney C P, Weese J L, Hyman N H, Bauer J, Techner L, Gabriel K, Du W, Schmidt W K, Wallin B A, Alvimopan Postoperative Ileus Study Group</AU>
<TI>Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.</TI>
<SO>Dis Colon Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>6</NO>
<PG>1114-25; discussion 1125-6; author reply 1127-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferraz-2001" NAME="Ferraz 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz AA, Wanderley GJ, Santos MA, Mathias CA, Araújo JG, Ferraz EM</AU>
<TI>Effects of propranolol on human postoperative ileus</TI>
<SO>Digestive surgery.</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>4</NO>
<PG>305-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-1980" NAME="Ferreira 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira Montero V, Martínez Laganga A, Aznar García E</AU>
<TI>Usefulness of caerulein in the treatment of post-operative intestinal atony</TI>
<SO>The Journal of international medical research.</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>1</NO>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frisell-1985" NAME="Frisell 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frisell J, Magnusson I, Leijonmarck CE, Ihre T</AU>
<TI>The effect of cholecystokinin on postoperative bowel function</TI>
<SO>Acta chirurgica Scandinavica.</SO>
<YR>1985</YR>
<VL>151</VL>
<NO>6</NO>
<PG>557-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1993" NAME="Garcia 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Caballero M, Vara Thorbeck C</AU>
<TI>The evolution of postoperative ileus after laparoscopic cholecystectomy. A comparative study with conventional cholecystectomy and sympathetic blockade treatment.</TI>
<SO>Surg Endosc</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>5</NO>
<PG>416-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groudine-1998" NAME="Groudine 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groudine SB, Fisher HA, Kaufman RP, Patel MK, Wilkins LJ, Mehta SA, Lumb PD</AU>
<TI>Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy</TI>
<SO>Anesthesia and analgesia.</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>2</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakansson-1985" NAME="Hakansson 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakansson T, Watt Boolsen S, Olsen O, Billesbolle P</AU>
<TI>Postoperativ tarmatoni og vasopressin. En randomiseret undersogelse af effekten af vasopressin-indgift pa varigheden af postoperativ tarmatoni. [Postoperative intestinal atony and vasopressin. A randomized study of the effect of administration of vasopressin on the duration of postoperative intestinal atony]</TI>
<SO>Ugeskr Laeger</SO>
<YR>1985</YR>
<VL>147</VL>
<NO>39</NO>
<PG>3069-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" NAME="Hallerbäck 1987(1)" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallerbäck B, Ander S, Glise H</AU>
<TI>Effect of combined blockade of beta-adrenoceptors and acetylcholinesterase in the treatment of postoperative ileus after cholecystectomy</TI>
<SO>Scandinavian journal of gastroenterology.</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>4</NO>
<PG>420-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" NAME="Hallerbäck 1987(2)" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallerbäck B, Carlsen E, Carlsson K, Enkvist C, Glise H, Haffner J, Innes R, Kirnö K</AU>
<TI>Beta-adrenoceptor blockade in the treatment of postoperative adynamic ileus</TI>
<SO>Scandinavian journal of gastroenterology.</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>2</NO>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallerb_x00e4_ck-1991" NAME="Hallerbäck 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallerbäck B, Bergman B, Bong H, Ekström P, Glise H, Lundgren K, Risberg O</AU>
<TI>Cisapride in the treatment of post-operative ileus</TI>
<SO>Alimentary pharmacology &amp; therapeutics.</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>5</NO>
<PG>503-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herzog-2006" NAME="Herzog 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herzog TJ, Coleman RL, Guerrieri JP, Gabriel K, Du W, Techner L, Fort JG, Wallin B</AU>
<TI>A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy</TI>
<SO>American journal of obstetrics and gynecology</SO>
<YR>2006</YR>
<VL>195</VL>
<NO>2</NO>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jepsen-1986" NAME="Jepsen 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jepsen S, Klaerke A, Nielsen PH, Simonsen O</AU>
<TI>Negative effect of Metoclopramide in postoperative adynamic ileus. A prospective, randomized, double blind study</TI>
<SO>The British journal of surgery.</SO>
<YR>1986</YR>
<VL>73</VL>
<NO>4</NO>
<PG>290-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2006" NAME="Kuo 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo CP, Jao SW, Chen KM, Wong CS, Yeh CC, Sheen MJ, Wu CT</AU>
<TI>Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery</TI>
<SO>British journal of anaesthesia</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>5</NO>
<PG>640-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lightfoot-2007" NAME="Lightfoot 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lightfoot A J, Eno M, Kreder K J, O'Donnell M A, Rao S S, Williams R D</AU>
<TI>Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin.</TI>
<SO>Urology</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>4</NO>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludwig-2006" NAME="Ludwig 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ludwig KA, Enker WE, Delaney CP, Wolff BG, Du W, Techner L</AU>
<TI>Accelerated gastrointestinal recovery and reduced length of stay following modified preoperative dose timing with alvimopan: results of a large, randomized, placebo-controlled study in partial bowel resection</TI>
<SO>Poster presented at: American College of Surgeons 92nd Annual Clinical Congress</SO>
<YR>October 8-12, 2006</YR>
<CY>Chicago, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manani-1982" NAME="Manani 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manani G, Valenti S, Segatto A, Giunta F, Maritano F, Nunziata A, Giron GP, Galzigna L</AU>
<TI>Double-blind study of the treatment of the adynamic ileus with fructose-1,6-diphosphate</TI>
<SO>Agressologie: revue internationale de physio-biologie et de pharmacologie appliquées aux effets de l'agression.</SO>
<YR>1982</YR>
<VL>23</VL>
<NO>2</NO>
<PG>67-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mieny-1972" NAME="Mieny 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mieny C J</AU>
<TI>Does pantothenic acid accelerate the return of bowel motility in post-operative patients?</TI>
<SO>S Afr J Surg</SO>
<YR>1972</YR>
<VL>10</VL>
<NO>2</NO>
<PG>103-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orlando-1994" NAME="Orlando 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orlando E, Finelli F, Colla M, Giotto E, Terragni P, Olivero G</AU>
<TI>[A double-blind study of neostigmine versus placebo in paralytic ileus as a result of surgical interventions]</TI>
<TO>Studio in doppia cecità tra neostigmina en versus placebo nell'ileo paralitico conseguente ad interventi chirurgici.</TO>
<SO>Minerva chirurgica.</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>5</NO>
<PG>451-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rimb_x00e4_ck-1990" NAME="Rimbäck 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rimbäck G, Cassuto J, Tollesson PO</AU>
<TI>Treatment of postoperative paralytic ileus by intravenous lidocaine infusion</TI>
<SO>Anesthesia and analgesia.</SO>
<YR>1990</YR>
<VL>70</VL>
<NO>4</NO>
<PG>414-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1995" NAME="Roberts 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JP, Benson MJ, Rogers J, Deeks JJ, Wingate DL, Williams NS</AU>
<TI>Effect of cisapride on distal colonic motility in the early postoperative period following left colonic anastomosis</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>2</NO>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadek-1988" NAME="Sadek 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadek SA, Cranford C, Eriksen C, Walker M, Campbell C, Baker PR, Wood RA, Cuschieri A</AU>
<TI>Pharmacological manipulation of adynamic ileus: controlled randomized double-blind study of ceruletide on intestinal motor activity after elective abdominal surgery</TI>
<SO>Alimentary pharmacology &amp; therapeutics.</SO>
<YR>1988</YR>
<VL>2</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2000" NAME="Smith 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith AJ, Nissan A, Lanouette NM, Shi W, Guillem JG, Wong WD, Thaler H, Cohen AM</AU>
<TI>Prokinetic effect of erythromycin after colorectal surgery: randomized, placebo-controlled, double-blind study</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>3</NO>
<PG>333-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taguchi-2001" NAME="Taguchi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A</AU>
<TI>Selective postoperative inhibition of gastrointestinal opioid receptors</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>13</NO>
<PG>935-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorup-1983" NAME="Thorup 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorup J, Wille Jorgensen P, Jorgensen T, Kjaergaard J</AU>
<TI>Dihydroergotamine in postoperative ileus.</TI>
<SO>Clin Pharmacol Ther</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>1</NO>
<PG>54-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollesson-1991_x0028_1_x0029_" NAME="Tollesson 1991(1)" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollesson PO, Cassuto J, Faxén A, Rimbäck G, Mattsson E, Rosén S</AU>
<TI>Lack of effect of metoclopramide on colonic motility after cholecystectomy</TI>
<SO>The European journal of surgery = Acta chirurgica.</SO>
<YR>1991</YR>
<VL>157</VL>
<NO>5</NO>
<PG>355-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollesson-1991_x0028_2_x0029_" NAME="Tollesson 1991(2)" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollesson PO, Cassuto J, Rimbäck G, Faxén A, Bergman L, Mattsson E</AU>
<TI>Treatment of postoperative paralytic ileus with cisapride</TI>
<SO>Scandinavian journal of gastroenterology.</SO>
<YR>1991</YR>
<VL>26</VL>
<NO>5</NO>
<PG>477-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viscusi-2006" NAME="Viscusi 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viscusi E R, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, Du W, Techner L, Wallin B</AU>
<TI>Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery Results of a randomized, double-blind, controlled study.</TI>
<SO>Surg Endosc</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>1</NO>
<PG>64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Ritter-1987" NAME="Von Ritter 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Ritter C, Hunter S, Hinder R A</AU>
<TI>Cisapride does not reduce postoperative paralytic ileus.</TI>
<SO>S Afr J Surg</SO>
<YR>1987</YR>
<VL>25</VL>
<NO>1</NO>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilkinson-2002" NAME="Wilkinson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson NW, Gustafson RJ, Frizzi JD</AU>
<TI>The effect of erythromycin on bile excretion and proximal small bowel motility following divided gastric bypass surgery: a prospective randomized placebo-controlled trial</TI>
<SO>Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand.</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>6</NO>
<PG>765-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-2004" NAME="Wolff 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA</AU>
<TI>Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus</TI>
<SO>Annals of surgery.</SO>
<YR>2004</YR>
<VL>240</VL>
<NO>4</NO>
<PG>728-34; discussion 734-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woods-1993" NAME="Woods 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woods MS, Kelley H</AU>
<TI>Oncotic pressure, albumin and ileus: the effect of albumin replacement on postoperative ileus</TI>
<SO>The American surgeon.</SO>
<YR>1993</YR>
<VL>59</VL>
<NO>11</NO>
<PG>758-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aloisio-1976" NAME="Aloisio 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aloisio F, Giannoni M F, Montesani C, Pizzirani F</AU>
<TI>Effetti del ceruletide nel trattamento dell'ileo paralitico postoperatorio. [Effects of ceruletide in the treatment of postoperative paralytic ileus]</TI>
<SO>Chir Ital</SO>
<YR>1976</YR>
<VL>28</VL>
<NO>6</NO>
<PG>846-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baig-2004" NAME="Baig 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baig M K, Wexner S D</AU>
<TI>Postoperative ileus: a review.</TI>
<SO>Dis Colon Rectum</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>4</NO>
<PG>516-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boghaert-1987" NAME="Boghaert 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boghaert A, Haesaert G, Mourisse P, Verlinden M</AU>
<TI>Placebo-controlled trial of cisapride in postoperative ileus</TI>
<SO>Acta anaesthesiologica Belgica.</SO>
<YR>1987</YR>
<VL>38</VL>
<NO>3</NO>
<PG>195-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2005" NAME="Chan 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan DC, Liu YC, Chen CJ, Yu JC, Chu HC, Chen FC, Chen TW, Hsieh HF, Chang TM, Shen KL</AU>
<TI>Preventing prolonged post-operative ileus in gastric cancer patients undergoing gastrectomy and intra-peritoneal chemotherapy</TI>
<SO>World journal of gastroenterology : WJG.</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>31</NO>
<PG>4776-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-JH-2005" NAME="Chen JH 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JH, Hsieh CB, Chao PC, Liu HD, Chen CJ, Liu YC, Yu JC</AU>
<TI>Effect of water-soluble contrast in colorectal surgery: a prospective randomized trial</TI>
<SO>World journal of gastroenterology : WJG.</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>18</NO>
<PG>2802-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-JY-2005" NAME="Chen JY 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JY, Wu GJ, Mok MS, Chou YH, Sun WZ, Chen PL, Chan WS, Yien HW, Wen YR</AU>
<TI>Effect of adding ketorolac to intravenous morphine patient-controlled analgesia on bowel function in colorectal surgery patients--a prospective, randomized, double-blind study</TI>
<SO>Acta anaesthesiologica Scandinavica.</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>4</NO>
<PG>546-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clevers-1988" NAME="Clevers 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clevers GJ, Smout AJPM, Akkermans LMA, Wittebol P</AU>
<TI>Restoration of gastrointestinal transit and colonic motility after major abdominal surgery; effects of cisapride</TI>
<SO>SURG RES COMMUN</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>3</NO>
<PG>205-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-1994" NAME="Costa 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa S D, Muller A, Grischke E M, Fuchs A, Bastert G</AU>
<TI>Das postoperative Vorgehen nach Sectio caesarea--Infusionstherapie und Rolle der Darmstimulation mit Parasympathomimetika und Dexpanthenon. [Postoperative management after cesarean section--infusion therapy and role of intestinal stimulation with parasympathomimetic drugs and dexpanthenon]</TI>
<SO>Zentralbl Gynakol</SO>
<YR>1994</YR>
<VL>116</VL>
<NO>7</NO>
<PG>375-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cyba-1985" NAME="Cyba 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cyba AS, Bauer J</AU>
<TI>Treatment of prolonged postoperative intestinal atony after aorto- iliac reconstructions. Results of a prospective randomized study of ceruletide-lyophilisate versus neostigmine</TI>
<SO>FORTSCHR-MED</SO>
<YR>1985</YR>
<VL>103</VL>
<NO>16</NO>
<PG>441-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1979" NAME="Davidson 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson ED, Hersh T, Brinner RA, Barnett SM, Boyle LP</AU>
<TI>The effects of metoclopramide on postoperative ileus. A randomized double-blind study</TI>
<SO>Annals of surgery.</SO>
<YR>1979</YR>
<VL>190</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delaney-2006" NAME="Delaney 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Times Cited: 0&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delaney CP, Senagore AJ, Viscusi ER, Wolff BG, Fort J, Du W, Techner L, Wallin B</AU>
<TI>Postoperative upper and lower gastrointestinal recovery and gastrointestinal morbidity in patients undergoing bowel resection: pooled analysis of placebo data from 3 randomized controlled trials</TI>
<SO>American Journal of Surgery</SO>
<YR>2006</YR>
<VL>191</VL>
<NO>3</NO>
<PG>315-319</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="58"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delaney-2007" NAME="Delaney 2007" YEAR="2007">
<REFERENCE NOTES="&lt;p&gt;Times Cited: 0&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delaney CP, Wolff BG, Viscusi ER, Senagore AJ, Fort JG, Du W, Techner L, Wallin B</AU>
<TI>Alvimopan, for postoperative ileus following bowel resection - A pooled analysis of phase III studies</TI>
<SO>Annals of Surgery</SO>
<YR>2007</YR>
<VL>245</VL>
<NO>3</NO>
<PG>355-363</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="59"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanning-1999" NAME="Fanning 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fanning J, Yu Brekke S</AU>
<TI>Prospective trial of aggressive postoperative bowel stimulation following radical hysterectomy.</TI>
<SO>Gynecol Oncol</SO>
<YR>1999</YR>
<VL>73</VL>
<NO>3</NO>
<PG>412-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferraz-1995" NAME="Ferraz 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz A A, Cowles V E, Condon R E, Carilli S, Ezberci F, Frantzides C T, Schulte W J</AU>
<TI>Nonopioid analgesics shorten the duration of postoperative ileus.</TI>
<SO>Am Surg</SO>
<YR>1995</YR>
<VL>61</VL>
<NO>12</NO>
<PG>1079-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gales-1999" NAME="Gales 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gales M A, Harms D W</AU>
<TI>Is rectally administered cisapride an effective prokinetic agent?</TI>
<SO>Ann Pharmacother</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Caballero1993" NAME="Garcia-Caballero1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Caballero M, Salvi M, Gutstein D, Linares F, Vara-Thorbeck C</AU>
<TI>Sympathico-adrenergic blockade in treating postoperative ileus</TI>
<SO>RES. SURG.</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>3</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1990" NAME="Jensen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen AG, Jensen VJ, Gregersen B, Johannesen NW, Jensen PF, Svendsen HP</AU>
<TI>Influence of a single dose of indomethacin on some biochemical changes and postoperative intestinal paralysis following minor surgery. A prospective randomized double-blind study</TI>
<SO>Acta anaesthesiologica Scandinavica.</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>8</NO>
<PG>624-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasparek-2007" NAME="Kasparek 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasparek MS, Glatzle J, Mueller MH, Vogt A, Koenigsrainer A, Zittel TT, Kreis ME</AU>
<TI>Postoperative colonic motility after tropisetron and a standardized meal in patients undergoing conventional colorectal surgery</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>521-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawaguchi-1985" NAME="Kawaguchi 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi T, Kobayashi Y, Tabuse K, Katsumi M</AU>
<TI>[Analysis of intestinal motility by enteric sound recording system--clinical evaluation of aclatonium napadisilate and prostaglandine F2 alpha on intestinal movement]</TI>
<SO>Nippon Heikatsukin Gakkai zasshi.</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>5</NO>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kivalo-1970" NAME="Kivalo 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kivalo I, Miettinen K</AU>
<TI>The effects of metoclopramide on postoperative nausea and bowel function</TI>
<SO>Annales chirurgiae et gynaecologiae Fenniae.</SO>
<YR>1970</YR>
<VL>59</VL>
<NO>3</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreis-2001" NAME="Kreis 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreis M E, Kasparek M, Zittel T T, Becker H D, Jehle E C</AU>
<TI>Neostigmine increases postoperative colonic motility in patients undergoing colorectal surgery.</TI>
<SO>Surgery</SO>
<YR>2001</YR>
<VL>130</VL>
<NO>3</NO>
<PG>449-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lykkegaard_x002d_Nielsen" NAME="Lykkegaard-Nielsen" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lykkegaard-Nielsen M, Madsen PV, Nielsen OV</AU>
<TI>Ceruletide vs. metoclopramide in postoperative intestinal paralysis. A double-blind clinical trial</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>5</NO>
<PG>288-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsen-1983" NAME="Madsen 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen PV, Lykkegaard-Nielsen M, Nielsen OV</AU>
<TI>Ceruletide reduces postoperative intestinal paralysis. A double-blind placebo-controlled trial</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>3</NO>
<PG>159-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsen-1986" NAME="Madsen 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen PV, Olsen O, Hagen K</AU>
<TI>Ceruletide and neostigmine in postoperative intestinal paralysis. A double-blind clinical controlled trial</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>11</NO>
<PG>712-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrh_x00f6_j-1988" NAME="Myrhöj 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrhöj T, Olsen O, Wengel B</AU>
<TI>Neostigmine in postoperative intestinal paralysis. A double-blind, clinical, controlled trial</TI>
<SO>Diseases of the colon and rectum.</SO>
<YR>1988</YR>
<VL>31</VL>
<NO>5</NO>
<PG>378-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nio-1980" NAME="Nio 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nio Y, Nitta N, Tanaka A, Kikuchi S, Nakamoto K, Henmi K</AU>
<TI>[Clinical evaluation of prostaglandin F2 alpha (PGF2 alpha) for the postoperative ileus after major abdominal surgery (author's transl)]</TI>
<SO>Nippon Geka Hokan</SO>
<YR>1980</YR>
<VL>49</VL>
<NO>4</NO>
<PG>506-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noblett-2006" NAME="Noblett 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF</AU>
<TI>Pre-operative oral carbohydrate loading in colorectal surgery: A randomized controlled trial</TI>
<SO>Colorectal Disease</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>7</NO>
<PG>563-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olesen-1985" NAME="Olesen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olesen KL, Olsen O, Blaabjerg I</AU>
<TI>[Postoperative intestinal atony. A randomized study of the effect of morphine and pethidine]</TI>
<TO>Postoperativ tarmatoni. En randomiseret undersøgelse af effekten af morfin og petidin.</TO>
<SO>Ugeskrift for laeger.</SO>
<YR>1985</YR>
<VL>147</VL>
<NO>11</NO>
<PG>955-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-1985" NAME="Olsen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen O, Hakansson T, Forrest J I</AU>
<TI>Bisakodyl til postoperativ tarmatoni. [Bisocadyl in the treatment of postoperative intestinal atony]</TI>
<SO>Ugeskr Laeger</SO>
<YR>1985</YR>
<VL>147</VL>
<NO>39</NO>
<PG>3070-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruppin-1976" NAME="Ruppin 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruppin H, Kirndörfer D, Domschke S, Domschke W, Schwemmle K, Wünsch E, Demling L</AU>
<TI>Effect of 13-Nle-motilin in postoperative ileus patients: a double-blind trial</TI>
<SO>Scandinavian journal of gastroenterology. Supplement.</SO>
<YR>1976</YR>
<VL>39</VL>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2001" NAME="Schmidt 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt WK</AU>
<TI>Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist</TI>
<SO>American journal of surgery.</SO>
<YR>2001</YR>
<VL>182</VL>
<NO>5A Suppl</NO>
<PG>27S-38S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seta-2001" NAME="Seta 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seta M L, Kale Pradhan P B</AU>
<TI>Efficacy of metoclopramide in postoperative ileus after exploratory laparotomy.</TI>
<SO>Pharmacotherapy</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1181-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinatra-2006" NAME="Sinatra 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinatra RS, Boice JA, Loeys TL, Ko AT, Kashuba MM, Jahr JS, Rhondeau S, Singla N, Cavanaugh Jr PF, Reicin AS</AU>
<TI>Evaluation of the effect of perioperative rofecoxib treatment on pain control and clinical outcomes in patients recovering from gynecologic abdominal surgery: A randomized, double-blind, placebo-controlled clinical study</TI>
<SO>Regional Anesthesia and Pain Medicine</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2</NO>
<PG>134-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thunedborg-1993" NAME="Thunedborg 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thunedborg LP, Thygesen V</AU>
<TI>[Effect of oxytocin on postoperative intestinal atonia after open cholecystectomy]</TI>
<TO>Effekten af oxytocin på postoperativ tarmatoni efter åben kolecystektomi.</TO>
<SO>Ugeskrift for laeger.</SO>
<YR>1993</YR>
<VL>155</VL>
<NO>44</NO>
<PG>3571-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Berge-1997" NAME="van Berge 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Berge Henegouwen MI, van Gulik TM, Akkermans LM, Jansen JB, Gouma DJ</AU>
<TI>The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers</TI>
<SO>Gut.</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>6</NO>
<PG>758-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-2007" NAME="Wolff 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff BG, Weese JL, Ludwig KA, Delaney CP, Stamos MJ, Michelassi F, Du W, Techner L</AU>
<TI>Postoperative Ileus-Related Morbidity Profile in Patients Treated with Alvimopan after Bowel Resection</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2007</YR>
<VL>204</VL>
<NO>4</NO>
<PG>609-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Asimadoline" NAME="Asimadoline" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<TI>Asimadoline for the treatment of post-operative ileus</TI>
<TO>A randomized, double-blind, placebo-controlled study evaluating asimadoline on the duration of PO in subjects undergoing laparoscopic/hand-assisted lap segmental colonic resection secondary to colon cancer, polypectomy or diverticulitis</TO>
<SO>Information obtained from Clinical Trails.gov on June 26, 2007</SO>
<YR>Record first received February 27, 2007</YR>
<CY>Massachusetts, United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study ID numbers: ASMP2004, ClinicalTrails.gov identifier: NCT00443040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lidocaine" NAME="Lidocaine" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caveno J, Charapov I, Bryson G, Reid D</AU>
<TI>Intraoperative Lidocaine Infusion for Analgesia (ILIA)</TI>
<TO>A Prospective Evaluation of the Addition of Intraoperative Intravenous Lidocaine Infusion to General Anesthetic in Total Abdominal Hysterectomy.</TO>
<SO>Information obtained from ClinicalTrials.gov on June 26, 2007</SO>
<YR>Record first received September 28, 2006</YR>
<CY>Ontario, Kanada</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study ID numbers: #2006512-01H, ClinicalTrails.gov identifier: NCT00382499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lidocaine_x002f_Ketamin" NAME="Lidocaine/Ketamin" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKay, W PS</AU>
<TI>Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function</TI>
<TO>A Randomised Controlled Trial of Lidocaine Infusion Plus Ketamine Injection Versus Placebo to Decrease Postoperative Ileus</TO>
<SO>Information obtained from ClinicalTrails.gov on June 26, 2007</SO>
<CY>Sakatchewan, Canada</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study ID numbers: Bio-REB 03-1316, ClinicalTrials.gov identifier: NCT00229567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Methylnaltrexone" NAME="Methylnaltrexone" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<TI>Study of intravenous (iv) methylnaltrexone bromide (MNTX) in the treatment of post-operative ileus (POI)</TI>
<TO>A phase III, double blind, randomized, parallel-group, placebo-controlled study of intravenous (iv) methylnaltrexone bromide (MNTX) in the treatment of post-operative ileus (POI)</TO>
<SO>Information obtained from ClinicalTrails.gov on June 26,2007</SO>
<YR>Record first received: November 16, 2006</YR>
<CY>New York, United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study ID numbers: MNTX 3301, ClinicalTrails.gov identifier: NCT00401375"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Barbey-2000" NAME="Barbey 2000" NOTES="&lt;p&gt;Times Cited: 3&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Barbey JT, Lazzara R, Zipes DP</AU>
<TI>Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride: An ongoing independent case review</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>4</NO>
<PG>A14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1997" NAME="Barnes 1997" NOTES="&lt;p&gt;Barnes J, Resch KL, Ernst E. Homeopathy for postoperative ileus? A meta-analysis. J Clin Gastroenterol 1997; 25(4):628-633.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Barnes J, Resch KL, Ernst E</AU>
<TI>Homeopathy for postoperative ileus? A meta-analysis</TI>
<SO>J Clin Gastroenterol</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>4</NO>
<PG>628-633</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-2000" NAME="Buckley 2000" NOTES="&lt;p&gt;Buckley CJ, Lee SD, Arko FR, Bohannon WT, Mettauer M, Patterson DE et al. Economic considerations for aortic surgery: retroperitoneal approach--is it worth it? Acta Chir Belg 2000; 100(6):247-250.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Buckley CJ, Lee SD, Arko FR, Bohannon WT, Mettauer M, Patterson DE et al</AU>
<TI>Economic considerations for aortic surgery: retroperitoneal approach--is it worth it?</TI>
<SO>Acta Chir Belg</SO>
<YR>2000</YR>
<VL>100</VL>
<NO>6</NO>
<PG>247-250</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bungard-1999" NAME="Bungard 1999" NOTES="&lt;p&gt;Times Cited: 26&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bungard TJ, Kale-Pradhan PB</AU>
<TI>Prokinetic agents for the treatment of postoperative ileus in adults: A review of the literature</TI>
<SO>Pharmacotherapy</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>4</NO>
<PG>416-423</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cali-2000" NAME="Cali 2000" NOTES="&lt;p&gt;Cali RL, Meade PG, Swanson MS, Freeman C. Effect of Morphine and incision length on bowel function after colectomy. Dis Colon Rectum 2000; 43(2):163-168.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cali RL, Meade PG, Swanson MS, Freeman C</AU>
<TI>Effect of Morphine and incision length on bowel function after colectomy</TI>
<SO>Dis Colon Rectum</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>2</NO>
<PG>163-168</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1996" NAME="Carpenter 1996" NOTES="&lt;p&gt;Times Cited: 13&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter RL</AU>
<TI>Gastrointestinal benefits of regional anesthesia analgesia</TI>
<SO>Regional Anesthesia</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>6</NO>
<PG>13-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="54"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chang-2002" NAME="Chang 2002" NOTES="&lt;p&gt;Chang SS, Baumgartner RG, Wells N, Cookson MS, Smith JA, Jr. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol 2002; 167(1):208-211.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chang SS, Baumgartner RG, Wells N, Cookson MS, Smith JA, Jr</AU>
<TI>Causes of increased hospital stay after radical cystectomy in a clinical pathway setting</TI>
<SO>J Urol</SO>
<YR>2002</YR>
<VL>167</VL>
<NO>1</NO>
<PG>208-211</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clin.-Consensus-2006" NAME="Clin. Consensus 2006" TYPE="CONFERENCE_PROC">
<AU>Delaney CP, Leslie JB, Marks J, Steinbrook RA, Kehlet H, Senagore AJ, Bauer AJ, Beart R, Billingham R, Coleman RL, Dozois EJ, Megibow AJ, Michelassi F</AU>
<TI>Clinical Consensus Update® in General Surgery, postoperative ileus: profiles, risk factors, and definitions-a framework for optimizing surgical outcomes in patients undergoing major abdominal and colorectal surgery</TI>
<SO>Pharmatecture, LLC</SO>
<YR>2006</YR>
<CY>Roswell</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-1954" NAME="Cochrane 1954" NOTES="&lt;p&gt;http://links.jstor.org/sici?sici=0006-341X%28195403%2910%3A1%3C101%3ATCOEFD%3E2.0.CO%3B2-D &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cochran William G.</AU>
<TI>The combination of estimates from different experiments</TI>
<SO>Biometrics</SO>
<YR>March 1954</YR>
<VL>10</VL>
<NO>1</NO>
<PG>101-129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks--2001" NAME="Deeks  2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>BMJ Publishing: Systematic reviews in health care: meta-analysis in context. 2 ed</SO>
<YR>2001</YR>
<PG>285-312</PG>
<EN>2nd</EN>
<PB>Egger M, Smith GD, Altman DG</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-1291</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dubois-1974" NAME="Dubois 1974" NOTES="&lt;p&gt;Times Cited: 26&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dubois A, Kopin IJ, PETTIGRE.KD, JACOBOWI.DM</AU>
<TI>Chemical and Histochemical Studies of Postoperative Sympathetic Activity in Digestive-Tract in Rats</TI>
<SO>Gastroenterology</SO>
<YR>1974</YR>
<VL>66</VL>
<NO>3</NO>
<PG>403-407</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2006" NAME="FDA 2006" TYPE="OTHER">
<AU>U.S. Food and Drug Administration</AU>
<TI>How To Obtain Domperidone (updated 6 September 2006)</TI>
<SO>http://www.fda.gov/cder/news/domperidone.htm</SO>
<YR>assessed 12 July 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowler-2006" NAME="Fowler 2006" NOTES="&lt;p&gt;Times Cited: 18&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fakenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE</AU>
<TI>Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>7</NO>
<PG>653-665</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="62"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frantzides-1992" NAME="Frantzides 1992" NOTES="&lt;p&gt;Frantzides CT, Cowles V, Salaymeh B, Tekin E, Condon RE. Morphine effects on human colonic myoelectric activity in the postoperative period. Am J Surg 1992; 163(1):144-148.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Frantzides CT, Cowles V, Salaymeh B, Tekin E, Condon RE</AU>
<TI>Morphine effects on human colonic myoelectric activity in the postoperative period</TI>
<SO>Am J Surg</SO>
<YR>1992</YR>
<VL>163</VL>
<NO>1</NO>
<PG>144-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedrich-2005" NAME="Friedrich 2005" NOTES="&lt;p&gt;Times Cited: 20&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Friedrich JO, Adhikari N, Herridge MS, Beyene J</AU>
<TI>Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2005</YR>
<VL>142</VL>
<NO>7</NO>
<PG>510-524</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="49"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" NOTES="&lt;p&gt;Times Cited: 5&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="50"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2007" NAME="Goldstein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein JL, Matuszewski KL, Delaney CP, Senagore A, Chiao EF, Shah M, Meyer K, Bramley T</AU>
<TI>Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States</TI>
<SO>P&amp;T (Pharmacy and Therapeutics)</SO>
<YR>February 2007</YR>
<VL>32</VL>
<NO>2</NO>
<PG>82-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood_x002d_Van-2004" NAME="Greenwood-Van 2004" NOTES="&lt;p&gt;Times Cited: 11&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL</AU>
<TI>Preclinical studies of opioids and opioid antagonists on gastrointestinal function</TI>
<SO>Neurogastroenterology and Motility</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>46-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Groudine-1994" NAME="Groudine 1994" NOTES="&lt;p&gt;Times Cited: 3&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Groudine S, Wilkins L</AU>
<TI>Epidural Drugs Also Act Systemically</TI>
<SO>Anesthesiology</SO>
<YR>1994</YR>
<VL>81</VL>
<NO>3</NO>
<PG>787</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="55"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herbert-2002" NAME="Herbert 2002" NOTES="&lt;p&gt;Manuskript nach einem Vortrag bei der 15. Irseer Fortbildungsveranstaltung der DGEM, 27.10.2001&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Herbert MK</AU>
<TI>Impairment of gastrointestinal motility in the critically ill patient and therapeutic options</TI>
<TO>Störungen der Magen-Darm-Motilität beim Intensivpatienten und deren Therapie</TO>
<SO>Aktuel Ernaehr Med</SO>
<YR>2002</YR>
<VL>27</VL>
<PG>13-22</PG>
<PB>Georg Thieme Verlag Stuttgart</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1434-0275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heritier-2003" NAME="Heritier 2003" NOTES="&lt;p&gt;Times Cited: 20&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Heritier SR, Gebski VJ, Keech AC</AU>
<TI>Inclusion of patients in clinical trial analysis: the intention-to-treat principle</TI>
<SO>Medical Journal of Australia</SO>
<YR>2003</YR>
<VL>179</VL>
<NO>8</NO>
<PG>438-440</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" NOTES="&lt;p&gt;Times Cited: 367&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-1558</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="47"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;Times Cited: 632&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-560</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="48"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jorgensen-2000" NAME="Jorgensen 2000" NOTES="&lt;p&gt;Jorgensen H, Wetterslev J, Moiniche S, Dahl JB. Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev 2000;(4):CD001893.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen H, Wetterslev J, Moiniche S, Dahl JB</AU>
<TI>Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery</TI>
<SO>Cochrane Database Syst Rev.</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>CD001893</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalff-1998" NAME="Kalff 1998" NOTES="&lt;p&gt;Kalff JC, Schraut WH, Simmons RL, Bauer AJ. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg 1998; 228(5):652-663.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kalff JC, Schraut WH, Simmons RL, Bauer AJ</AU>
<TI>Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus</TI>
<SO>Ann Surg</SO>
<YR>1998</YR>
<VL>228</VL>
<NO>5</NO>
<PG>652-663</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalff-1999" NAME="Kalff 1999" NOTES="&lt;p&gt;Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus. Gastroenterology 1999; 117(2):378-387.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ</AU>
<TI>Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>2</NO>
<PG>378-387</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keene-2002" NAME="Keene 2002" NOTES="&lt;p&gt;Times Cited: 4&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Keene ON</AU>
<TI>Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>23</NO>
<PG>3687-3700</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="56"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kehlet-2001" NAME="Kehlet 2001" NOTES="&lt;p&gt;Kehlet H, Holte K. Review of postoperative ileus. Am J Surg 2001; 182(5A Suppl):3S-10S.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kehlet H, Holte K</AU>
<TI>Review of postoperative ileus</TI>
<SO>Am J Surg</SO>
<YR>2001</YR>
<VL>182</VL>
<NO>5A Suppl</NO>
<PG>3S-10S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kehlet-2006" NAME="Kehlet 2006" NOTES="&lt;p&gt;Times Cited: 8&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kehlet H, Buchler MW, Beart RW, Billingham RP, Williamson R</AU>
<TI>Care after colonic operation - Is it evidence-based? Results from a multinational survey in Europe and the United States</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2006</YR>
<VL>202</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kerbl-1994" NAME="Kerbl 1994" NOTES="&lt;p&gt;Kerbl K, Clayman RV, McDougall EM, Gill IS, Wilson BS, Chandhoke PS et al. Transperitoneal nephrectomy for benign disease of the kidney: a comparison of laparoscopic and open surgical techniques. Urology 1994; 43(5):607-613.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kerbl K, Clayman RV, McDougall EM, Gill IS, Wilson BS, Chandhoke PS et al</AU>
<TI>Transperitoneal nephrectomy for benign disease of the kidney: a comparison of laparoscopic and open surgical techniques</TI>
<SO>Urology</SO>
<YR>1994</YR>
<VL>43</VL>
<NO>5</NO>
<PG>607-613</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Layton-2003" NAME="Layton 2003" NOTES="&lt;p&gt;Times Cited: 12&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Layton D, Key C, Shakir SAW</AU>
<TI>Prolongation of them QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>1</NO>
<PG>31-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liu-1995" NAME="Liu 1995" NOTES="&lt;p&gt;Times Cited: 352&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Liu S, Carpenter RL, Neal JM</AU>
<TI>Epidural-Anesthesia and Analgesia - Their Role in Postoperative Outcome</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>82</VL>
<NO>6</NO>
<PG>1474-1506</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="53"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lobo-2002" NAME="Lobo 2002" NOTES="&lt;p&gt;Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet 2002; 359(9320):1812-1818.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP</AU>
<TI>Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9320</NO>
<PG>1812-1818</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luckey-2003" NAME="Luckey 2003" NOTES="&lt;p&gt;Times Cited: 39&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Luckey A, Livingston E, Tache Y</AU>
<TI>Mechanisms and treatment of postoperative ileus</TI>
<SO>Archives of Surgery</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>2</NO>
<PG>206-214</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mann-2000" NAME="Mann 2000" NOTES="&lt;p&gt;Mann C, Pouzeratte Y, Boccara G, Peccoux C, Vergne C, Brunat G et al. Comparison of intravenous or epidural patient-controlled analgesia in the elderly after major abdominal surgery. Anesthesiology 2000; 92(2):433-441.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mann C, Pouzeratte Y, Boccara G, Peccoux C, Vergne C, Brunat G et al</AU>
<TI>Comparison of intravenous or epidural patient-controlled analgesia in the elderly after major abdominal surgery</TI>
<SO>Anesthesiology</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>2</NO>
<PG>433-441</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" NOTES="&lt;p&gt;Times Cited: 639&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9263</NO>
<PG>1191-1194</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="61"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1989" NAME="Moore 1989" NOTES="&lt;p&gt;Times Cited: 423&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moore FA, Moore EE, Jones TN, Mccroskey BL, Peterson VM</AU>
<TI>Ten Versus Tpn Following Major Abdominal-Trauma - Reduced Septic Morbidity</TI>
<SO>Journal of Trauma-Injury Infection and Critical Care</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>7</NO>
<PG>916-923</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1992" NAME="Moore 1992" NOTES="&lt;p&gt;Times Cited: 556&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moore FA, Feliciano DV, Andrassy RJ, Mcardle AH, Booth FVM, Morgensteinwagner TB, Kellum JM, Welling RE, Moore EE</AU>
<TI>Early Enteral Feeding, Compared with Parenteral, Reduces Postoperative Septic Complications - the Results of A Metaanalysis</TI>
<SO>Annals of Surgery</SO>
<YR>1992</YR>
<VL>216</VL>
<NO>2</NO>
<PG>172-183</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NHS-CRD-2001" NAME="NHS CRD 2001" TYPE="OTHER">
<AU>NHS CRD 2001</AU>
<TI>Undertaking Systematic Reviews of Research on Effectiveness (CRD Report 4, 2nd Edition)</TI>
<SO>NHS Centre for Reviews and Dissemination. York: The University of York.</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peeters-1993" NAME="Peeters 1993" NOTES="&lt;p&gt;Times Cited: 147&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Peeters TL</AU>
<TI>Erythromycin and Other Macrolides As Prokinetic Agents</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>105</VL>
<NO>6</NO>
<PG>1886-1899</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="64"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Resnick-1997_x0028_1_x0029_" NAME="Resnick 1997(1)" NOTES="&lt;p&gt;Times Cited: 32&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Resnick J, Greenwald DA, Brandt LJ</AU>
<TI>Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery .2</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>6</NO>
<PG>934-940</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Resnick-1997_x0028_2_x0029_" NAME="Resnick 1997(2)" NOTES="&lt;p&gt;Times Cited: 30&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Resnick J, Greenwald DA, Brandt LJ</AU>
<TI>Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery .1</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>5</NO>
<PG>751-762</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" NAME="Robinson 2002" NOTES="&lt;p&gt;Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31(1):150-153.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>Int J Epidemiol</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-153</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwenk-2005" NAME="Schwenk 2005" TYPE="COCHRANE_REVIEW">
<AU>Schwenk W, Haase O, Neudecker J, Müller JM</AU>
<TI>Short term benefits for laparoscopic colorectal resection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="DOI: 10.1002/14651858"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD003145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Senn-1997" NAME="Senn 1997" TYPE="BOOK">
<AU>Senn S</AU>
<SO>Statistical issues in drug development</SO>
<YR>1997</YR>
<PB>Wiley</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2007" NAME="Tan 2007" NOTES="&lt;p&gt;Times Cited: 0&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tan EK, Cornish J, Darzi AW, Tekkis PP</AU>
<TI>Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>1</NO>
<PG>47-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tonini-1999" NAME="Tonini 1999" NOTES="&lt;p&gt;Times Cited: 57&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tonini M, De Ponti F, Di Nucci A, Crema F</AU>
<TI>Review article: cardiac adverse effects of gastrointestinal prokinetics</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1585-1591</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="57"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wattwil-1989" NAME="Wattwil 1989" NOTES="&lt;p&gt;Wattwil M, Thoren T, Hennerdal S, Garvill JE. Epidural analgesia with bupivacaine reduces postoperative paralytic ileus after hysterectomy. Anesth Analg 1989; 68(3):353-358.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wattwil M, Thoren T, Hennerdal S, Garvill JE</AU>
<TI>Epidural analgesia with bupivacaine reduces postoperative paralytic ileus after hysterectomy</TI>
<SO>Anesth Analg</SO>
<YR>1989</YR>
<VL>68</VL>
<NO>3</NO>
<PG>353-358</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weber-1993" NAME="Weber 1993" NOTES="&lt;p&gt;Times Cited: 61&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Weber FH, Richards RD, Mccallum RW</AU>
<TI>Erythromycin - A Motilin Agonist and Gastrointestinal Prokinetic Agent</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>4</NO>
<PG>485-490</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-www.biospace.com" NAME="www.biospace.com" TYPE="OTHER">
<AU>Biospace an onTargetjobs company</AU>
<TI>Bowel Drug Linked to Heart Risk; Halting Studies</TI>
<SO>http://www.biospace.com/news_story.aspx?StoryID=51757&amp;full=1</SO>
<YR>accessed 15 August 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Altaparmakov-1984">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, details not reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Unclear, Bulgaria, Germany<BR/>Number eligible: Not stated<BR/>Number enrolled: 46<BR/>Number in intervention group: 23<BR/>Number in control group: 23<BR/>Number of withdrawals: Not reported<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Dihydroergotamine with Heparin<BR/>Dose: 0.5mg and 5000IE<BR/>Administration:<BR/> - Route: 12 hours interval, Heparin subcutaneous administration<BR/> - Start: 1. POD<BR/> - Duration: 5 days<BR/>Control: 5000IE Heparin subcutaneous<BR/>Planned follow up duration: 5 days<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Time to passage of first bowel movement<BR/>Occurrence of Bowel Sounds<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>POI defined as postoperative gut motility depressed<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Alvarez-1979">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Not reported<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Mexico<BR/>Number eligible: Not stated<BR/>Number enrolled: 50<BR/>Number in intervention group: 25<BR/>Number in control group: 25<BR/>Number of withdrawals: Not reported<BR/>Inclusion criteria: Abdominal surgery<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Cholecystectomy, vagotomy, pylorolplasty, hernioplasty, adhesiolysis, explorative laparotomy, appendectomy, gastrectomy, exploration biliary tract, jejunal bypass, <BR/> pseudocystogastrostomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cerulein<BR/>Dose: 0.3mcg/kg body weight<BR/>Administration:<BR/> - Route: 4h interval, intravenous administration<BR/> - Start: 1. POD, 1h after operation<BR/> - Duration: Maximum of 33h<BR/>Control: No treatment<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first bowel sounds<BR/>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time to first oral intake<BR/>Length of hospital stay<BR/>Time to first mobilization out of bed<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Benson-1994">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Single blind, outcome assessor blinded<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, United Kingdom<BR/>Number eligible: Not stated<BR/>Number enrolled: 29<BR/>Number in intervention group: 13 (11)<BR/>Number in control group: 16 (12)<BR/>Number of withdrawals (intervention/placebo): 2/4<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Previous abdominal surgery (exception: appendectomy, herniorrhaphy), disease or medication associated with alteration of the gastrointestinal motility<BR/>Type of surgery: Major abdominal surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 30mg<BR/>Administration:<BR/> - Route: 8 hours interval, rectal administration<BR/> - Start: 1. POD<BR/> - Duration: Maximum of 92 hours<BR/>Control: Placebo<BR/>Planned follow up duration: Until first flatus or 92 hours<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Meperidin bolus, intravenous; Meperidin infusion, subcutaneous (1.0mg/kg over 3 hours)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Contious manometric recording<BR/>Time to passage of first flatus<BR/>Occurrence of bowel sounds<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted from figures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bonacini-1993">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: After surgery<BR/>Blinding: Double blind, Surgical staff blinded<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 80<BR/>Number in intervention group: 41 (41)<BR/>Number in control group: 39 (36)<BR/>Number of withdrawals: 3 - allocation stated<BR/>Inclusion criteria: Operations that involved the opening of the peritoneal cavity<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Standard open cholecystectomy, celiotomy, major operation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Erythromycin<BR/>Dose: 250mg<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: 3 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until resolution of 'ileus symptoms'<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Meperidine, application form unclear<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Time to first tolerated oral intake<BR/>Length of hospital stay<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brown-1999">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Sealed opaque envelopes, numbered medication kits distributed by pharmacy<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, patient and care giver blinded<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 35<BR/>Number in intervention group: 17<BR/>Number in control group: 18<BR/>Number of withdrawals: Not reported<BR/>Inclusion criteria: Elective or emergent colorectal surgery with resection of a portion of the large bowel<BR/>Exclusion criteria: Extraintestinal surgery, preoperative intestinal motility disorder, diabetes with known gastroparesis<BR/>Type of surgery: Left and right hemicolectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 20mg<BR/>Administration:<BR/> - Route: 6 hour interval, oral administration<BR/> - Start: 1. POD<BR/> - Duration: Until hospital discharge<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to regular diet intake<BR/>Length of hospital stay<BR/>Hospital cost analysis<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Military population</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cheape-1991">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre, USA<BR/>Number eligible: 100<BR/>Number enrolled: 93<BR/>Number in intervention group: 40<BR/>Number in control group: 53<BR/>Number of withdrawals (intervention/placebo): 3/4<BR/>Inclusion criteria: Major elective intraabdominal colorectal surgery<BR/>Exclusion criteria: Need for 2nd laparotomy, improper dose/interval of metoclopramide administration, insertion/ removal of the nasogastric tube, death<BR/>Type of surgery: Abdominal/segmental colectomy , abdominoperineal resection, ileoanal reservoir, small bowel resection, relocation of stoma, colostomy creation, stricturoplasty, rectopexy,<BR/> gastrocolic fistula resection, colocutaneous fistula resection<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Metoclopramide<BR/>Dose: 10 mg<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: Day of operation<BR/> - Duration: Until regular diet was tolerated<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to toleration of regular diet<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Prolonged ileus defined as an ileus greater than 7 days duration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clevers-1991">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, The Netherlands<BR/>Number eligible: Not stated<BR/>Number enrolled: 40<BR/>Number in intervention group: 19 (17)<BR/>Number in control group: 21 (20)<BR/>Number of withdrawals (intervention/placebo): 2/1<BR/>Inclusion criteria: Elective major surgery- developing moderate or severe nausea or vomiting in the postoperative days<BR/>Exclusion criteria: Operation of esophagus, stomach, emergency surgery, intrabdominal infections, intestinal obstruction<BR/>Type of surgery: Elective major abdominal surgery (colonic surgery, abdominal vascular surgery, various abdominal procedures)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 30 mg<BR/>Administration:<BR/> - Route: 6 hour interval, rectal administration<BR/> - Start: unclear <BR/> - Duration: Maximum 48 hours<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported <BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA, GA with epidural anaesthesia<BR/>Type of analgesia: Morphine, epidural anaesthesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time to tolerance of normal diet<BR/>Time to mobilization out of bed<BR/>Occurrence of bowel sounds<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Conte-1983">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Italy<BR/>Number eligible: Not stated<BR/>Number enrolled: 166<BR/>Number in intervention group: 86 (84)<BR/>Number in control group: 80<BR/>Number of withdrawals(intervention/no treatment): 2/0<BR/>Inclusion criteria: Major/minor abdominal surgery-with or without opening of the gastrointestinal tract<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Appendectomy, cholecystectomy, herniotomy, gastric resection, cholecystojejunostomy, laparocele, hemicolectomy, intrahepatoduodenogastrojejunostomy, fistula biliodigestive, hyster- and adnexectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Bromopride<BR/>Dose: 20 mg<BR/>Administration:<BR/> - Route: 14h/20h (1. POD)- 6/14/22h (2.POD), intramuscular administration<BR/> - Start: Day of operation<BR/> - Duration: 2 days<BR/>Control: No treatment<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus or stool (canalization time)<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Delaney-2005">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Stratified by type of surgery, (1:1:1 ratio) <BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No- stated MITT-population*<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Multi centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 451<BR/>Number in intervention (6 mg) group: 152 (141)<BR/>Number in intervention (12 mg) group: 146 (138)<BR/>Number in control group: 153 (145)<BR/>Number excluded post randomisation (intervention A/intervention B/placebo): 27, allocation not stated <BR/>Inclusion criteria: Male or female between 18-80years undergo laparotomy (partial colectomy, total abdominal hysterectomy)<BR/>Exclusion criteria: Anterior resection, opioid taking within 4 weeks, severe cardiovascular, pulmonary., renal, hepatic, hematological, systemic disease, pregnancy, laboratory abnormalities, complete bowel obstruction, inflammatory bowel disease<BR/>Type of surgery: Partial colectomy, total abdominal hysterectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Alvimopan<BR/>Dose A: 6mg<BR/>Dose B: 12mg<BR/>Administration:<BR/> - Route: 2 hours before surgery, 12 hour interval, oral administration<BR/> - Start: On the day of surgery<BR/> - Duration: Until hospital discharge or maximum of 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until hospital discharge or maximum of 10 POD<BR/>Co-Medication for ileus allowed at discretion of the physician: Not allowed ('prophylactic antiemetics after surgery')<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Patient-controlled analgesia with opioids, intravenous<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GI-3<BR/>GI-2<BR/>Time to passage of first stool<BR/>Time to first tolerance of solid food<BR/>Length of hospital stay<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Modified intention to treat -population- all treated patients who received the protocol-specified surgeries of bowel resection or radical or simple hysterectomy and had one on-treatment primary efficacy evaluation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ferraz-2001">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Not reported<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Brazil<BR/>Number eligible: Not stated<BR/>Number enrolled: 35<BR/>Number in intervention group: 14 (12)<BR/>Number in control group: 21 (15)<BR/>Number of withdrawals(intervention/no treatment): 2/6<BR/>Inclusion criteria: Hepatosplenic schistosomiasis with indication of splenectomy<BR/>Exclusion criteria: Chronic diarrhea or constipation, autoimmune disease., inflammatory bowel disease., diverticular disease, diabetes mellitus, chagas disease, drug use (laxatives, constipants, antidepressive drugs, calcium-channelblockers), contraindication to propranolol use<BR/>Type of surgery: Splenectomy, division of left gastric vein, postoperative endoscopic sclerosis of oesophageal varices <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Propranolol<BR/>Dose: 40 mg<BR/>Administration:<BR/> - Route: Initially 40mg, dose adjustment to achieve decrease in cardiac frequency, oral administration<BR/> - Start: Prior to operation<BR/> - Duration: Until decrease of 20% in cardiac frequency<BR/>Control: No treatment<BR/>Planned follow up duration: Until clinical recovery of ileus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Tenoxicam<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus or stool<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Precise timing of drug initiation unclear. Dose range 80-160mg</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ferreira-1980">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: After surgery<BR/>Blinding: Not reported<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Spain<BR/>Number eligible: Not stated<BR/>Number enrolled: 60<BR/>Number in intervention group: 30 (29)<BR/>Number in control group: 30<BR/>Number of withdrawals(intervention/no treatment): 1/0 - allocation stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Laparotomy and surgical procedures not involving the digestive tube (gall-bladder, spleen), gastrostomy, duodenotomy, hiatal hernia repair, and surgical procedures involving the digestive tube<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cerulein<BR/>Dose: 2ng/kg/min<BR/>Administration:<BR/> - Route: Single dose, intravenous administration<BR/> - Start: 24 hours after surgery<BR/>Control: No treatment<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time of restoration of peristalsis and removal of nasogastric tube<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Stratified reporting of results in patients with and patients without bowel resection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Frisell-1985">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Patients were consecutively numbered, each number corresponded to box containing a set of coded vials for infusion <BR/>Time point of randomisation: After surgery<BR/>Blinding: Double blind, patient and care giver were blinded<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 60<BR/>Number in intervention group: 30 (27)<BR/>Number in control group: 30<BR/>Number of withdrawals (intervention/placebo): 3- allocation stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Previous abdominal surgery (except appendectomy), history of laxatives<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cholecystokinin<BR/>Dose: 75 IDU 10 ml<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: 2 days<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time to evaluate barium contrast medium in the caecum<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Garcia-1993">
<CHAR_METHODS>
<P>Design: Parallel group RCT <BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Spain<BR/>Number eligible: Not stated<BR/>Number enrolled: 100-included, 96 analysed<BR/>Number in intervention group: 20 (17)<BR/>Number in control group: 20<BR/>Number of withdrawals(intervention/ no treatment): 3/0<BR/>Inclusion criteria: Patients with cholecystolithiasis<BR/>Exclusion criteria: Treatment with digitalis or verapamil, history of cardiac insufficiency or impairment, hypotension or bradycardia, insulin-dependent diabetes, chronic bronchitis, obstructive peripheral arteriopathy<BR/>Type of surgery: Elective cholecystectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug A: Propranolol <BR/>Trial drug B: Neostigmine<BR/> - Dose A: 7.5mg iv or 80mg oral<BR/> - Dose B: 0.5mg<BR/>Administration:<BR/> - Route A and B: 8 hour interval if intravenous administration; 12 hour interval if oral administration, 12 hour interval, subcutaneous administration<BR/> - Start: Day of operation<BR/> - Duration: Until passage of flatus or stool<BR/>Control: No treatment<BR/>Planned follow up duration: Until passage of first stool<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Magnesium noramidopirinometasulphate (NSAID) 6g/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Occurrence of bowel sounds<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Allocation in 5 groups:<BR/>I: Control: conventional cholecystectomy (CC), no additional treatment<BR/>II: CC with intraoperative local injection 20ml 0.5% bupivacaine<BR/>III: CC with postoperative instilling of 7.5mg propranolol/8h i.v. and 0.5mg of neostigmine/12h s.c.<BR/>IV: II+III<BR/>V: Laparoscopic cholecystectomy without additional treatment<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Groudine-1998">
<CHAR_METHODS>
<P>Design: Parallel group RCT <BR/>Randomisation: Quasi-randomisation (even-numbered intervention, odd-numbered control)<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, nursing staff, surgeons and patients<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 40<BR/>Number in intervention group: 19 (18)<BR/>Number in control group: 20<BR/>Number of withdrawals (intervention/placebo): 2/0<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Preexisting disorder of the gastrointestinal tract, using of enemas, opioids, anticholinergic medication chronically, ASA physical Status &gt; III<BR/>Type of surgery: Radical retropubic prostatectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Lidocaine <BR/>Dose: 1.5 mg/kg bolus, infusion 3mg/min &gt;70kg, 2mg/min &lt;70kg<BR/>Administration:<BR/> - Route: Until 60 minutes after end of operation, intravenous administration<BR/> - Start: With operation<BR/> - Duration: 60 minutes<BR/>Control: Placebo<BR/>Planned follow up duration: Until hospital discharge<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anesthesia: GA<BR/>Type of analgesia: Ketorolac bolus 30mg, 15mg/6 hours, intravenous; Morphine, no further details available<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Length of hospital stay<BR/>Amount of analgesia used<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only male patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hakansson-1985">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: After surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Denmark<BR/>Number eligible: Not stated<BR/>Number enrolled: 60<BR/>Number in intervention group: 30<BR/>Number in control group: 30<BR/>Number of withdrawals(intervention/no treatment): Not reported<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Uremia, cardial, pulmonary disease, neurological disorder, mental retardation<BR/>Type of surgery: Elective abdominal surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Vasopressin<BR/>Dose: 10IE<BR/>Administration:<BR/> - Route: 4 hour interval, intramuscular administration<BR/> - Start: 1. POD<BR/> - Duration: Until passage of first flatus<BR/>Control: No treatment<BR/>Planned follow up duration: Until passage of first flatus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 62<BR/>Number in intervention group A: 21 (16)<BR/>Number in intervention group B: 22 (18)<BR/>Number in control group: 19 (17)<BR/>Number of withdrawals(intervention A/intervention B/placebo): 5/4/2<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Obstructive pulmonary disease, cardiac decompensation, cardiac arrhythmias, pregnancy or lactation, insulin-treated diabetes, renal or hepatic insufficiency, treatment with beta-blocking agents, treatment with anticholinergic agents , choledochotomy and/or duodenotomy, postoperative peritonitis due to bile leakage or infection<BR/>Type of surgery: Elective cholecystectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug A: Propranolol and Neostigmine<BR/>Study drug B: Neostigmine<BR/> - Dose A: 10 mg, after occurrence of flatus: change to 80mg tablets<BR/> - Dose B: 0,5mg<BR/>Administration:<BR/> - Route A: both 12 hour interval, intravenous administration<BR/> - Route B: 12 hour interval, subcutaneous administration<BR/> - Start: Day of operation<BR/> - Duration: Until passage of first stool<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first stool<BR/>Co-Medication for ileus allowed at discretion of the physician: Not allowed (No enemas or laxatives were used before and after operation)<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Preanesthetic medication pethidine chloride 50mg, intramuscular<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool<BR/>Blood pressure and heart rate<BR/>Number of analgesic injections<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available. Allocation method to different propranolol dosages unclear<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 40<BR/>Number in intervention group A: 10<BR/>Number in intervention group B: 10<BR/>Number in control group: 19<BR/>Number of withdrawals(intervention A/ intervention B/placebo): 1-allocation stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Obstructive pulmonary disease, cardiac decompensation, cardiac arrhythmias, insulin-treated diabetes, renal or hepatic insufficiency, treatment with beta-blocking agents<BR/>Type of surgery: Elective colonic surgery <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Propranolol<BR/> - Dose A: 4mg, after occurrence of flatus changed to 40mg tablets<BR/> - Dose B: 10mg, after occurrence of flatus changed to 80mg tablets<BR/>Administration:<BR/> - Route A : 12 hour interval, intravenous administration<BR/> - Start A: 1. POD<BR/> - Start B: 30 minutes before operation<BR/> - Duration: Not reported<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first stool or flatus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not allowed ('laxative drugs, enemas after surgery')<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Occurrence of bowel sounds<BR/>Measurement of the abdominal circumference<BR/>Blood pressure and heart rate<BR/>Number of analgesic injections<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Outcome reporting stratified for age and type of surgery<BR/>Numbers in tables and text not consistent<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hallerb_x00e4_ck-1991">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Multi centre trial, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 74<BR/>Number in intervention group: 36<BR/>Number in control group: 33<BR/>Number of withdrawals (intervention/placebo): 2/3<BR/>Inclusion criteria: No bowel movement over 48h after completion of the operation<BR/>Exclusion criteria: Diabetes, previous operation with vagotomy, pregnancy or lactation, renal or hepatic insufficiency, severe pulmonary disease, cardiac decompensation, psychiatric disease or drug abuse, enterostomy, treatment with cholinergic or anticholinergic agents, treatment with adrenoceptor stimulating/blocking agents, postoperative complications (anastomotic leakage or intraabdominal sepsis), epidural anaesthesia<BR/>Type of surgery: Elective colonic surgery (fundoplicatio, gastric resection, cholecystectomy, choledochotomy, small/large bowel resection)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 30 mg<BR/>Administration:<BR/> - Route: 8 hour interval, rectal administration<BR/> - Start: 48 hours after surgery<BR/> - Duration: Until passage of stool, total of seven suppositories, maximum 56 hours<BR/>Control: Placebo <BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not allowed ('laxative drugs, enemas after surgery')<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Piritramine 10-15mg, intramuscular; Dextropropoxyohene 32.5mg, tablets; Paracetamol 0.325g, tablets<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first of stool<BR/>Number of analgesic injections<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Stratified reporting of results in patients with and patients without bowel resection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herzog-2006">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available (4:1 ratio)<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, investigators, research facility staff, clinical monitors and patients <BR/>Intention-to-treat analysis: No- stated MITT-population*<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Teaching Hospital, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 519<BR/>Number in intervention group: 413 (408)<BR/>Number in control group: 106 (102)<BR/>Number of withdrawals (intervention/placebo): 33/12<BR/>Inclusion criteria: Woman, age 18 or older, scheduled for patient controlled analgesia<BR/>Exclusion criteria: opioid exposure within two weeks before study entry, complete bowel obstruction, previous or planned colectomy, colostomy or ileostomy, increased risk of postoperative mortality<BR/>Type of surgery: Simple total abdominal hysterectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Alvimopan<BR/>Dose: 12mg<BR/>Administration:<BR/> - Route: 12 hours interval, oral administration<BR/> - Start: 1. POD<BR/> - Duration: Maximum 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: 30 days after the last dose of the study drug<BR/>Co-Medication for ileus allowed at discretion of the physician: Not allowed ('concomitant cathartics')<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Morphine , patient controlled analgesia, no further details available<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GI-3<BR/>GI-2<BR/>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time to tolerance of first solid food<BR/>Length of hospital stay<BR/>Amount of analgesia used<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Modified intention to treat population (MITT)-population: included all randomly assigned and treated patients who underwent simple total abdominal hysterectomy and who had &gt;1 on-treatment evaluations for flatus, bowel movement or toleration of solid food.<BR/>Data extracted from figures<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jepsen-1986">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Unclear<BR/>Reporting of patient baseline characteristics: Unclear<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Denmark<BR/>Number eligible: Not stated<BR/>Number enrolled: 60<BR/>Number in intervention group: 30<BR/>Number in control group: 30(25)<BR/>Number of withdrawals (intervention/placebo): 0/5<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Implantation of prosthesis (arteriosclerotic stenosis in the aorta and iliacal arteries) <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Metoclopramide<BR/>Dose: 10mg<BR/>Administration:<BR/> - Route: 6 hour interval, intravenous administration<BR/> - Start: Immediately after operation<BR/> - Duration: Maximum 5 days<BR/>Control: Placebo<BR/>Planned follow up duration: 5 days<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Patient controlled analgesia: Morphine 4mg/8h, epidural analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Amount of gastric drainage<BR/>Vomiting<BR/>Oral intake of fluids<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kuo-2006">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Computer generated randomisation list<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, identical packages<BR/>Intention-to-treat analysis: Yes<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Taiwan<BR/>Number eligible: Not stated<BR/>Number enrolled: 60 - 40 analysed<BR/>Number in intervention group: 20<BR/>Number in control group: 20<BR/>Number of withdrawals(intervention/placebo): Not reported<BR/>Inclusion criteria: Colon cancer<BR/>Exclusion criteria: Other systemic diseases: diabetes mellitus, hypertension, opioid or non steroidal anti-inflammatory drugs within 1 week before surgery<BR/>Type of surgery: Colon surgery, not in detail reported <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Lidocaine<BR/> - Dose A: 2mg/kg<BR/> - Dose B: 3mg/kg/h<BR/>Administration:<BR/> - Route A: 10 minutes intravenous administration<BR/> - Route B: after Route A was completed, via epidural catheter, <BR/> - Start: 30 minutes before surgery<BR/> - Duration: Throughout the surgical procedure not stated how long<BR/>Control: Placebo<BR/>Planned follow up duration: 72 hours<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Morphine 0.1mg/ml, ropivacaine 0.2%, patient controlled epidural analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Length of hospital stay<BR/>PCEA, trigger time, - delivery time, - consumption<BR/>Postoperative pain relief<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>I: TEA - thoracic epidural anaesthesia<BR/>II: IV - Lidocaine intravenous<BR/>III: C - Control group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lightfoot-2007">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Using "permuted blocks method"<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: 27<BR/>Number enrolled: 22<BR/>Number in intervention group: 11<BR/>Number in control group: 11<BR/>Number of withdrawals(intervention/placebo): 5 - allocation not stated<BR/>Inclusion criteria: Patients undergoing cystectomy with urinary diversion secondary to bladder cancer or interstitial cystitis<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Neobladder, ileal conduit, indiana pouch<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Erythromycin<BR/>Dose: 125mg<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: Until maximum of 21 doses (=7days)<BR/>Control: Placebo <BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Local anesthetics per epidural analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Time to tolerance of regular diet<BR/>Length of hospital stay<BR/>Amount of analgesia and narcotics used<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Placebo group: solely male</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ludwig-2006">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No- stated MITT-population*<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Multi centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 654<BR/>Number in intervention group: 329 (317)<BR/>Number in control group: 325 (312)<BR/>Number excluded post randomisation (intervention A/placebo): 25, allocation not stated <BR/>Inclusion criteria: Adult patients (= 18 years of age) undergoing laparotomy (small or large bowel resection with primary anastomosis, scheduled for postoperative pain management with opioid based intravenous patient controlled analgesia<BR/>Exclusion criteria: Undergoing total colectomy, colostomy, ileostomy or ileal pouch-anal anastomosis, complete bowel obstruction, history of total colectomy, gastrectomy, gastric bypass, short bowel syndrome or multiple previous abdominal operations performed by laparotomy, current opioid use or exposure (&gt;3 doses) within one week of study entry<BR/>Type of surgery: laparotomy (small or large bowel resection with primary anastomosis)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Alvimopan<BR/>Dose: 12mg<BR/>Administration:<BR/> - Route: 30 to 90 minutes before surgery, 12 hour interval, oral administration<BR/> - Start: On the day of surgery<BR/> - Duration: Until hospital discharge, maximum of 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until hospital discharge or maximum of 10 days<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Opioid based patient controlled analgesia, no further details available<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GI-3 (but not reported)<BR/>GI-2<BR/>Time until actual discharge (Length of hospital stay)<BR/>Time to hospital discharge order written<BR/>Incidence of POI*-related morbidity<BR/>Daily opioid consumption<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Modified intention to treat population- all randomised and treated patients who received the protocol-specified surgery and had = one efficacy evaluation.<BR/>Alvimopan trial 314. Information abstracted from poster presented at the American College of Surgeons 92nd Annual Clinical Congress.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Manani-1982">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Sealed opaque envelopes<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, patient and attending staff were blinded<BR/>Intention-to-treat analysis: Unclear<BR/>Reporting of patient baseline characteristics: Inadequate<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Italy<BR/>Number eligible: Not stated<BR/>Number enrolled: 150, 100 hysterectomy or cholecystectomy patients, 50 arthrodesis patients<BR/>Number in intervention group: 50<BR/>Number in control group: 50<BR/>Number of withdrawals (intervention/placebo): 4 in vertebral arthrodesis group<BR/>Inclusion criteria: uterine fibromatosis (hysterectomy), scoliosis (vertebral arthrodesis), cholecystic calculosis (cholecystectomy), ASA class I<BR/>Exclusion criteria: Reoperations, hyper-or hypotension, additional complicating disease, bowel anastomosis<BR/>Type of surgery: Hysterectomy, cholecystectomy, (vertebral arthrodesis)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Fructose-1,6 diphosphate<BR/>Dose: 5g<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: On the day of operation<BR/> - Duration: Until passage of first flatus<BR/>Control: Fructose <BR/>Planned follow up duration: Until passage of first flatus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: No Morphine or morphine-like, anticholinesterase or sympatholytic substances<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool or flatus (canalization time)<BR/>Effect on nausea and vomiting<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Subgroup of 50 vertebral arthrodesis patients not considered for this review.<BR/>Only hysterectomy and cholecystectomy subgroup considered for analysis.<BR/>Placebo: Fructose <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mieny-1972">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Random number tables<BR/>Time point of randomisation: After surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Not reported<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, South Africa<BR/>Number eligible: Not stated<BR/>Number enrolled: 89<BR/>Number in intervention group: 44<BR/>Number in control group: 45<BR/>Number of withdrawals (intervention/placebo): Not reported<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Exploration of the common bile duct, other intraabdominal procedures<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Panthothenic Acid<BR/>Dose: 500mg<BR/>Administration:<BR/> - Route: 24 hour interval, intravenous administration<BR/> - Start: Immediately after surgery<BR/> - Duration: Maximum 3 days<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to return of mixing sounds and propulsive sounds<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Orlando-1994">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Randomisation list, no details available<BR/>Time point of randomisation: Unclear <BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Italy<BR/>Number eligible: Not stated<BR/>Number enrolled: 40<BR/>Number in intervention group: 20 (19)<BR/>Number in control group: 20<BR/>Number of withdrawals (intervention/placebo): 1/0<BR/>Inclusion criteria: Not in detail reported (abdominal surgery)<BR/>Exclusion criteria: allergy against anticholinergic drugs, bromides, bowel obstruction, obstruction or infection within the urinary passage<BR/>Type of surgery: Cholecystectomy, emergency abdominal surgery with opening the peritoneum<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Neostigmine<BR/>Dose: 2 Puffs (5.4mg/puff)<BR/>Administration:<BR/> - Route: 4 hour interval, endonasal administration<BR/> - Start: On the day of operation<BR/> - Duration: Maximum 4 days<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus or stool (canalization time)<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rimb_x00e4_ck-1990">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 30<BR/>Number in intervention group: 15<BR/>Number in control group: 15<BR/>Number of withdrawals (intervention/placebo): Not reported<BR/>Inclusion criteria: Stool frequency between 3 stools daily and 3 stools weekly<BR/>Exclusion criteria: Laxatives or drugs with effect on the gastrointestinal motility, history of gastrointestinal disease or complication to surgery, possibility of pregnancy<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Lidocaine<BR/>Dose: 100 mg bolus, 3mg/min<BR/>Administration:<BR/> - Route: Bolus, then continuous infusion over 24 hours, intravenous administration<BR/> - Start: 30 minutes before surgery<BR/> - Duration: 24 hours after surgery<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Meperidine, intramuscular<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Radioopaque marker to study transit time<BR/>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Amount of analgesia used<BR/>Blood pressure and heart rate<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted from figures </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roberts-1995">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, identical packages of suppositories and tablets<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Not reported<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Teaching Hospital, United Kingdom<BR/>Number eligible: Not stated<BR/>Number enrolled: 14<BR/>Number in intervention group: 7<BR/>Number in control group: 7<BR/>Number of withdrawals (intervention/placebo): Reported in relation to manometric outcomes: 5 - allocation stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Drugs with effect on the gastrointestinal motility, disseminated malignant disease, neurologic or benign colonic disease, previous gastrointestinal surgery (except appendectomy)<BR/>Type of surgery: Distal left colonic anastomosis (localized colonic malignancy)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/> - Dose A: 20mg <BR/> - Dose B: 30mg<BR/>Administration:<BR/> - Route A: 8 hour interval/day, oral administration<BR/> - Route B: 8 hour interval/day, rectal administration<BR/> - Start A: 1 day before surgery<BR/> - Start B: On the day of surgery<BR/> - Duration: Until passage of first flatus<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first flatus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Pethidine bolus 0.7-1mg/kg, 1mg/kg/3h, subcutaneous infusion<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Continuous manometric recording<BR/>Time to passage of first flatus<BR/>Occurrence of bowel sounds<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sadek-1988">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Sealed envelopes, no further details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Teaching Hospital, United Kingdom<BR/>Number eligible: Not stated<BR/>Number enrolled: 96<BR/>Number in intervention group: 47<BR/>Number in control group: 44<BR/>Number of withdrawals (intervention/placebo): 5- allocation not stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Drugs with effect on the gastrointestinal motility within 1 month of surgery, major resections of the small and large intestines, significant renal, hepatic or cardiac disease, history of pancreatitis<BR/>Type of surgery: Elective abdominal surgery <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Ceruletide<BR/>Dose: 2.5ng /kg/min<BR/>Administration:<BR/> - Route: Single dose, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: 1 hour<BR/>Control: Placebo<BR/>Planned follow up duration: Until resolution of ileus<BR/>Co-Medication for ileus allowed at discretion of the physician: Allowed (stemetil (prochlorperazine) 12.5mg, intramuscular)<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Morphine 10mg i.m./4h, intramuscular</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Time to first solid food<BR/>Incidence of nausea and vomiting<BR/>Postoperative complications<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-2000">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Using of a randomisation book<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, identical packages, nursing and research staff, physicians and patients blinded<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Used for endpoint nasogastric intubation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 150<BR/>Number in intervention group: 75 (65)<BR/>Number in control group: 75 (69)<BR/>Number of withdrawals (intervention/placebo): 10/6<BR/>Inclusion criteria: Primary resection of the colon or rectum<BR/>Exclusion criteria: Preoperative factors (History of-allergic reaction to erythromycin, -major abdominal or pelvic surgery (excluding appendectomy, cholecystectomy, hysterectomy), planned hepatic resection, metastatic disease, medication known to interact with erythromycin, history of ventricular arrhythmias, baseline QTc(QT/RR) &gt;460ms, ejection fraction &lt;30%), operative factors (need for ileostomy, resection incorporating the upper gastrointestinal tract, gross fecal spillage, need to leave nasogastric tube in, unexpected intra-abdominal adhesions)<BR/>Type of surgery: Elective colorectal resection<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Erythromycin<BR/>Dose: 200 mg<BR/>Administration:<BR/> - Route: 6 hour interval, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: Until tolerance of solid food or maximum 5 days<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Allowed (cimetidine)<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Morphine, patient controlled analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Time to first solid food <BR/>Length of hospital stay<BR/>NG tube replacement<BR/>12-lead ECG serial evaluations<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Taguchi-2001">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Computer generated randomisation list generated by hospital pharmacy<BR/>Time point of randomisation: Before and on the day of surgery<BR/>Blinding: Double blind, identical packages, patient, care giver and assessor of outcome blinded<BR/>Intention-to-treat analysis: Yes<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: 185<BR/>Number enrolled: 79<BR/>Number in intervention group A: 26<BR/>Number in intervention group B: 26<BR/>Number in control group: 26<BR/>Number of withdrawals (intervention A/intervention B/placebo): 8/0/4<BR/>Inclusion criteria: Age 18-78 years, generally healthy or well-controlled systemic disease<BR/>Exclusion criteria: Treatment with corticosteroids or immunsuppressive drugs within 2 weeks before surgery, opioid analgesics within 4 weeks before surgery, likely to receive nonsteroidal anti-inflammatory drugs after surgery, Crohn's disease, history of abdominal radiation therapy, history of treatment with vinca alkaloids<BR/>Type of surgery: Partial colectomy or total abdominal hysterectomy (simple or radical)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: ADL 8-2689 (Alvimopan)<BR/> - Dose A: 1mg<BR/> - Dose B: 6mg<BR/>Administration:<BR/> - Route: 2 hours before surgery, 12 hour interval, oral administration<BR/> - Start: On the day of operation<BR/> - Duration: Until first bowel movement or hospital discharge or maximum of 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Morphine hydrochloride, patient controlled analgesia, intravenous<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first stool/bowel movement<BR/>Time to passage of first flatus<BR/>Time to tolerance of solid food<BR/>Length of hospital stay<BR/>Time until ready for discharge<BR/>Time until actual discharge<BR/>Amount of analgesia used<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thorup-1983">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Not reported<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Teaching Hospital, Denmark<BR/>Number eligible: Not stated<BR/>Number enrolled: 85<BR/>Number in intervention group: 43<BR/>Number in control group: 34<BR/>Number of withdrawals: 5/3<BR/>Inclusion criteria: Major abdominal surgery<BR/>Exclusion criteria: Peripheral arterial insufficiency, hepatic failure, suspected dihydroergotamine intolerance<BR/>Type of surgery: Major abdominal surgery (biliary-, colonic-, gastric operations and others) <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Dihydroergotamine<BR/>Dose: 0.5mg <BR/>Administration: <BR/> - Route: 1-2 hours before surgery, 12 hour interval, subcutaneous administration<BR/> - Start: On the day of operation<BR/> - Duration: 7 days<BR/>Control: No details reported<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Allowed (oral bisacodyl, rectal DSS-dioctyl sodium sulfosuccinate)<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Number of doses laxatives used<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tollesson-1991_x0028_1_x0029_">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, detail only given for radiologist assessing marker outcomes<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Unclear, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 20<BR/>Number in intervention group: 10<BR/>Number in control group: 10<BR/>Number of withdrawals (intervention/placebo): Not reported<BR/>Inclusion criteria: Stool frequency between 3 stools daily and 3 stools weekly<BR/>Exclusion criteria: Hepatic, renal, cardiovascular or hormonal diseases, laxatives and drugs with effect on the gastrointestinal motility, history of gastrointestinal diseases or complications to surgery, possibility to pregnancy<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Metoclopramide<BR/>Dose: 20 mg<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: Immediately after operation<BR/> - Duration: Maximum of 10 injections or 4 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first flatus or stool<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Pethidine, intramuscular<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Radioopaque marker to study transit time<BR/>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted from figures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tollesson-1991_x0028_2_x0029_">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Unclear, Sweden<BR/>Number eligible: Not stated<BR/>Number enrolled: 40<BR/>Number in intervention group: 20<BR/>Number in control group: 20<BR/>Number of withdrawals (intervention/placebo): Not reported<BR/>Inclusion criteria: Stool frequency between 3 stools daily and 3 stools weekly<BR/>Exclusion criteria: Hepatic, renal, cardiovascular disease, laxatives and drugs with effect on the gastrointestinal motility, history of gastrointestinal diseases or complications to surgery, possibility to pregnancy<BR/>Type of surgery: Elective cholecystectomy <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 10 mg<BR/>Administration:<BR/> - Route: 12-24 hour interval, intravenous administration<BR/> - Start: On the day of operation<BR/> - Duration: Maximum of 6 injections<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first flatus or stool<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: GA<BR/>Type of analgesia: Morphine, intramuscular<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Electromyographic analysis<BR/>Radioopaque marker to study transit time<BR/>Time to passage of first flatus<BR/>Time to passage of first stool<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Viscusi-2006">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available (1:1:1 ratio)<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No- stated MITT-population*<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Multi centre Phase III trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 666<BR/>Number in intervention group A: 220<BR/>Number in intervention group B: 222 (221)<BR/>Number in control group: 224<BR/>Number excluded post randomisation (intervention A/intervention B/placebo): 51- allocation not stated<BR/>Inclusion criteria: Age &gt;18 years, laparotomy for partial small or large bowel resection, simple or radical total abdominal hysterectomy<BR/>Exclusion criteria: Pregnancy, acute treatment with opioids less than 1 week before the study or chronic treatment with opioids less than 2 weeks before study, complete bowel obstruction or colectomy, colostomy, ileostomy, any other condition known to be associated with an increased risk of postoperative morbidity<BR/>Type of surgery: Partial small or large bowel resection, simple or radical total abdominal hysterectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Alvimopan<BR/> - Dose A: 6mg<BR/> - Dose B: 12mg<BR/>Administration:<BR/> - Route: 2 hours before surgery, 12 hour interval, oral administration<BR/> - Start: 1. POD<BR/> - Duration: until hospital discharge or maximum of 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until hospital discharge or maximum of 10 POD<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Opioid based patient controlled analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GI-3<BR/>GI-2<BR/>Time to passage of first stool/bowel movement<BR/>Time to tolerance of solid food<BR/>Length of hospital stay<BR/>Amount of analgesic use<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Modified intention to treat (MITT) -population: included all randomized patients who had a protocol-specified surgery, took at least one dose of study drug, and had an efficacy assessment (bowel movement, flatus, or solid food)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Von-Ritter-1987">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Unclear<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: Yes, no details reported<BR/>Reporting of patient baseline characteristics: No<BR/>Withdrawals: Not stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, South Africa<BR/>Number eligible: Not stated<BR/>Number enrolled: 32<BR/>Number in intervention group: 17<BR/>Number in control group: 15<BR/>Number of withdrawals (intervention/placebo): Not reported<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Biliary-, upper gastrointestinal tract-, colon-, miscellaneous surgery <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Cisapride<BR/>Dose: 10mg<BR/>Administration:<BR/> - Route: 4/6/8/12 hour interval, intravenous/intramuscular administration<BR/> - Start: 1. POD<BR/> - Duration: 48 hours<BR/>Control: Placebo<BR/>Planned follow up duration: Until passage of first flatus<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Onset and intensity of borborygmi<BR/>Color of gastric aspirate<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted from figures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wilkinson-2002">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Computer generated randomisation list<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, surgical team, nursing staff and nuclear medicine staff were blinded<BR/>Intention-to-treat analysis: No<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 22<BR/>Number in intervention group: 11<BR/>Number in control group: 11 (10)<BR/>Number of withdrawals (intervention/placebo): 1 - allocation not stated <BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Elective gastric bypass <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Erythromycin<BR/>Dose: 250 mg<BR/>Administration:<BR/> - Route: 8 hour interval, intravenous administration<BR/> - Start: 1. POD<BR/> - Duration: Up to 2. POD<BR/>Control: Placebo<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Intrathecal narcotics, epidural analgesia, morphine, patient controlled analgesia<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Length of hospital stay<BR/>HIDA (hepatic iminodiacetic acid)-Scan to evaluate bile excretion and proximal small bowel motility<BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolff-2004">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: No details available<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Double blind, no details given<BR/>Intention-to-treat analysis: No- stated MITT-population*<BR/>Reporting of patient baseline characteristics: Yes<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Multi centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 510<BR/>Number in intervention group A: 169 (155)<BR/>Number in intervention group B: 176 (165)<BR/>Number in control group: 165 (149)<BR/>Number of withdrawals (intervention A/ intervention B/placebo): 14/11/16<BR/>Inclusion criteria: Age &gt;18 years, partial small or large bowel resection with primary anastomosis, or radical total abdominal hysterectomy, postoperative pain management with patient-controlled analgesia with opioids, nasogastric tube removed at the end of surgery<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Partial small or large bowel resection with primary anastomosis, radical total abdominal hysterectomy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Alvimopan<BR/> - Dose A: 6 mg<BR/> - Dose B: 12 mg<BR/>Administration:<BR/> - Route: 2 hours before surgery, then 1. POD: 12 hour interval, oral administration<BR/> - Start: Day of surgery<BR/> - Duration: Until hospital discharge or maximum of 7 days<BR/>Control: Placebo<BR/>Planned follow up duration: Until hospital discharge or maximum of 10 days<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anaesthesia: Not reported<BR/>Type of analgesia: Opioid based patient controlled analgesia, intravenous<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GI-3<BR/>GI-2<BR/>Length of hospital stay<BR/>Amount of analgesic used<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Modified intention to treat (MITT)-population: included all treated patients who received protocol-specified surgeries and had at least one on-treatment primary efficacy evaluation (flatus, bowel movement, or tolerating solid food).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woods-1993">
<CHAR_METHODS>
<P>Design: Parallel group RCT<BR/>Randomisation: Quasi-randomisation with even and odd numbered patients<BR/>Time point of randomisation: Before surgery<BR/>Blinding: Not reported<BR/>Intention-to-treat analysis: Unclear<BR/>Reporting of patient baseline characteristics: Inadequate<BR/>Withdrawals: Stated<BR/>Sample size calculation: Not used<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Single centre trial, USA<BR/>Number eligible: Not stated<BR/>Number enrolled: 83<BR/>Number in intervention group: 37<BR/>Number in control group: 32<BR/>Number of withdrawals(intervention/no treatment): 14- allocation not stated<BR/>Inclusion criteria: Not reported<BR/>Exclusion criteria: Not reported<BR/>Type of surgery: Elective abdominal aortic aneurysma resections, aorto-femoral, aorto-iliacal bypass <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study drug: Albumin<BR/>Dose: Not reported. Albumin substitution if blood level &lt;3.5 g/dl, replacement calculated, using the NIH-Formula<BR/>Administration:<BR/> - Route: Repeated administration, scheme not stated intravenous administration<BR/> - Start: Not in detail reported<BR/> - Duration: Until achievement of albumin level &gt;3.5gm/dl<BR/>Control: No treatment<BR/>Planned follow up duration: Not reported<BR/>Co-Medication for ileus allowed at discretion of the physician: Not reported<BR/>Type of anesthesia: Not reported<BR/>Type of analgesia: Narcotics, patient controlled analgesia, epidural</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to passage of first flatus<BR/>Time to first solid food intake<BR/>Length of hospital stay<BR/>Amount of analgesic used<BR/>Albumin, hemoglobin, potassium, chloride, sodium levels<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Data in parentheses are numbers analysed unless otherwise indicated<BR/>RCT = Randomised controlled trail, GA = General anaesthesia, POD = postoperative day, PCEA = Patient controlled epidural analgesia<BR/>CCE = Cholecystectomy, DCO = Hospital discharge order, ASA classification = American Society of Anesthesiologists physical status classification</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aloisio-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baig-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate Publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boghaert-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate follow-up duration (maximum 2 hours).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Effect of metoclopramide on intra-peritoneal chemotherapy (IPC) induced ileus.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-JH-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Effect of water soluble contrast medium on POI*. Intervention not systemic pharmacologic treatment directed to treat POI*.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-JY-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indirect effect of ketorolac on POI* indirect via opiate dose reduction.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clevers-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population cesearean section.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cyba-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head to head comparison of ceruletide and neostigmine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davidson-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Effect of metoclopramide on postoperative ileus. Outcome not according to protocol: number of doses of metoclopramide or placebo until resolution of ileus.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delaney-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Post hoc analysis of original trials (Delaney 2005, Viscusi 2006, Wolff 2004).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delaney-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Post hoc analysis of original trials (Delaney 2005, Viscusi 2006, Wolff 2004).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fanning-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferraz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gales-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garcia_x002d_Caballero1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jensen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population inguinal hernia repair.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kasparek-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawaguchi-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kivalo-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kreis-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lykkegaard_x002d_Nielsen">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head to head comparison of ceruletide and metoclopramide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madsen-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate follow-up duration (maximum 24 hours).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madsen-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head to head comparison between ceruletide and neostigmine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Myrh_x00f6_j-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate follow-up duration (maximum 9 hours).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nio-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of prostaglandin F and panthothenic acid. Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noblett-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Food intervention. No pharmacological treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olesen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Head-to-head comparison of morphine and pethidine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not systemic pharmacologic treatment directed to treat POI*.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruppin-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Effect of 13- Nle- Motilin in patients with postoperative ileus. Outcome: intensity of bowel sounds not according to protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article on alvimopan. Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seta-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sinatra-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Effect of Rofecoxib on POI* indirect via opioid dosage reduction.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thunedborg-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Berge-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study on healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolff-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Post hoc analysis of original trials (Delaney 2005, Viscusi 2006, Wolff 2004).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>*POI = postoperative ileus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Asimadoline">
<CHAR_STUDY_NAME>
<P>A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Asimadoline on the Duration of POI in Subjects Undergoing Laparoscopic/Hand-Assisted Lap Segmental Colonic Resection Secondary to Colon Cancer, Polypectomy or Diverticulitis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Subjects undergoing laparoscopic/<BR/>hand-assisted lap segmental colonic resection secondary to colon cancer, polypectomy or diverticulitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drug: Asimadoline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No details available</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Lahey Clinic<BR/>Burlington<BR/>Massachusetts, United States<BR/>01805<BR/>Status: Recruiting<BR/>Contact: Nancy Shinopulos<BR/>tel: 781-744-3035<BR/>nancy.m.shinopulos@lahey.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier:<BR/>NCT00443040</P>
<P>Study ID numbers:<BR/>ASMP2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Lidocaine">
<CHAR_STUDY_NAME>
<P>A prospective evaluation of the addition of intraoperative intravenous lidocaine infusion to general anesthetic in total abdominal hysterectomy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients undergoing elective total abdominal hysterectomy </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drug: Lidocaine 1.5 mg/kg bolus, followed by continuous intravenous infusion at 3.0 mg/kg/hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>- Length of hospital stay<BR/>- Total opioid use at 48 hours postoperatively</P>
<P>Secondary outcomes:<BR/>- Intraoperative data: BIS scores (to control depth of anesthesia)<BR/>- Intraoperative serum lidocaine levels<BR/>- Intraoperative opioid use<BR/>- Opioid use in the recovery room<BR/>- Patient Controlled Analgesia (PCA) morphine requirements postoperatively <BR/> up to 48 hours<BR/>- Oral pain controlling medication use up to 48 hours postoperatively if IV PCA <BR/> discontinued before 48 hours<BR/>- Verbal Analogue Scale (VAS) pain scores in recovery room and during first 2<BR/> days post-operatively <BR/>- Incidence of side effects that can be attributed to local anesthetic toxicity;<BR/>- Incidence of nausea and vomiting and anti-emetic use up to 48 hours<BR/> postoperatively<BR/>- Time of first flatus and first bowel movement.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>ILIA Charapov MD<BR/>tel: 613-2605795<BR/>charapov@rogers.com</P>
<P>The Ottawa Hospital<BR/>Ottawa<BR/>Ontario, Canada<BR/>K1H 8L6<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier:<BR/>NCT00382499 </P>
<P>Study ID numbers:<BR/>#2006512-01H</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Lidocaine_x002f_Ketamin">
<CHAR_STUDY_NAME>
<P>A randomised controlled trial of lidocaine infusion plus ketamine injection versus placebo to decrease postoperative ileus</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients undergoing elective or urgent colon surgery with an anastomotic procedure </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drug: Lidocaine infusion plus ketamine injection or placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: <BR/>Mean time after surgery to completion of the following postoperative markers:<BR/>- Drinking and retaining 500ml clear fluids<BR/>- Presence of bowel sounds<BR/>- Passage of flatus<BR/>- Passage of stool</P>
<P>Secondary outcomes:<BR/>- Outcome pain after cough by VAS<BR/>- Narcotic usage<BR/>- Nausea<BR/>- Vomiting<BR/>- Infection, dehiscence and other surgical complications<BR/>- Time to readiness for discharge from hospital</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>September 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>William PS McKay MD<BR/>Principal Investigator</P>
<P>Saskatoon Health Region<BR/>University of Saskatchewan<BR/>410 22nd Street East<BR/>Saskatoon<BR/>Saskatchewan, Canada<BR/>S7K 5T6<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00229567 </P>
<P>Study ID numbers:<BR/>Bio-REB 03-1316</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Methylnaltrexone">
<CHAR_STUDY_NAME>
<P>A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of intravenous (IV) methylnaltrexone bromide (MNTX) in the treatment of post-operative ileus (POI)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients must be scheduled for a segmental colectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drug: Methylnaltrexone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No details available</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not available</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>David Jacobs MD<BR/>tel: 914-784-1800<BR/>djacobs@progenics.com</P>
<P>Progenics Pharmaceuticals<BR/>Tarrytown<BR/>New York, United States<BR/>10591</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00401375 </P>
<P>Study ID numbers:<BR/>MNTX 3301</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Altaparmakov-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Alvarez-1979">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benson-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bonacini-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brown-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheape-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clevers-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Conte-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Delaney-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferraz-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferreira-1980">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Frisell-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Groudine-1998">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hakansson-1985">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hallerb_x00e4_ck-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Herzog-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jepsen-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kuo-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lightfoot-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ludwig-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Manani-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mieny-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Orlando-1994">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rimb_x00e4_ck-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sadek-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Smith-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Taguchi-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Thorup-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tollesson-1991_x0028_1_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tollesson-1991_x0028_2_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Viscusi-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Von-Ritter-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wilkinson-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolff-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Woods-1993">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Adverse drug reactions (Adr)</TITLE>
<TABLE COLS="6" ROWS="41">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Nr Treatment/Control</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
<TH>
<P>Adr-Treatment</P>
</TH>
<TH>
<P>Adr-Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Delaney 2005</P>
</TD>
<TD>
<P>296/153*</P>
</TD>
<TD>
<P>Alvimopan 6mg and 12mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe: <BR/>Death 2/296 (0.7)<BR/>Any of postoperative ileus, <BR/>small bowel obstruction, <BR/>anastomotic leakage, <BR/>gastrointestinal disorders, <BR/>infections 28/296 (9.4)<BR/>
<BR/>Mild:<BR/>Nausea 182/296 (61.5)<BR/>Vomiting 60/296 (20.2)<BR/>Abdominal distension 41/296 (13.8)<BR/>Hypertension 37/296 (12.5)<BR/>Headache 41/296 (13.8)<BR/>Tachycardia 31/296 (10.5)<BR/>Postoperative ileus 26/296 (8.8)<BR/>
</P>
</TD>
<TD>
<P>Severe: <BR/>Death 1 /153 (0.65)<BR/>Any of postoperative ileus, <BR/>small bowel obstruction, <BR/>anastomotic leakage, <BR/>gastrointestinal disorders, <BR/>infections 28/153 (18.3)<BR/>
<BR/>Mild:<BR/>Nausea 104/153 (67.9)<BR/>Vomiting 49/153 (32)<BR/>Abdominal distension 24/153 (15.7)<BR/>Hypertension 14/153 (9.2)<BR/>Headache 18/153 (11.8)<BR/>Tachycardia 15/153 (9.8)<BR/>Postoperative ileus 11/153 (7.2)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Herzog 2006</P>
</TD>
<TD>
<P>413/106*</P>
</TD>
<TD>
<P>Alvimopan, 12mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Serious adverse events <BR/>(life-threatening) 23/413 (5.6)<BR/>
<BR/>Mild:<BR/>Nausea 298/413 (72.2)<BR/>Vomiting 129/413 (31.2)<BR/>Abdominal distension 34/413 (8.2)<BR/>Hypertension 28/413 (6.8)<BR/>Headache 55/413 (13.3)<BR/>Tachycardia 21/413 (5.1)<BR/>Constipation 94/413 (22.8)<BR/>
</P>
</TD>
<TD>
<P>Serious adverse events<BR/>(life-threatening) 7/106 (6.6)<BR/>
<BR/>Mild:<BR/>Nausea 67/106 (65.7)<BR/>Vomiting 27/106 (25.5)<BR/>Abdominal distension 11/106 (10.4)<BR/>Hypertension 6/106 (5.7)<BR/>Headache 12/106 (11.3)<BR/>Tachycardia 3/106 (2.8)<BR/>Constipation 33/106 (31.1)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Ludwig 2006</P>
</TD>
<TD>
<P>329/325*</P>
</TD>
<TD>
<P>Alvimopan 12mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Serious adverse events not reported<BR/>
<BR/>Mild:<BR/>Nausea 190/329 (57.8)<BR/>Vomiting 46/329 (14.0)<BR/>Abdominal pain 19/329 (5.8)<BR/>Hypertension 36/329 (10.9)<BR/>Tachycardia 27/329 (8.2)<BR/>Postoperative ileus 24/329 (7.3)<BR/>
</P>
</TD>
<TD>
<P>Serious adverse events not reported<BR/>
<BR/>Mild:<BR/>Nausea 67/325 (66.2)<BR/>Vomiting 80/325 (24.6)<BR/>Abdominal pain 11/325 (3.4)<BR/>Hypertension 34/325 (10.5)<BR/>Tachycardia 35/325 (10.8)<BR/>Postoperative Ileus 51/325 (15.7)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Taguchi 2001</P>
</TD>
<TD>
<P>52/26</P>
</TD>
<TD>
<P>ADL 8-2689 (Alvimopan), 1mg and 6mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 27% in 6mg- and 67% in 1mg in <BR/> alvimopan group<BR/>Vomiting 0% in 6mg- and 26% in 1mg in<BR/> alvimopan group<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 63%<BR/>
<BR/>
<BR/>Vomiting 23%<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Viscusi 2006</P>
</TD>
<TD>
<P>441/224*</P>
</TD>
<TD>
<P>Alvimopan, 6mg and 12mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe: <BR/>Serious adverse events <BR/>(requiring a prolonged <BR/>hospital stay) 30/441 (6.8)<BR/> (5.9 in 6mg group)<BR/>
<BR/>Mild:<BR/>Nausea 216/441 (48.9)<BR/>Vomiting: 90/441 (20.4)<BR/>Abdominal distension: 48/441 (10.9)<BR/>Hypertension: 35/441 (7.9)<BR/>Headache: 35/441 (7.9)<BR/>Tachycardia: 17/441 (3.9)<BR/>Postoperative ileus: 26/441 (5.9)<BR/>
</P>
</TD>
<TD>
<P>Severe: <BR/>Serious adverse events <BR/>(requiring a prolonged <BR/>hospital stay) 26/224 (11.6 )<BR/>
<BR/>
<BR/>Mild:<BR/>Nausea 121/224 (9.4)<BR/>Vomiting: 56/224 (25)<BR/>Abdominal distension: 29/224 (12.9)<BR/>Hypertension: 23/224 (10.3)<BR/>Headache: 18/224 (8.0)<BR/>Tachycardia: 15/224 (6.7)<BR/>Postoperative ileus: 23/224 (10.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolff 2004</P>
</TD>
<TD>
<P>345/165*</P>
</TD>
<TD>
<P>Alvimopan, 6mg and 12mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Serious adverse events 17/345 (5)<BR/>(no details reported)<BR/>
<BR/>Mild:<BR/>Nausea 199/345 (57.7)<BR/>Vomiting 76/345 (22.1)<BR/>Abdominal distension 39/345 (11.3)<BR/>Hypertension 42/345 (12.2)<BR/>Tachycardia 41/345 (11.9)<BR/>Postoperative ileus 25/345 (7.3)<BR/>
</P>
</TD>
<TD>
<P>Serious adverse events 2/165 (1.2)<BR/>(no details reported)<BR/>
<BR/>Mild:<BR/>Nausea 106/165 (64.2)<BR/>Vomiting 42/165 (25.5)<BR/>Abdominal distension 25/165 (15.2)<BR/>Hypertension 18/165 (10.9)<BR/>Tachycardia 23/165 (13.9)<BR/>Postoperative ileus 26/165 (15.8)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Alvarez 1979</P>
</TD>
<TD>
<P>25/25</P>
</TD>
<TD>
<P>Cerulein 0.3mcg/kg</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Mild:<BR/>Not reported according to treatment arm<BR/>
<BR/>Nausea 1/25 (4)<BR/>Colic pain 1/25 (4)<BR/>Tachycardia 3/25 (12)<BR/>Diaforesis 3/25 (12)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>Not reported for control group patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferreira 1980</P>
</TD>
<TD>
<P>30/30</P>
</TD>
<TD>
<P>Cerulein 2ng/kg/min</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Mild:<BR/>
<BR/>Nausea 1/30 (3.3)<BR/>Vomiting 1/30 (3.3)<BR/>Colic pain 1/30 (3.3)<BR/>Tachycardia 1/30 (3.3)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>Not reported for control group patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Frisell 1985</P>
</TD>
<TD>
<P>27/30</P>
</TD>
<TD>
<P>Cholecystokinin 75 IU</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 15/27 (55.5)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 5/30 (16.6)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Sadek 1988</P>
</TD>
<TD>
<P>47/44</P>
</TD>
<TD>
<P>Ceruletide 2.5ng /kg/min</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe:<BR/>Pulmonary embolism 2/47 (4.3)<BR/>"Intra-abdominal sepsis" 1/47 (2.1)<BR/>(unclear)<BR/>
<BR/>Mild: <BR/>Nausea 31/47 (65.9)<BR/>(encountered during first <BR/>hour after infusion)<BR/>Vomiting 11/47 (23.4)<BR/>(encountered during first <BR/>hour after infusion)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>Mild:<BR/>Nausea 11/44 (25)<BR/>(encountered during first<BR/> hour after infusion)<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Benson 1994</P>
</TD>
<TD>
<P>11/12</P>
</TD>
<TD>
<P>Cisapride 30mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Hypokalemia 2/11 (18.2)<BR/>(3.0-3.5mmol/l)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Hypokalemia 3/12 (25)<BR/>(3.0-3.5mmol/l)<BR/>Anastomotic leakage 1/12 (8.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Brown 1999</P>
</TD>
<TD>
<P>17/18</P>
</TD>
<TD>
<P>Cisapride 20mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe:<BR/>Transient ischemic attack 1/17 (5.9)<BR/>
<BR/>Mild: <BR/>Wound infection 3/17 (17.6)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>
<BR/>
<BR/>
<BR/>Mild:<BR/>Wound infection 2/18 (11.1)<BR/>Azotemia 1/18 (5.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Clevers 1991</P>
</TD>
<TD>
<P>17/20</P>
</TD>
<TD>
<P>Cisapride 30mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe nausea 17/17 (100)<BR/>Repeated vomiting 10/17 (58.8)<BR/>Reinsertion <BR/>of nasogastric tube 5/17 (29.4)<BR/>
</P>
</TD>
<TD>
<P>Severe nausea 18/20 (90)<BR/>Repeated vomiting 10/20 (50)<BR/>Reinsertion <BR/>of nasogastric tube 2/20 (10)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Hallerbäck 1991</P>
</TD>
<TD>
<P>36/33</P>
</TD>
<TD>
<P>Cisapride 30mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe: <BR/>Prolonged ileus 1/36 (2.7)<BR/>
</P>
</TD>
<TD>
<P>Severe: <BR/>Prolonged ileus 0/33 (0)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Roberts 1995</P>
</TD>
<TD>
<P>7/7</P>
</TD>
<TD>
<P>Cisapride 20mg and 30mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Tollesson 1991(2)</P>
</TD>
<TD>
<P>20/20</P>
</TD>
<TD>
<P>Cisapride 10mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Von Ritter 1987</P>
</TD>
<TD>
<P>17/15</P>
</TD>
<TD>
<P>Cisapride 10mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Altaparmakov 1984</P>
</TD>
<TD>
<P>23/23</P>
</TD>
<TD>
<P>Dihydroergotamine</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Thorup 1983</P>
</TD>
<TD>
<P>43/34</P>
</TD>
<TD>
<P>Dihydroergotamine</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Cheape 1991</P>
</TD>
<TD>
<P>40/53</P>
</TD>
<TD>
<P>Metoclopramide 10mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe:<BR/>Death 1/40 (2.5)<BR/>Reoperation 1/40 (2.5)<BR/>Prolonged Ileus 7/40 (17.5)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>
<BR/>Reoperation 1/53 (1.9)<BR/>Prolonged Ileus 8/53 (15.1)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Jepsen 1986</P>
</TD>
<TD>
<P>30/25</P>
</TD>
<TD>
<P>Metoclopramide 20mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe:<BR/>Renal failure 1/30 (3.3)<BR/>
</P>
</TD>
<TD>
<P>Severe:<BR/>Ischaemic colitis 2/25 (8)<BR/>Intraperitoneal bleeding 2/25 (8)<BR/>Abdominal wound rupture 1/25 (4)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Tollesson 1991(1)</P>
</TD>
<TD>
<P>10/10</P>
</TD>
<TD>
<P>Metoclopramide 20mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Conte 1983</P>
</TD>
<TD>
<P>84/80</P>
</TD>
<TD>
<P>Bromopride 20mg</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 36/84 (42.9)<BR/>Abdominal pain 41/84 (48.8)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 51/80 (63.8)<BR/>Abdominal pain 55/80 (68.8)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bonancini 1993</P>
</TD>
<TD>
<P>41/36</P>
</TD>
<TD>
<P>Erythromycin 250mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe:<BR/>Gastrointestinal bleeding 1/41 (2.4)<BR/>
<BR/>Mild: <BR/>Vomiting 3/41 (7.3)<BR/>Abdominal pain 2/41 (4.9)<BR/>Skin rash 3/41 (7.3)<BR/>
</P>
</TD>
<TD>
<P>Severe:<BR/>Gastrointestinal bleeding 1/36 (2.7)<BR/>
<BR/>Mild: <BR/>Vomiting 2/36 (5.5)<BR/>Abdominal pain 2/36 (5.5)<BR/>Skin rash 1/36 (2.7)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Lightfoot 2006</P>
</TD>
<TD>
<P>11/11</P>
</TD>
<TD>
<P>Erythromycin 125mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea (=2days) 4 (36)<BR/>Vomiting (=2days) 3 (27)<BR/>Abdominal pain (=2days) 2 (18)<BR/>QTc prolongation(=2days) 1 (9)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea (=2days) 2 (18)<BR/>Vomiting (=2days) 1 (9)<BR/>Abdominal pain (=2days) 0 (0)<BR/>QTc prolongation (=2days) 1 (9)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Smith 2000</P>
</TD>
<TD>
<P>65/69</P>
</TD>
<TD>
<P>Erythromycin 200mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Severe Nausea 17/65 (26.1)<BR/>Vomiting 11/65 (16.9)<BR/>Skin rash 1/65 (1.5)<BR/>Cardiac arrhythmia 0/65 (0)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Severe Nausea 18/69 (26.1)<BR/>Vomiting 11/69 (15.9)<BR/>Skin rash 0/69 (0)<BR/>Cardiac arrhythmia 11/69 (15.9)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilkinson 2002</P>
</TD>
<TD>
<P>11/10</P>
</TD>
<TD>
<P>Erythromycin 250mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Severe: <BR/>Venous thrombosis 0/11 (0)<BR/>
<BR/>Mild:<BR/>Nausea 1/11 (0.91)<BR/>Wound infection Superficial 1/11 (0.91)<BR/>
</P>
</TD>
<TD>
<P>Severe: <BR/>Venous thrombosis 1/10 (1)<BR/>
<BR/>Mild:<BR/>Nausea 1/10 (1)<BR/>Wound infection Superficial 1/10 (1)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Groudine 1998</P>
</TD>
<TD>
<P>18/20</P>
</TD>
<TD>
<P>Lidocaine 1.5 mg/kg Bolus, Infusion 3mg/min &gt;70kg, 2mg/min &lt;70kg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Fever 1/18 (5.6)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Fever 2/20 (10)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Rimbäck 1990</P>
</TD>
<TD>
<P>15/15</P>
</TD>
<TD>
<P>Lidocaine 100 mg Bolus, 3mg/min<BR/>
</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 9/15 (60)<BR/>Vomiting 7/15 (46.6)<BR/>Sedation 2/15 (13.3)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 6/15 (40)<BR/>Vomiting 8/15 (53.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Kuo 2006</P>
</TD>
<TD>
<P>20/20</P>
</TD>
<TD>
<P>Lidocaine 2mg/kg Bolus, Infusion 3mg/kg/h</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Bradycardia 3/20 (15)<BR/>Nausea or vomiting 5/20 (25)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>
<BR/>Nausea or vomiting 9/20 (45)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Orlando 1994</P>
</TD>
<TD>
<P>19/20</P>
</TD>
<TD>
<P>Neostigmine 2x 5.4mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Asthenia in all patients<BR/>Fasciculations 0/19 (0)<BR/>(no details reported)<BR/>Miosis in combination with <BR/>sweating and secretion 1/19 (5.2)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Asthenia in all patients<BR/>Fasciculations 2/20 (10)<BR/>(no details reported)<BR/>Miosis in combination with <BR/>sweating and secretion 0/20 (0)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Hallerbäck 1987(1)</P>
</TD>
<TD>
<P>I(Pro/Neo):21<BR/>II(N): 22<BR/>III(P): 19<BR/>
</P>
</TD>
<TD>
<P>Propranolol 10 mg and 80mg <BR/>Neostigmine 0,5mg<BR/>
</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea 1/21 (4.8)<BR/>Pulmonary obstruction and <BR/>itching 1/22 (4.5)<BR/>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferraz 2001</P>
</TD>
<TD>
<P>12/15</P>
</TD>
<TD>
<P>Propranolol 40mg</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Severe:<BR/>Primary peritonitis 1/12 (8.3)<BR/>Arrhythmia 1/12 (8.3)<BR/>
</P>
</TD>
<TD>
<P>Severe:<BR/>Reoperation 2/15 (13.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Garcia 1993</P>
</TD>
<TD>
<P>17/20</P>
</TD>
<TD>
<P>Propranolol 7.5mg iv or 80mg<BR/>Neostigmine 0.5mg<BR/>
<BR/>
</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Hallerbäck 1987(2)</P>
</TD>
<TD>
<P>20/19</P>
</TD>
<TD>
<P>Propranolol 4mg and 10mg</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Woods 1993</P>
</TD>
<TD>
<P>37/32</P>
</TD>
<TD>
<P>Albumin</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Severe:<BR/>Death 1/37 (2.7)<BR/>
<BR/>Mild:<BR/>Respiratory insufficiency<BR/>and Bronchitis 5/37 (13.5)<BR/>Total complication rate (35.1)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>Total complication rate (31.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Manani 1982</P>
</TD>
<TD>
<P>50/50</P>
</TD>
<TD>
<P>Fructose-1,6 diphosphate 5g</P>
</TD>
<TD>
<P>Placebo<BR/>(Fructose)<BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea and/or Vomiting reported to resolve earlier in treatment group <BR/>
</P>
</TD>
<TD>
<P>Mild:<BR/>Nausea and/or Vomiting reported to resolve earlier in treatment group <BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Mieny 1972</P>
</TD>
<TD>
<P>44/45</P>
</TD>
<TD>
<P>Panthothenic Acid</P>
</TD>
<TD>
<P>Placebo<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>Hakansson 1985</P>
</TD>
<TD>
<P>30/30</P>
</TD>
<TD>
<P>Vasopressin, 10IE</P>
</TD>
<TD>
<P>No Treatment</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without serious adverse drug reactions</P>
</TD>
<TD>
<P>Trial reported: <BR/>Treatment was without serious adverse drug reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>* safety population <BR/>- Data in parentheses are numbers with percentages <BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Alvimopan versus Placebo</NAME>
<IV_OUTCOME CHI2="13.847286757477923" CI_END="1.71265688471111" CI_START="1.3538462592129874" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="1.5227193164472252" ESTIMABLE="YES" I2="49.448580631004816" I2_Q="38.717549855637536" ID="CMP-001.01" LOG_CI_END="0.23367036471546107" LOG_CI_START="0.13156934930748487" LOG_DATA="YES" LOG_EFFECT_SIZE="0.18261985701147293" NO="1" P_CHI2="0.0539651784411066" P_Q="0.20145590757863086" P_Z="2.3618268385656696E-12" Q="1.6317885424690264" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.013955813537066177" TOTALS="YES" TOTAL_1="1765" TOTAL_2="1450" WEIGHT="100.00000000000001" Z="7.0112592156724025">
<NAME>GI-2</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="12.123815325118144" CI_END="1.8951002714839649" CI_START="1.32818658518904" DF="4.0" EFFECT_SIZE="1.586520330211091" ESTIMABLE="YES" I2="67.00708570087839" ID="CMP-001.01.01" LOG_CI_END="0.2776321938292061" LOG_CI_START="0.12325908950936264" LOG_EFFECT_SIZE="0.2004456416692843" NO="1" P_CHI2="0.016453934997741948" P_Z="3.5838932024673455E-7" STUDIES="5" TAU2="0.027088447877387567" TOTAL_1="1249" TOTAL_2="932" WEIGHT="64.88208669818484" Z="5.089827535188309">
<NAME>12mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.7313524654126982" CI_START="0.9911366382441477" EFFECT_SIZE="1.3099644507332475" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.238385489713352" LOG_CI_START="-0.0038664694855959814" LOG_EFFECT_SIZE="0.11725951011387804" ORDER="1" SE="0.1423" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" WEIGHT="10.51585083552287"/>
<IV_DATA CI_END="2.820188383413985" CI_START="1.7633163303854817" EFFECT_SIZE="2.2299964644001817" ESTIMABLE="YES" ESTIMATE="0.802" LOG_CI_END="0.4502781193635478" LOG_CI_START="0.24633022960926823" LOG_EFFECT_SIZE="0.348304174486408" ORDER="2" SE="0.1198" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="12.706571557550971"/>
<IV_DATA CI_END="1.7648699601759155" CI_START="1.2747154653615307" EFFECT_SIZE="1.4999023410169836" ESTIMABLE="YES" ESTIMATE="0.4054" LOG_CI_END="0.24671271105041132" LOG_CI_START="0.10541325487674527" LOG_EFFECT_SIZE="0.17606298296357825" ORDER="3" SE="0.083" STUDY_ID="STD-Ludwig-2006" TOTAL_1="317" TOTAL_2="312" WEIGHT="17.255887944010333"/>
<IV_DATA CI_END="1.7238422093080552" CI_START="1.0727702890923985" EFFECT_SIZE="1.359884813220988" ESTIMABLE="YES" ESTIMATE="0.3074" LOG_CI_END="0.2364975104660572" LOG_CI_START="0.030506737008062012" LOG_EFFECT_SIZE="0.1335021237370596" ORDER="4" SE="0.121" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" WEIGHT="12.578176451134278"/>
<IV_DATA CI_END="2.14741196362518" CI_START="1.2986647494092518" EFFECT_SIZE="1.6699605443302317" ESTIMABLE="YES" ESTIMATE="0.5128" LOG_CI_END="0.33191536831445356" LOG_CI_START="0.1134970523255215" LOG_EFFECT_SIZE="0.22270621031998755" ORDER="5" SE="0.1283" STUDY_ID="STD-Wolff-2004" TOTAL_1="165" TOTAL_2="149" WEIGHT="11.825599909966375"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.09168288989075249" CI_END="1.6310521613775326" CI_START="1.2185485494199386" DF="2.0" EFFECT_SIZE="1.409792979580636" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.21246785008760682" LOG_CI_START="0.08584283702927334" LOG_EFFECT_SIZE="0.14915534355844007" NO="2" P_CHI2="0.9551934025503549" P_Z="3.885797828208655E-6" STUDIES="3" TAU2="0.0" TOTAL_1="516" TOTAL_2="518" WEIGHT="35.11791330181518" Z="4.617398954842618">
<NAME>6mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.925048030270981" CI_START="1.1072163599974907" EFFECT_SIZE="1.4599468048175503" ESTIMABLE="YES" ESTIMATE="0.3784" LOG_CI_END="0.2844415696998067" LOG_CI_START="0.04423249420457427" LOG_EFFECT_SIZE="0.16433703195219043" ORDER="1" SE="0.1411" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" WEIGHT="10.621453317925708"/>
<IV_DATA CI_END="1.7624339294829543" CI_START="1.1119377697601693" EFFECT_SIZE="1.3998988723829044" ESTIMABLE="YES" ESTIMATE="0.3364" LOG_CI_END="0.24611284503999947" LOG_CI_START="0.04608048238450835" LOG_EFFECT_SIZE="0.14609666371225388" ORDER="2" SE="0.1175" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" WEIGHT="12.95637718461239"/>
<IV_DATA CI_END="1.78451607988712" CI_START="1.0670018703552526" EFFECT_SIZE="1.3798847759572466" ESTIMABLE="YES" ESTIMATE="0.322" LOG_CI_END="0.25152046564263625" LOG_CI_START="0.02816518070305797" LOG_EFFECT_SIZE="0.1398428231728471" ORDER="3" SE="0.1312" STUDY_ID="STD-Wolff-2004" TOTAL_1="155" TOTAL_2="149" WEIGHT="11.54008279927708"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.8461167631537028" CI_END="1.4221737339519553" CI_START="1.1944137226048321" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="1.30332798011873" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.15295265341754782" LOG_CI_START="0.07715478434968887" LOG_DATA="YES" LOG_EFFECT_SIZE="0.11505371888361832" NO="2" P_CHI2="0.6974919096153938" P_Q="0.9166039543886053" P_Z="2.6803509766200796E-9" Q="0.010964704907407974" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1448" TOTAL_2="1138" WEIGHT="100.0" Z="5.950065564439685">
<NAME>GI-3</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.8805519350853244" CI_END="1.4566946935854461" CI_START="1.1567615536066205" DF="3.0" EFFECT_SIZE="1.2980941479270371" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.1633685381906281" LOG_CI_START="0.06324384587890966" LOG_EFFECT_SIZE="0.11330619203476887" NO="1" P_CHI2="0.41041084184325016" P_Z="9.16501986651725E-6" STUDIES="4" TAU2="0.0" TOTAL_1="932" TOTAL_2="620" WEIGHT="57.31015772442832" Z="4.4359897740736365">
<NAME>12mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.6471513886808122" CI_START="0.9945674451773783" EFFECT_SIZE="1.2799231025575897" ESTIMABLE="YES" ESTIMATE="0.2468" LOG_CI_END="0.2167335167454745" LOG_CI_START="-0.0023657604780294443" LOG_EFFECT_SIZE="0.10718387813372253" ORDER="1" SE="0.1287" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" WEIGHT="11.968289971802474"/>
<IV_DATA CI_END="1.4721613403554115" CI_START="0.9139936815470754" EFFECT_SIZE="1.1599767942949202" ESTIMABLE="YES" ESTIMATE="0.1484" LOG_CI_END="0.167955408769369" LOG_CI_START="-0.0390568065404839" LOG_EFFECT_SIZE="0.06444930111444255" ORDER="2" SE="0.1216" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="13.40670479969952"/>
<IV_DATA CI_END="1.5406313575021535" CI_START="1.0304624635235262" EFFECT_SIZE="1.2599852316726825" ESTIMABLE="YES" ESTIMATE="0.2311" LOG_CI_END="0.1876987331016857" LOG_CI_START="0.013032176433997318" LOG_EFFECT_SIZE="0.10036545476784148" ORDER="3" SE="0.1026" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" WEIGHT="18.831914560894802"/>
<IV_DATA CI_END="1.959668977793894" CI_START="1.2100049250644607" EFFECT_SIZE="1.5398730839347279" ESTIMABLE="YES" ESTIMATE="0.4317" LOG_CI_END="0.29218271765306103" LOG_CI_START="0.0827871380222065" LOG_EFFECT_SIZE="0.18748492783763382" ORDER="4" SE="0.123" STUDY_ID="STD-Wolff-2004" TOTAL_1="165" TOTAL_2="149" WEIGHT="13.103248392031526"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.9546001231609703" CI_END="1.4976303765972188" CI_START="1.1465548316227299" DF="2.0" EFFECT_SIZE="1.3103874786766356" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.1754046403248252" LOG_CI_START="0.05939482880147512" LOG_EFFECT_SIZE="0.11739973456315024" NO="2" P_CHI2="0.6204563700104685" P_Z="7.281567890484417E-5" STUDIES="3" TAU2="0.0" TOTAL_1="516" TOTAL_2="518" WEIGHT="42.68984227557168" Z="3.9668929466715483">
<NAME>6mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.8549680512340971" CI_START="1.1332986359456974" EFFECT_SIZE="1.449907846101417" ESTIMABLE="YES" ESTIMATE="0.3715" LOG_CI_END="0.26833643400916546" LOG_CI_START="0.05434436604495064" LOG_EFFECT_SIZE="0.161340400027058" ORDER="1" SE="0.1257" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" WEIGHT="12.546385898351566"/>
<IV_DATA CI_END="1.526015646311615" CI_START="1.0075683100081518" EFFECT_SIZE="1.2399858893552747" ESTIMABLE="YES" ESTIMATE="0.2151" LOG_CI_END="0.18355898648384275" LOG_CI_START="0.00327449963093624" LOG_EFFECT_SIZE="0.09341674305738948" ORDER="2" SE="0.1059" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" WEIGHT="17.6765406567784"/>
<IV_DATA CI_END="1.6387790099905828" CI_START="0.9996486033037855" EFFECT_SIZE="1.2799231025575897" ESTIMABLE="YES" ESTIMATE="0.2468" LOG_CI_END="0.21452039273311588" LOG_CI_START="-1.5263646567078545E-4" LOG_EFFECT_SIZE="0.10718387813372253" ORDER="3" SE="0.1261" STUDY_ID="STD-Wolff-2004" TOTAL_1="155" TOTAL_2="149" WEIGHT="12.466915720441714"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.489776076898167" CI_END="2.0212709735496968" CI_START="1.426468418263835" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.6980221460634835" ESTIMABLE="YES" I2="56.483050961687475" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.30562453935831224" LOG_CI_START="0.15426216090331138" LOG_DATA="YES" LOG_EFFECT_SIZE="0.2299433501308118" NO="3" P_CHI2="0.04248900291000868" P_Q="0.37866972357074125" P_Z="2.6008858010029826E-9" Q="0.7750162908501306" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.02512448253917996" TOTALS="YES" TOTAL_1="1154" TOTAL_2="866" WEIGHT="100.0" Z="5.95498946754275">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.501898206300083" CI_END="2.3353767077758616" CI_START="1.2945919886321713" DF="2.0" EFFECT_SIZE="1.7387811755148508" ESTIMABLE="YES" I2="76.47584161243006" ID="CMP-001.03.01" LOG_CI_END="0.36835694439366157" LOG_CI_START="0.1121329151308487" LOG_EFFECT_SIZE="0.2402449297622552" NO="1" P_CHI2="0.014250729294602138" P_Z="2.374152539108944E-4" STUDIES="3" TAU2="0.05189305727798377" TOTAL_1="767" TOTAL_2="471" WEIGHT="57.65453743717004" Z="3.675466435815005">
<NAME>12mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.9343879165289495" CI_START="1.1169581419676087" EFFECT_SIZE="1.4699082736996785" ESTIMABLE="YES" ESTIMATE="0.3852" LOG_CI_END="0.2865435706335339" LOG_CI_START="0.04803689822473129" LOG_EFFECT_SIZE="0.16729023442913257" ORDER="1" SE="0.1401" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" WEIGHT="17.66419547776682"/>
<IV_DATA CI_END="2.9568710174374058" CI_START="1.835778017669588" EFFECT_SIZE="2.3298409419734853" ESTIMABLE="YES" ESTIMATE="0.8458" LOG_CI_END="0.4708323804486969" LOG_CI_START="0.2638201651388439" LOG_EFFECT_SIZE="0.3673262727937704" ORDER="2" SE="0.1216" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="19.806968849619494"/>
<IV_DATA CI_END="1.9173724481325303" CI_START="1.2049574653224318" EFFECT_SIZE="1.5199842910967336" ESTIMABLE="YES" ESTIMATE="0.4187" LOG_CI_END="0.28270648244385194" LOG_CI_START="0.0809717167019311" LOG_EFFECT_SIZE="0.18183909957289154" ORDER="3" SE="0.1185" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" WEIGHT="20.183373109783727"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.2128615797479534" CI_END="1.9208259774914798" CI_START="1.32451523595958" DF="2.0" EFFECT_SIZE="1.5950433451208836" ESTIMABLE="YES" I2="9.619290320554008" ID="CMP-001.03.02" LOG_CI_END="0.2834880205417417" LOG_CI_START="0.1220569583713508" LOG_EFFECT_SIZE="0.20277248945654627" NO="2" P_CHI2="0.33073760625818605" P_Z="8.488150000280048E-7" STUDIES="3" TAU2="0.003052778014018534" TOTAL_1="387" TOTAL_2="395" WEIGHT="42.34546256282995" Z="4.923795594814007">
<NAME>6mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="2.032492798097098" CI_START="1.1819161542038328" EFFECT_SIZE="1.549914859395157" ESTIMABLE="YES" ESTIMATE="0.4382" LOG_CI_END="0.3080290153966195" LOG_CI_START="0.07258666854339037" LOG_EFFECT_SIZE="0.19030784197000494" ORDER="1" SE="0.1383" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" WEIGHT="17.864231795961945"/>
<IV_DATA CI_END="6.53327974470335" CI_START="1.2872278142604252" EFFECT_SIZE="2.899968862889118" ESTIMABLE="YES" ESTIMATE="1.0647" LOG_CI_END="0.8151312543906285" LOG_CI_START="0.10965541537415593" LOG_EFFECT_SIZE="0.4623933348823922" ORDER="2" SE="0.4144" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="4.015795667099419"/>
<IV_DATA CI_END="1.933724266016544" CI_START="1.2262395194074491" EFFECT_SIZE="1.5398730839347279" ESTIMABLE="YES" ESTIMATE="0.4317" LOG_CI_END="0.2863945471592001" LOG_CI_START="0.08857530851606751" LOG_EFFECT_SIZE="0.18748492783763382" ORDER="3" SE="0.1162" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" WEIGHT="20.465435099768587"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="13.38756193948071" CI_END="1.479570375656104" CI_START="1.0606425912560127" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.25271519396131" ESTIMABLE="YES" I2="62.65190015476451" I2_Q="49.919292480086476" ID="CMP-001.04" LOG_CI_END="0.17013562717303796" LOG_CI_START="0.025569062699639985" LOG_DATA="YES" LOG_EFFECT_SIZE="0.09785234493633899" NO="4" P_CHI2="0.020005353337000376" P_Q="0.15763444829754836" P_Z="0.007971605235434276" Q="1.9967769017687527" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.025442627165182863" TOTALS="YES" TOTAL_1="1154" TOTAL_2="866" WEIGHT="99.99999999999999" Z="2.6532701053888013">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.43833175657767287" CI_END="1.2913738179134393" CI_START="1.0047899295771965" DF="2.0" EFFECT_SIZE="1.1391046517151442" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.11105197701252954" LOG_CI_START="0.002075273734909731" LOG_EFFECT_SIZE="0.05656362537371963" NO="1" P_CHI2="0.8031886031820616" P_Z="0.041889902243781696" STUDIES="3" TAU2="0.0" TOTAL_1="767" TOTAL_2="471" WEIGHT="57.04488857614571" Z="2.03461226543222">
<NAME>12mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.4275269496529255" CI_START="0.8786720535616325" EFFECT_SIZE="1.1199678729169462" ESTIMABLE="YES" ESTIMATE="0.1133" LOG_CI_END="0.1545843158496376" LOG_CI_START="-0.05617318625036073" LOG_EFFECT_SIZE="0.04920556479963841" ORDER="1" SE="0.1238" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" WEIGHT="17.688057867454045"/>
<IV_DATA CI_END="1.347652378153969" CI_START="0.881470186074921" EFFECT_SIZE="1.0899153143871725" ESTIMABLE="YES" ESTIMATE="0.0861" LOG_CI_END="0.12957788202203882" LOG_CI_START="-0.05479237223829888" LOG_EFFECT_SIZE="0.037392754891869995" ORDER="2" SE="0.1083" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="19.399951204986753"/>
<IV_DATA CI_END="1.4695559436434653" CI_START="0.9798455948547835" EFFECT_SIZE="1.1999741321260697" ESTIMABLE="YES" ESTIMATE="0.1823" LOG_CI_END="0.16718612361937887" LOG_CI_START="-0.008842355517453295" LOG_EFFECT_SIZE="0.07917188405096284" ORDER="3" SE="0.1034" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" WEIGHT="19.95687950370491"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="10.952453281134284" CI_END="2.3746557562506316" CI_START="1.0392086490666843" DF="2.0" EFFECT_SIZE="1.5709114553187409" ESTIMABLE="YES" I2="81.73925102748422" ID="CMP-001.04.02" LOG_CI_END="0.37560066069912723" LOG_CI_START="0.016702752601445145" LOG_EFFECT_SIZE="0.19615170665028617" NO="2" P_CHI2="0.004185111995402169" P_Z="0.032161827012109956" STUDIES="3" TAU2="0.1001091443931554" TOTAL_1="387" TOTAL_2="395" WEIGHT="42.95511142385428" Z="2.1423935434919836">
<NAME>6mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.6581914605902877" CI_START="1.019051683848911" EFFECT_SIZE="1.2999164588766532" ESTIMABLE="YES" ESTIMATE="0.2623" LOG_CI_END="0.21963467427050806" LOG_CI_START="0.008196210935937804" LOG_EFFECT_SIZE="0.11391544260322292" ORDER="1" SE="0.1242" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" WEIGHT="17.645123447617756"/>
<IV_DATA CI_END="7.018996322051641" CI_START="1.9502932897203689" EFFECT_SIZE="3.6998785692870064" ESTIMABLE="YES" ESTIMATE="1.3083" LOG_CI_END="0.8462750148423178" LOG_CI_START="0.2900999265057309" LOG_EFFECT_SIZE="0.5681874706740244" ORDER="2" SE="0.3267" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="5.455818404846243"/>
<IV_DATA CI_END="1.4598362086744534" CI_START="0.9699369170316229" EFFECT_SIZE="1.1899365662138601" ESTIMABLE="YES" ESTIMATE="0.1739" LOG_CI_END="0.16430413136028496" LOG_CI_START="-0.013256510554333991" LOG_EFFECT_SIZE="0.0755238104029755" ORDER="3" SE="0.1043" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" WEIGHT="19.854169571390283"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="8.057586855095158" CI_END="1.4349804618388597" CI_START="1.2404764547753457" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="1.334188695789976" ESTIMABLE="YES" I2="0.7146910871800691" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.15684598791786064" LOG_CI_START="0.09358852543355115" LOG_DATA="YES" LOG_EFFECT_SIZE="0.12521725667570593" NO="5" P_CHI2="0.42786524000953274" P_Q="0.5270781290591149" P_Z="8.530370180762405E-15" Q="0.40002236073974373" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1791" TOTAL_2="1476" WEIGHT="100.00000000000001" Z="7.759442244088311">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.4925846271720244" CI_END="1.434422471719169" CI_START="1.2008180259675134" DF="4.0" EFFECT_SIZE="1.3124329929155445" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.1566770802819488" LOG_CI_START="0.07947719865515299" LOG_EFFECT_SIZE="0.11807713946855089" NO="1" P_CHI2="0.47900680858437217" P_Z="2.0282809756908967E-9" STUDIES="5" TAU2="0.0" TOTAL_1="1249" TOTAL_2="932" WEIGHT="67.14138015878679" Z="5.995525793022592">
<NAME>12mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.498432571925444" CI_START="0.9292108423130785" EFFECT_SIZE="1.17998296271946" ESTIMABLE="YES" ESTIMATE="0.1655" LOG_CI_END="0.17563720487287915" LOG_CI_START="-0.03188573136290272" LOG_EFFECT_SIZE="0.07187573675498823" ORDER="1" SE="0.1219" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" WEIGHT="9.29161755828529"/>
<IV_DATA CI_END="1.4332486219570928" CI_START="0.8908817010403084" EFFECT_SIZE="1.1299800751972633" ESTIMABLE="YES" ESTIMATE="0.1222" LOG_CI_END="0.15632153288053943" LOG_CI_START="-0.05017996150338464" LOG_EFFECT_SIZE="0.05307078568857741" ORDER="2" SE="0.1213" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="9.383765267942417"/>
<IV_DATA CI_END="1.616180032375712" CI_START="1.2125609855594068" EFFECT_SIZE="1.3998988723829044" ESTIMABLE="YES" ESTIMATE="0.3364" LOG_CI_END="0.20848973682990282" LOG_CI_START="0.08370359059460493" LOG_EFFECT_SIZE="0.14609666371225388" ORDER="3" SE="0.0733" STUDY_ID="STD-Ludwig-2006" TOTAL_1="317" TOTAL_2="312" WEIGHT="25.697494865011503"/>
<IV_DATA CI_END="1.6017428294246898" CI_START="1.0713373149928254" EFFECT_SIZE="1.3099644507332475" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.2045927884477222" LOG_CI_START="0.029926231780033737" LOG_EFFECT_SIZE="0.11725951011387804" ORDER="4" SE="0.1026" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" WEIGHT="13.116078754077387"/>
<IV_DATA CI_END="1.7950119737862293" CI_START="1.12320736053298" EFFECT_SIZE="1.419919244605666" ESTIMABLE="YES" ESTIMATE="0.3506" LOG_CI_END="0.2540673499237769" LOG_CI_START="0.050459940786783335" LOG_EFFECT_SIZE="0.1522636453552801" ORDER="5" SE="0.1196" STUDY_ID="STD-Wolff-2004" TOTAL_1="165" TOTAL_2="149" WEIGHT="9.652423713470185"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.16497986718339" CI_END="1.5666927391479186" CI_START="1.2151505216484442" DF="3.0" EFFECT_SIZE="1.379770814026164" ESTIMABLE="YES" I2="27.970840300152982" ID="CMP-001.05.02" LOG_CI_END="0.19498383068872635" LOG_CI_START="0.08463007766469957" LOG_EFFECT_SIZE="0.13980695417671296" NO="2" P_CHI2="0.2441916617283868" P_Z="6.829545916090182E-7" STUDIES="4" TAU2="0.0" TOTAL_1="542" TOTAL_2="544" WEIGHT="32.858619841213226" Z="4.9661490881046655">
<NAME>6mg Alvimopan versus Placebo</NAME>
<IV_DATA CI_END="1.90319799044074" CI_START="1.1820667339330493" EFFECT_SIZE="1.4999023410169836" ESTIMABLE="YES" ESTIMATE="0.4054" LOG_CI_END="0.2794839704641833" LOG_CI_START="0.07264199546297327" LOG_EFFECT_SIZE="0.17606298296357825" ORDER="1" SE="0.1215" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" WEIGHT="9.352897639944567"/>
<IV_DATA CI_END="4.5625249807761525" CI_START="1.2622852969302147" EFFECT_SIZE="2.3998350360202987" ESTIMABLE="YES" ESTIMATE="0.8754" LOG_CI_END="0.6592052553239364" LOG_CI_START="0.10115752359227688" LOG_EFFECT_SIZE="0.38018138945810664" ORDER="2" SE="0.3278" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.2849340527925708"/>
<IV_DATA CI_END="1.6164950823204243" CI_START="1.077819182296042" EFFECT_SIZE="1.3199581083550238" ESTIMABLE="YES" ESTIMATE="0.2776" LOG_CI_END="0.20857438774475884" LOG_CI_START="0.032545908607926576" LOG_EFFECT_SIZE="0.12056014817634274" ORDER="3" SE="0.1034" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" WEIGHT="12.913907155295549"/>
<IV_DATA CI_END="1.5869653589813628" CI_START="0.9844978021908487" EFFECT_SIZE="1.2499455620426687" ESTIMABLE="YES" ESTIMATE="0.2231" LOG_CI_END="0.20056744687618494" LOG_CI_START="-0.0067852490509539955" LOG_EFFECT_SIZE="0.09689109891261549" ORDER="4" SE="0.1218" STUDY_ID="STD-Wolff-2004" TOTAL_1="155" TOTAL_2="149" WEIGHT="9.306880993180538"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.350129522753835" CI_END="3.2347016201928733" CI_START="0.862687559186767" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="1.6704900015928472" ESTIMABLE="YES" I2="77.01217872319918" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5098342260618357" LOG_CI_START="-0.0641464648756416" LOG_DATA="YES" LOG_EFFECT_SIZE="0.22284388059309704" NO="6" P_CHI2="0.037006339419830225" P_Q="1.0" P_Z="0.12803817927346736" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.18073295500000014" TOTALS="YES" TOTAL_1="434" TOTAL_2="128" WEIGHT="100.0" Z="1.521883878791284">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.5683560628886413" CI_START="1.0122464034788419" EFFECT_SIZE="1.2599852316726825" ESTIMABLE="YES" ESTIMATE="0.2311" LOG_CI_END="0.19544466714494088" LOG_CI_START="0.005286242390742114" LOG_EFFECT_SIZE="0.10036545476784148" ORDER="1" SE="0.1117" STUDY_ID="STD-Herzog-2006" TOTAL_1="408" TOTAL_2="102" WEIGHT="58.83564479366363"/>
<IV_DATA CI_END="4.579697165290673" CI_START="1.3644714331397574" EFFECT_SIZE="2.4997731806046426" ESTIMABLE="YES" ESTIMATE="0.9162" LOG_CI_END="0.6608367610188283" LOG_CI_START="0.1349644476206903" LOG_EFFECT_SIZE="0.3979006043197594" ORDER="2" SE="0.3089" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="41.16435520633636"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Cholecystokinin-like acting drugs versus Placebo or No treatment</NAME>
<IV_OUTCOME CHI2="19.798667012392766" CI_END="1.0422350547173074" CI_START="0.705005511561904" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.857193944168252" ESTIMABLE="YES" I2="84.8474647403172" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.01796567621345563" LOG_CI_START="-0.15180748778652312" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06692090578653374" NO="3" P_CHI2="1.8685621487135595E-4" P_Q="1.0" P_Z="0.1223098058046495" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03209140640792251" TOTALS="YES" TOTAL_1="128" TOTAL_2="129" WEIGHT="100.0" Z="1.5451507418972377">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Cerulein/Ceruletide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.1663623837365775" CI_START="0.9211892028312676" EFFECT_SIZE="1.0365521860893812" ESTIMABLE="YES" ESTIMATE="0.0359" LOG_CI_END="0.06683350480186104" LOG_CI_START="-0.03565116100120758" LOG_EFFECT_SIZE="0.015591171900326765" ORDER="1" SE="0.0602" STUDY_ID="STD-Alvarez-1979" TOTAL_1="25" TOTAL_2="25" WEIGHT="27.845640142138784"/>
<IV_DATA CI_END="0.7485598324996774" CI_START="0.4769250834325274" EFFECT_SIZE="0.5975005946182375" ESTIMABLE="YES" ESTIMATE="-0.515" LOG_CI_END="-0.12577348071046623" LOG_CI_START="-0.32154983564988315" LOG_EFFECT_SIZE="-0.22366165818017475" ORDER="2" SE="0.115" STUDY_ID="STD-Ferreira-1980" TOTAL_1="29" TOTAL_2="30" WEIGHT="21.946123866013018"/>
<IV_DATA CI_END="1.0386353509326955" CI_START="0.6496589871279318" EFFECT_SIZE="0.8214370274599259" ESTIMABLE="YES" ESTIMATE="-0.1967" LOG_CI_END="0.016463100132448612" LOG_CI_START="-0.1873145493131879" LOG_EFFECT_SIZE="-0.08542572459036962" ORDER="3" SE="0.1197" STUDY_ID="STD-Frisell-1985" TOTAL_1="27" TOTAL_2="30" WEIGHT="21.42460701105574"/>
<IV_DATA CI_END="1.0684555704030112" CI_START="0.8796649227413118" EFFECT_SIZE="0.9694755730760259" ESTIMABLE="YES" ESTIMATE="-0.031" LOG_CI_END="0.02875646760445609" LOG_CI_START="-0.055682725482457625" LOG_EFFECT_SIZE="-0.013463128939000809" ORDER="4" SE="0.0496" STUDY_ID="STD-Sadek-1988" TOTAL_1="47" TOTAL_2="44" WEIGHT="28.783628980792454"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6863634768396197" CI_END="0.9704389998457682" CI_START="0.8962447530697502" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9326043436452706" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.013031758434281726" LOG_CI_START="-0.047573373828494504" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.030302566131388094" NO="4" P_CHI2="0.40740443830841744" P_Q="1.0" P_Z="5.841631926151128E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="69" WEIGHT="100.0" Z="3.4388628081716583">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Cerulein/ Ceruletide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9883040674829435" CI_START="0.899213189396243" EFFECT_SIZE="0.9427067691570997" ESTIMABLE="YES" ESTIMATE="-0.059" LOG_CI_END="-0.005109417240813828" LOG_CI_START="-0.04613733162376988" LOG_EFFECT_SIZE="-0.02562337443229187" ORDER="1" SE="0.0241" STUDY_ID="STD-Alvarez-1979" TOTAL_1="25" TOTAL_2="25" WEIGHT="70.88044039567426"/>
<IV_DATA CI_END="0.9779415709066205" CI_START="0.8439224725118956" EFFECT_SIZE="0.9084640160687062" ESTIMABLE="YES" ESTIMATE="-0.096" LOG_CI_END="-0.0096870922378336" LOG_CI_START="-0.07369744828759076" LOG_EFFECT_SIZE="-0.041692270262712154" ORDER="2" SE="0.0376" STUDY_ID="STD-Sadek-1988" TOTAL_1="47" TOTAL_2="44" WEIGHT="29.119559604325744"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5938079514681864" CI_END="0.9691717599117311" CI_START="0.6757187394639557" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8092512094100437" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.013599248984785126" LOG_CI_START="-0.17023403677587082" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09191664288032798" NO="5" P_CHI2="0.44095052811019764" P_Q="1.0" P_Z="0.021431368155249837" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="69" WEIGHT="100.0" Z="2.300297554149406">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Cerulein/ Ceruletide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.987236889958156" CI_START="0.5570196609497742" EFFECT_SIZE="0.7415594094350105" ESTIMABLE="YES" ESTIMATE="-0.299" LOG_CI_END="-0.005578624779703353" LOG_CI_START="-0.2541294753984412" LOG_EFFECT_SIZE="-0.12985405008907228" ORDER="1" SE="0.146" STUDY_ID="STD-Alvarez-1979" TOTAL_1="25" TOTAL_2="25" WEIGHT="39.71421096915147"/>
<IV_DATA CI_END="1.0812910373562366" CI_START="0.6795287524432893" EFFECT_SIZE="0.8571862980955736" ESTIMABLE="YES" ESTIMATE="-0.1541" LOG_CI_END="0.03394260320966934" LOG_CI_START="-0.1677921625322515" LOG_EFFECT_SIZE="-0.06692477966129108" ORDER="2" SE="0.1185" STUDY_ID="STD-Sadek-1988" TOTAL_1="47" TOTAL_2="44" WEIGHT="60.285789030848534"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.4928330696952603" CI_END="1.084649986201216" CI_START="0.5536340494761339" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.7749188113117477" ESTIMABLE="YES" I2="59.884999434709584" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.03528961506451759" LOG_CI_START="-0.2567772078488806" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11074379639218151" NO="6" P_CHI2="0.11436596354398942" P_Q="1.0" P_Z="0.13719183353599856" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.037395654999999986" TOTALS="YES" TOTAL_1="74" TOTAL_2="74" WEIGHT="100.0" Z="1.4863300821009164">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Cerulein/ Ceruletide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.0793687510061765" CI_START="0.7279110804777751" EFFECT_SIZE="0.8863884440688815" ESTIMABLE="YES" ESTIMATE="-0.1206" LOG_CI_END="0.03316984057556081" LOG_CI_START="-0.13792166961062524" LOG_EFFECT_SIZE="-0.05237591451753216" ORDER="1" SE="0.1005" STUDY_ID="STD-Frisell-1985" TOTAL_1="27" TOTAL_2="30" WEIGHT="61.970284461175766"/>
<IV_DATA CI_END="0.921265322713583" CI_START="0.4206337413829332" EFFECT_SIZE="0.6225072525676868" ESTIMABLE="YES" ESTIMATE="-0.474" LOG_CI_END="-0.03561527577917018" LOG_CI_START="-0.37609589306511254" LOG_EFFECT_SIZE="-0.20585558442214133" ORDER="3" SE="0.2" STUDY_ID="STD-Sadek-1988" TOTAL_1="47" TOTAL_2="44" WEIGHT="38.02971553882424"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Cisapride versus Placebo</NAME>
<IV_OUTCOME CHI2="22.140768322154482" CI_END="0.970074240896339" CI_START="0.5372729520060916" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.721938121359057" ESTIMABLE="YES" I2="86.450334711293" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.013195027406120417" LOG_CI_START="-0.26980502261794503" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1415000250120327" NO="3" P_CHI2="6.0976699487680364E-5" P_Q="1.0" P_Z="0.030654511521441764" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.07584922688601002" TOTALS="YES" TOTAL_1="90" TOTAL_2="91" WEIGHT="99.99999999999999" Z="2.1615288415103904">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Cisapride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9259947751362704" CI_START="0.6912088116435273" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.033391463788787226" LOG_CI_START="-0.1603907340364437" LOG_EFFECT_SIZE="-0.0968910989126155" ORDER="1" SE="0.0746" STUDY_ID="STD-Brown-1999" TOTAL_1="17" TOTAL_2="18" WEIGHT="27.907516135648095"/>
<IV_DATA CI_END="1.2479172108077614" CI_START="0.8013352098515513" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.09618577438327873" LOG_CI_START="-0.09618577438327872" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.113" STUDY_ID="STD-Clevers-1991" TOTAL_1="17" TOTAL_2="20" WEIGHT="25.638893888249402"/>
<IV_DATA CI_END="0.6191301784297003" CI_START="0.41281312263072306" EFFECT_SIZE="0.505554212990537" ESTIMABLE="YES" ESTIMATE="-0.6821" LOG_CI_END="-0.20821802653779192" LOG_CI_START="-0.3842465056746242" LOG_EFFECT_SIZE="-0.29623226610620806" ORDER="3" SE="0.1034" STUDY_ID="STD-Hallerb_x00e4_ck-1991" TOTAL_1="36" TOTAL_2="33" WEIGHT="26.254363953126006"/>
<IV_DATA CI_END="0.957851145696558" CI_START="0.45233279106488367" EFFECT_SIZE="0.658230569145509" ESTIMABLE="YES" ESTIMATE="-0.4182" LOG_CI_END="-0.01870197696061649" LOG_CI_START="-0.3445419277032634" LOG_EFFECT_SIZE="-0.18162195233193987" ORDER="4" SE="0.1914" STUDY_ID="STD-Tollesson-1991_x0028_2_x0029_" TOTAL_1="20" TOTAL_2="20" WEIGHT="20.19922602297649"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.7147090915332868" CI_END="1.1041678210673218" CI_START="0.7137752108845936" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8877655204694029" ESTIMABLE="YES" I2="73.07999158590265" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.04303508627764471" LOG_CI_START="-0.14643853898469508" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05170172635352518" NO="4" P_CHI2="0.05393526517560132" P_Q="1.0" P_Z="0.2847850242192209" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.018187275" TOTALS="YES" TOTAL_1="34" TOTAL_2="38" WEIGHT="100.0" Z="1.0696319495776914">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Cisapride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9193038745049459" CI_START="0.6962395850389873" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.03654090949868218" LOG_CI_START="-0.1572412883265487" LOG_EFFECT_SIZE="-0.0968910989126155" ORDER="1" SE="0.0709" STUDY_ID="STD-Brown-1999" TOTAL_1="17" TOTAL_2="18" WEIGHT="53.36065637995717"/>
<IV_DATA CI_END="1.1964235176407287" CI_START="0.8358244260961508" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.07788494120415934" LOG_CI_START="-0.0778849412041593" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.0915" STUDY_ID="STD-Clevers-1991" TOTAL_1="17" TOTAL_2="20" WEIGHT="46.63934362004284"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.8832257113037166" CI_END="1.011785231874801" CI_START="0.7236407761164971" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8556687738004064" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.005088336110214737" LOG_CI_START="-0.14047696925356593" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0676943165716756" NO="5" P_CHI2="0.3473198078178712" P_Q="1.0" P_Z="0.06831245057156853" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="38" WEIGHT="100.0" Z="1.8229401862890606">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Cisapride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9912867179140927" CI_START="0.6798734947082817" EFFECT_SIZE="0.8209443130725476" ESTIMABLE="YES" ESTIMATE="-0.1973" LOG_CI_END="-0.003800712822242464" LOG_CI_START="-0.16757188973678075" LOG_EFFECT_SIZE="-0.08568630127951157" ORDER="1" SE="0.0962" STUDY_ID="STD-Brown-1999" TOTAL_1="17" TOTAL_2="18" WEIGHT="79.00249580251395"/>
<IV_DATA CI_END="1.441564928667507" CI_START="0.6936905720398857" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.15883420796389205" LOG_CI_START="-0.15883420796389208" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.1866" STUDY_ID="STD-Clevers-1991" TOTAL_1="17" TOTAL_2="20" WEIGHT="20.997504197486048"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.267062546890745" CI_END="1.0093478690110869" CI_START="0.7915984411424654" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8938669921636249" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.004040870453666914" LOG_CI_START="-0.10149506970047202" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04872709962340252" NO="6" P_CHI2="0.514167952286581" P_Q="1.0" P_Z="0.07031537816028989" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="74" WEIGHT="100.00000000000001" Z="1.8098736827184785">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Cisapride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.0007146007783518" CI_START="0.5407953538344237" EFFECT_SIZE="0.7356506009072533" ESTIMABLE="YES" ESTIMATE="-0.307" LOG_CI_END="3.102363404340425E-4" LOG_CI_START="-0.2669670482290307" LOG_EFFECT_SIZE="-0.13332840594429832" ORDER="1" SE="0.157" STUDY_ID="STD-Benson-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="15.591096727448274"/>
<IV_DATA CI_END="1.2210612162426162" CI_START="0.8189597595091473" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.08673743725359383" LOG_CI_START="-0.08673743725359387" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.1019" STUDY_ID="STD-Clevers-1991" TOTAL_1="17" TOTAL_2="20" WEIGHT="37.01072586844772"/>
<IV_DATA CI_END="1.0931581980933938" CI_START="0.6299776501196946" EFFECT_SIZE="0.8298585619513459" ESTIMABLE="YES" ESTIMATE="-0.1865" LOG_CI_END="0.038683016101052285" LOG_CI_START="-0.20067485785096517" LOG_EFFECT_SIZE="-0.08099592087495648" ORDER="3" SE="0.1406" STUDY_ID="STD-Roberts-1995" TOTAL_1="7" TOTAL_2="7" WEIGHT="19.44040594337985"/>
<IV_DATA CI_END="1.1914503975326813" CI_START="0.7211043761094689" EFFECT_SIZE="0.9269088928142737" ESTIMABLE="YES" ESTIMATE="-0.0759" LOG_CI_END="0.07607596650936624" LOG_CI_START="-0.14200186886227978" LOG_EFFECT_SIZE="-0.03296295117645681" ORDER="4" SE="0.1281" STUDY_ID="STD-Tollesson-1991_x0028_2_x0029_" TOTAL_1="20" TOTAL_2="20" WEIGHT="23.419504987313687"/>
<IV_DATA CI_END="1.4096613799739557" CI_START="0.450521481448021" EFFECT_SIZE="0.7969207822901396" ESTIMABLE="YES" ESTIMATE="-0.227" LOG_CI_END="0.14911480168348487" LOG_CI_START="-0.3462844964675612" LOG_EFFECT_SIZE="-0.09858484739203818" ORDER="5" SE="0.291" STUDY_ID="STD-Von-Ritter-1987" TOTAL_1="17" TOTAL_2="15" WEIGHT="4.538266473410476"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Dihydroergotamine versus No treatment</NAME>
<IV_OUTCOME CHI2="8.476226828587336" CI_END="1.176571530758646" CI_START="0.4290043271648902" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.710460609685349" ESTIMABLE="YES" I2="88.20229778859444" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.07061833565094515" LOG_CI_START="-0.3675383272689904" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1484599958090226" NO="3" P_CHI2="0.0035981880192422766" P_Q="1.0" P_Z="0.18411746394882805" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.11742195500000001" TOTALS="YES" TOTAL_1="66" TOTAL_2="57" WEIGHT="100.0" Z="1.328183590734631">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Dihydroergotamine</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Medians</EFFECT_MEASURE>
<IV_DATA CI_END="0.6540870109938586" CI_START="0.47745512241061083" EFFECT_SIZE="0.5588355696457262" ESTIMABLE="YES" ESTIMATE="-0.5819" LOG_CI_END="-0.18436447509934928" LOG_CI_START="-0.32106744293965517" LOG_EFFECT_SIZE="-0.25271595901950217" ORDER="1" SE="0.0803" STUDY_ID="STD-Altaparmakov-1984" TOTAL_1="23" TOTAL_2="23" WEIGHT="53.47708784027402"/>
<IV_DATA CI_END="1.2760563042761097" CI_START="0.6868946753126336" EFFECT_SIZE="0.9362244820588583" ESTIMABLE="YES" ESTIMATE="-0.0659" LOG_CI_END="0.10586983747052295" LOG_CI_START="-0.16310985018537155" LOG_EFFECT_SIZE="-0.028620006357424305" ORDER="2" SE="0.158" STUDY_ID="STD-Thorup-1983" TOTAL_1="43" TOTAL_2="34" WEIGHT="46.522912159725976"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Dopaminantagonists versus Placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.3661895933034556" CI_START="0.6767688169286482" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.9615583782382694" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.1355109728534947" LOG_CI_START="-0.16955966023470967" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.017024343690607454" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8268447978719031" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.21875">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Metoclopramide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.3661895933034556" CI_START="0.6767688169286482" EFFECT_SIZE="0.9615583782382694" ESTIMABLE="YES" ESTIMATE="-0.0392" LOG_CI_END="0.1355109728534947" LOG_CI_START="-0.16955966023470967" LOG_EFFECT_SIZE="-0.017024343690607454" ORDER="5456" SE="0.1792" STUDY_ID="STD-Tollesson-1991_x0028_1_x0029_" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0186495006377745" CI_START="0.7957440174099942" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.9003245225862656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.008024776622694501" LOG_CI_START="-0.09922661782237735" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.045600920599841444" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.09558070454332203" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="53" WEIGHT="100.0" Z="1.6666666666666665">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Metoclopramide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.0186495006377745" CI_START="0.7957440174099942" EFFECT_SIZE="0.9003245225862656" ESTIMABLE="YES" ESTIMATE="-0.105" LOG_CI_END="0.008024776622694501" LOG_CI_START="-0.09922661782237735" LOG_EFFECT_SIZE="-0.045600920599841444" ORDER="5457" SE="0.063" STUDY_ID="STD-Cheape-1991" TOTAL_1="40" TOTAL_2="53" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.597735192307976" CI_END="1.332759564563565" CI_START="0.6586857055090246" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.9369469963975828" ESTIMABLE="YES" I2="64.2712645151871" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.12475180792727583" LOG_CI_START="-0.18132176131317504" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.028284976692949645" NO="6" P_CHI2="0.06087901247234506" P_Q="1.0" P_Z="0.717165412635067" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.06216647497441804" TOTALS="YES" TOTAL_1="124" TOTAL_2="115" WEIGHT="100.00000000000001" Z="0.3622497411933304">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Dopaminantagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.8718420464331115" CI_START="0.628227454680059" EFFECT_SIZE="0.7400777727467076" ESTIMABLE="YES" ESTIMATE="-0.301" LOG_CI_END="-0.05956219004011684" LOG_CI_START="-0.20188308806564073" LOG_EFFECT_SIZE="-0.13072263905287881" ORDER="1" SE="0.0836" STUDY_ID="STD-Conte-1983" TOTAL_1="84" TOTAL_2="80" WEIGHT="46.74127370613336"/>
<IV_DATA CI_END="2.0245171187133377" CI_START="0.7779202922075037" EFFECT_SIZE="1.2549553572014318" ESTIMABLE="YES" ESTIMATE="0.2271" LOG_CI_END="0.3063214533846533" LOG_CI_START="-0.10906489970419633" LOG_EFFECT_SIZE="0.09862827684022848" ORDER="2" SE="0.244" STUDY_ID="STD-Jepsen-1986" TOTAL_1="30" TOTAL_2="25" WEIGHT="26.55996203105514"/>
<IV_DATA CI_END="1.7036674638633211" CI_START="0.6579783446610439" EFFECT_SIZE="1.0587616812699951" ESTIMABLE="YES" ESTIMATE="0.0571" LOG_CI_END="0.2313848294549212" LOG_CI_START="-0.18178839962156984" LOG_EFFECT_SIZE="0.024798214916675682" ORDER="3" SE="0.2427" STUDY_ID="STD-Tollesson-1991_x0028_1_x0029_" TOTAL_1="10" TOTAL_2="10" WEIGHT="26.69876426281151"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Erythromycin versus Placebo</NAME>
<IV_OUTCOME CHI2="0.9542022502471488" CI_END="1.0756485460307013" CI_START="0.9024688156958479" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.9852610158944115" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.03167039451582417" LOG_CI_START="-0.044567795965463355" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.006448700724819569" NO="3" P_CHI2="0.6205798135339754" P_Q="1.0" P_Z="0.7402125348102172" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="116" WEIGHT="100.0" Z="0.33157190872272874">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.2077666581568172" CI_START="0.863490038996716" EFFECT_SIZE="1.0212220516375285" ESTIMABLE="YES" ESTIMATE="0.021" LOG_CI_END="0.08198303621915998" LOG_CI_START="-0.06374266797922336" LOG_EFFECT_SIZE="0.009120184119968244" ORDER="1" SE="0.0856" STUDY_ID="STD-Bonacini-1993" TOTAL_1="41" TOTAL_2="36" WEIGHT="27.36987627297612"/>
<IV_DATA CI_END="1.9780090649123003" CI_START="0.7279733664089942" EFFECT_SIZE="1.1999741321260697" ESTIMABLE="YES" ESTIMATE="0.1823" LOG_CI_END="0.29622827757075104" LOG_CI_START="-0.13788450946882547" LOG_EFFECT_SIZE="0.07917188405096284" ORDER="2" SE="0.255" STUDY_ID="STD-Lightfoot-2007" TOTAL_1="11" TOTAL_2="11" WEIGHT="3.0841820316425115"/>
<IV_DATA CI_END="1.0698838230282126" CI_START="0.8667973504999438" EFFECT_SIZE="0.9630017980998817" ESTIMABLE="YES" ESTIMATE="-0.0377" LOG_CI_END="0.029336620902885198" LOG_CI_START="-0.062082424838390396" LOG_EFFECT_SIZE="-0.016372901967752606" ORDER="3" SE="0.0537" STUDY_ID="STD-Smith-2000" TOTAL_1="65" TOTAL_2="69" WEIGHT="69.54594169538136"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.20732649726256563" CI_END="1.1517376555339547" CI_START="0.932405576284667" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="1.0362850054096548" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.06135356612791582" LOG_CI_START="-0.030395137830119514" LOG_DATA="YES" LOG_EFFECT_SIZE="0.015479214148898163" NO="4" P_CHI2="0.9015289288903267" P_Q="1.0" P_Z="0.5083920864291986" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="116" WEIGHT="100.0" Z="0.6613434507957683">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.4007971541482664" CI_START="0.6882236161407305" EFFECT_SIZE="0.9818664282414203" ESTIMABLE="YES" ESTIMATE="-0.0183" LOG_CI_END="0.14637525076602387" LOG_CI_START="-0.16227042880368286" LOG_EFFECT_SIZE="-0.007947589018829486" ORDER="1" SE="0.1813" STUDY_ID="STD-Bonacini-1993" TOTAL_1="41" TOTAL_2="36" WEIGHT="8.836483525163288"/>
<IV_DATA CI_END="1.7942075015199408" CI_START="0.7052778635551347" EFFECT_SIZE="1.124906588764854" ESTIMABLE="YES" ESTIMATE="0.1177" LOG_CI_END="0.2538726681137914" LOG_CI_START="-0.15163974707376598" LOG_EFFECT_SIZE="0.05111646052001276" ORDER="2" SE="0.2382" STUDY_ID="STD-Lightfoot-2007" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.119075866406114"/>
<IV_DATA CI_END="1.162036311989086" CI_START="0.9253586309246131" EFFECT_SIZE="1.0369668898990494" ESTIMABLE="YES" ESTIMATE="0.0363" LOG_CI_END="0.06521969935387115" LOG_CI_START="-0.033689919967695076" LOG_EFFECT_SIZE="0.01576488969308804" ORDER="3" SE="0.0581" STUDY_ID="STD-Smith-2000" TOTAL_1="65" TOTAL_2="69" WEIGHT="86.0444406084306"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5980111394686882" CI_END="1.1057653358474324" CI_START="0.9042231995296466" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.999929332457519" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.04366297130886217" LOG_CI_START="-0.04372435452528657" LOG_DATA="YES" LOG_EFFECT_SIZE="-3.069160821218693E-5" NO="5" P_CHI2="0.8968875326531774" P_Q="1.0" P_Z="0.9989015274540249" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="126" WEIGHT="100.00000000000001" Z="0.0013767316060837103">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.5514224793185976" CI_START="0.6665952501187041" EFFECT_SIZE="1.016941913602326" ESTIMABLE="YES" ESTIMATE="0.0168" LOG_CI_END="0.19073007985877605" LOG_CI_START="-0.17613778526682683" LOG_EFFECT_SIZE="0.007296147295974668" ORDER="1" SE="0.2155" STUDY_ID="STD-Bonacini-1993" TOTAL_1="41" TOTAL_2="36" WEIGHT="5.673846133564421"/>
<IV_DATA CI_END="1.6820753848553307" CI_START="0.7338663296623623" EFFECT_SIZE="1.111043873525788" ESTIMABLE="YES" ESTIMATE="0.1053" LOG_CI_END="0.22584545548867593" LOG_CI_START="-0.13438303759985112" LOG_EFFECT_SIZE="0.04573120894441239" ORDER="2" SE="0.2116" STUDY_ID="STD-Lightfoot-2007" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.884922887109667"/>
<IV_DATA CI_END="1.0998634198746664" CI_START="0.8855148884034219" EFFECT_SIZE="0.9868867379336502" ESTIMABLE="YES" ESTIMATE="-0.0132" LOG_CI_END="0.04133875817865862" LOG_CI_START="-0.05280413250090447" LOG_EFFECT_SIZE="-0.005732687161122903" ORDER="3" SE="0.0553" STUDY_ID="STD-Smith-2000" TOTAL_1="65" TOTAL_2="69" WEIGHT="86.16320412553752"/>
<IV_DATA CI_END="2.33703668087083" CI_START="0.6161383471461657" EFFECT_SIZE="1.1999741321260697" ESTIMABLE="YES" ESTIMATE="0.1823" LOG_CI_END="0.36866552889833537" LOG_CI_START="-0.21032176079640968" LOG_EFFECT_SIZE="0.07917188405096284" ORDER="4" SE="0.3401" STUDY_ID="STD-Wilkinson-2002" TOTAL_1="11" TOTAL_2="10" WEIGHT="2.2780268537883988"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.7828984365394203" CI_END="1.034656771679638" CI_START="0.8810389993145886" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9547633040469722" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.0147963044913461" LOG_CI_START="-0.055004867056448296" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0201042812825511" NO="6" P_CHI2="0.8535530204915351" P_Q="1.0" P_Z="0.25888690258077995" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="126" WEIGHT="100.0" Z="1.129025956874731">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.2877643964634233" CI_START="0.8054874241614879" EFFECT_SIZE="1.0184684711046268" ESTIMABLE="YES" ESTIMATE="0.0183" LOG_CI_END="0.10983641374164778" LOG_CI_START="-0.09394123570398873" LOG_EFFECT_SIZE="0.007947589018829544" ORDER="1" SE="0.1197" STUDY_ID="STD-Bonacini-1993" TOTAL_1="41" TOTAL_2="36" WEIGHT="11.733087975262066"/>
<IV_DATA CI_END="1.5809779056156326" CI_START="0.6325199083731661" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.1989258006493118" LOG_CI_START="-0.19892580064931187" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.2337" STUDY_ID="STD-Lightfoot-2007" TOTAL_1="11" TOTAL_2="11" WEIGHT="3.0781033891080143"/>
<IV_DATA CI_END="1.0267702717157376" CI_START="0.845676637825711" EFFECT_SIZE="0.9318345514113311" ESTIMABLE="YES" ESTIMATE="-0.0706" LOG_CI_END="0.011473285966765804" LOG_CI_START="-0.07279566681150491" LOG_EFFECT_SIZE="-0.03066119042236958" ORDER="3" SE="0.0495" STUDY_ID="STD-Smith-2000" TOTAL_1="65" TOTAL_2="69" WEIGHT="68.61044403121015"/>
<IV_DATA CI_END="1.2181927076609276" CI_START="0.8208881843662624" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.085715995401736" LOG_CI_START="-0.08571599540173601" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.1007" STUDY_ID="STD-Wilkinson-2002" TOTAL_1="11" TOTAL_2="10" WEIGHT="16.578364604419775"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Lidocaine versus Placebo</NAME>
<IV_OUTCOME CHI2="0.043205290585922956" CI_END="0.9451059633813378" CI_START="0.7318708996054245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8316823622287244" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.024519496536339155" LOG_CI_START="-0.13556552076371708" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08004250865002811" NO="3" P_CHI2="0.8353393261220775" P_Q="1.0" P_Z="0.004720645419663632" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="2.825502943987664">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9600033206763431" CI_START="0.728489938635965" EFFECT_SIZE="0.8362731373001477" ESTIMABLE="YES" ESTIMATE="-0.1788" LOG_CI_END="-0.01772726472197558" LOG_CI_START="-0.13757644200662725" LOG_EFFECT_SIZE="-0.07765185336430144" ORDER="1" SE="0.0704" STUDY_ID="STD-Groudine-1998" TOTAL_1="18" TOTAL_2="20" WEIGHT="85.84913310179502"/>
<IV_DATA CI_END="1.1299323401060288" CI_START="0.5726058012683843" EFFECT_SIZE="0.8043667154883234" ESTIMABLE="YES" ESTIMATE="-0.2177" LOG_CI_END="0.05305243888311807" LOG_CI_START="-0.24214425630379394" LOG_EFFECT_SIZE="-0.09454590871033788" ORDER="2" SE="0.1734" STUDY_ID="STD-Rimb_x00e4_ck-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="14.150866898204988"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.7811734898759264" CI_END="1.095903210492272" CI_START="0.7274873577312748" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8928917800776554" ESTIMABLE="YES" I2="73.55318388120791" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.03977219921649155" LOG_CI_START="-0.13817454944205848" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04920117511278344" NO="5" P_CHI2="0.05183233783724073" P_Q="1.0" P_Z="0.2784376112886112" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.01679502000000001" TOTALS="YES" TOTAL_1="38" TOTAL_2="40" WEIGHT="100.0" Z="1.0838358322931971">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9618894628460828" CI_START="0.6403475125747325" EFFECT_SIZE="0.7848206960225594" ESTIMABLE="YES" ESTIMATE="-0.2423" LOG_CI_END="-0.016874832779455846" LOG_CI_START="-0.19358427315085994" LOG_EFFECT_SIZE="-0.10522955296515792" ORDER="1" SE="0.1038" STUDY_ID="STD-Groudine-1998" TOTAL_1="18" TOTAL_2="20" WEIGHT="39.63027251871071"/>
<IV_DATA CI_END="1.0430558268416805" CI_START="0.9054214981981189" EFFECT_SIZE="0.9718051087760714" ESTIMABLE="YES" ESTIMATE="-0.0286" LOG_CI_END="0.01830755352762333" LOG_CI_START="-0.04314919789248932" LOG_EFFECT_SIZE="-0.012420822182433016" ORDER="2" SE="0.0361" STUDY_ID="STD-Kuo-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="60.36972748128928"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.584423981831965" CI_END="0.877196498271521" CI_START="0.7944221076950424" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.8347839786553" ESTIMABLE="YES" I2="22.613316775434697" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="-0.056903110674850994" LOG_CI_START="-0.09994867851523269" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07842589459504186" NO="6" P_CHI2="0.27466268877781896" P_Q="1.0" P_Z="9.21006629835769E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="7.141823726503015">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.8860366664992912" CI_START="0.5172634007137199" EFFECT_SIZE="0.6769891721958864" ESTIMABLE="YES" ESTIMATE="-0.3901" LOG_CI_END="-0.052548305507058836" LOG_CI_START="-0.2862882492738583" LOG_EFFECT_SIZE="-0.16941827739045856" ORDER="1" SE="0.1373" STUDY_ID="STD-Groudine-1998" TOTAL_1="18" TOTAL_2="20" WEIGHT="3.3914936794370614"/>
<IV_DATA CI_END="0.8835203656345689" CI_START="0.7979103241506339" EFFECT_SIZE="0.839624928963621" ESTIMABLE="YES" ESTIMATE="-0.1748" LOG_CI_END="-0.05378343531310219" LOG_CI_START="-0.09804591556027469" LOG_EFFECT_SIZE="-0.07591467543668841" ORDER="2" SE="0.026" STUDY_ID="STD-Kuo-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="94.57696876366138"/>
<IV_DATA CI_END="1.2810724912057823" CI_START="0.6390979110849292" EFFECT_SIZE="0.9048374180359595" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.10757370557599022" LOG_CI_START="-0.19443260195664064" LOG_EFFECT_SIZE="-0.04342944819032521" ORDER="3" SE="0.1774" STUDY_ID="STD-Rimb_x00e4_ck-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.031537556901552"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Neostigmine versus Placebo</NAME>
<IV_OUTCOME CHI2="6.766617663893936E-32" CI_END="0.9874081068912001" CI_START="0.6499056001678515" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8010755634269013" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-0.005503311425116124" LOG_CI_START="-0.1871497207471664" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09632651608614125" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.03764259715984495" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="2.0787253983130274">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Neostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9874081068912001" CI_START="0.6499056001678515" EFFECT_SIZE="0.8010755634269013" ESTIMABLE="YES" ESTIMATE="-0.2218" LOG_CI_END="-0.005503311425116124" LOG_CI_START="-0.1871497207471664" LOG_EFFECT_SIZE="-0.09632651608614125" ORDER="5482" SE="0.1067" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0085055963185845" CI_START="0.32612660061815824" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.5734984758757153" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.0036783125076704846" LOG_CI_START="-0.48661377638408654" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.24146773193820803" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0535380386228547" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.9305555555555558">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Neostigmine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.0085055963185845" CI_START="0.32612660061815824" EFFECT_SIZE="0.5734984758757153" ESTIMABLE="YES" ESTIMATE="-0.556" LOG_CI_END="0.0036783125076704846" LOG_CI_START="-0.48661377638408654" LOG_EFFECT_SIZE="-0.24146773193820803" ORDER="5483" SE="0.288" STUDY_ID="STD-Orlando-1994" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Propranolol versus Placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.45651575043336157" CI_START="0.2929164327656071" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.36567877313053654" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-0.34054423410274964" LOG_CI_START="-0.533256263486593" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.4369002487946714" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="6.282293673265318E-19" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.00000000000001" Z="8.886925795053003">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.45651575043336157" CI_START="0.2929164327656071" EFFECT_SIZE="0.36567877313053654" ESTIMABLE="YES" ESTIMATE="-1.006" LOG_CI_END="-0.34054423410274964" LOG_CI_START="-0.533256263486593" LOG_EFFECT_SIZE="-0.4369002487946714" ORDER="5484" SE="0.1132" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.00000000000001"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.09777530866570945" CI_END="1.1094499803984827" CI_START="0.7390573487877241" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9055093379562108" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="0.04510772682344386" LOG_CI_START="-0.13132186025781403" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04310706671718507" NO="6" P_CHI2="0.7545158857416724" P_Q="1.0" P_Z="0.33818553463848877" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="0.9577565718150818">
<NAME>Time to first passage of flatus</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.2095324904116047" CI_START="0.6236076256838782" EFFECT_SIZE="0.868489311697668" ESTIMABLE="YES" ESTIMATE="-0.141" LOG_CI_END="0.08261753885495215" LOG_CI_START="-0.20508858275166916" LOG_EFFECT_SIZE="-0.06123552194835846" ORDER="1" SE="0.169" STUDY_ID="STD-Ferraz-2001" TOTAL_1="12" TOTAL_2="15" WEIGHT="37.604916630329065"/>
<IV_DATA CI_END="1.2008711776496468" CI_START="0.7180275969768448" EFFECT_SIZE="0.9285788313151068" ESTIMABLE="YES" ESTIMATE="-0.0741" LOG_CI_END="0.0794964213607582" LOG_CI_START="-0.14385886357882005" LOG_EFFECT_SIZE="-0.032181221109030954" ORDER="3" SE="0.1312" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_2_x0029_" TOTAL_1="20" TOTAL_2="19" WEIGHT="62.395083369670935"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Propranolol and Neostigmine versus Placebo</NAME>
<IV_OUTCOME CHI2="3.452835881237646" CI_END="1.162403332979582" CI_START="0.6204223021267096" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8492237348584601" ESTIMABLE="YES" I2="71.03829911424702" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.0653568465519795" LOG_CI_START="-0.20731259912974417" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07097787628888239" NO="3" P_CHI2="0.06314345347779005" P_Q="1.0" P_Z="0.30754531041334465" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.036462595" TOTALS="YES" TOTAL_1="33" TOTAL_2="37" WEIGHT="100.0" Z="1.0203862840410167">
<NAME>Time to passage of first stool</NAME>
<GROUP_LABEL_1>Propra/Neostigm</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.2803730214072344" CI_START="0.7810223921314106" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.1073365145993933" LOG_CI_START="-0.10733651459939333" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.1261" STUDY_ID="STD-Garcia-1993" TOTAL_1="17" TOTAL_2="20" WEIGHT="48.99107369689261"/>
<IV_DATA CI_END="0.9140150556324449" CI_START="0.5764355363138296" EFFECT_SIZE="0.7258586355430396" ESTIMABLE="YES" ESTIMATE="-0.3204" LOG_CI_END="-0.03904665051973484" LOG_CI_START="-0.23924925348386894" LOG_EFFECT_SIZE="-0.13914795200180186" ORDER="2" SE="0.1176" STUDY_ID="STD-Hallerb_x00e4_ck-1987_x0028_1_x0029_" TOTAL_1="16" TOTAL_2="17" WEIGHT="51.00892630310738"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0463616687290116" CI_START="0.611818830136679" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8001148492945542" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="0.019681821801688627" LOG_CI_START="-0.21337716073053892" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09684766946442512" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.10332863794811942" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="1.6289262235208182">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Propra/Neostigm</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.0463616687290116" CI_START="0.611818830136679" EFFECT_SIZE="0.8001148492945542" ESTIMABLE="YES" ESTIMATE="-0.223" LOG_CI_END="0.019681821801688627" LOG_CI_START="-0.21337716073053892" LOG_EFFECT_SIZE="-0.09684766946442512" ORDER="5489" SE="0.1369" STUDY_ID="STD-Garcia-1993" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Albumin versus No treatment</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.290014126623884" CI_START="0.947950333251162" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.1058342195970503" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.11059446617615483" LOG_CI_START="-0.023214416417220555" LOG_DATA="YES" LOG_EFFECT_SIZE="0.0436900248794671" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2005809599589673" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.2798982188295165">
<NAME>Time to tolerance of regular diet</NAME>
<GROUP_LABEL_1>Albumin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.290014126623884" CI_START="0.947950333251162" EFFECT_SIZE="1.1058342195970503" ESTIMABLE="YES" ESTIMATE="0.1006" LOG_CI_END="0.11059446617615483" LOG_CI_START="-0.023214416417220555" LOG_EFFECT_SIZE="0.0436900248794671" ORDER="1" SE="0.0786" STUDY_ID="STD-Woods-1993" TOTAL_1="37" TOTAL_2="32" WEIGHT="99.99999999999999"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.3400623548439228" CI_START="0.8809837075535023" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.0865418085482381" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="0.12712500712195954" LOG_CI_START="-0.05503212312601969" LOG_DATA="YES" LOG_EFFECT_SIZE="0.03604644199796993" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4379255945491132" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="0.7757009345794393">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Albumin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.3400623548439228" CI_START="0.8809837075535023" EFFECT_SIZE="1.0865418085482381" ESTIMABLE="YES" ESTIMATE="0.083" LOG_CI_END="0.12712500712195954" LOG_CI_START="-0.05503212312601969" LOG_EFFECT_SIZE="0.03604644199796993" ORDER="1" SE="0.107" STUDY_ID="STD-Woods-1993" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Fructose 1,6 Disphosphate versus Fructose</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.9808862418118833" CI_START="0.7241902010951128" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8428215734716199" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.06" LOG_CI_END="-0.008381356960626226" LOG_CI_START="-0.14014735585028593" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07426435640545608" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.02715361955143982" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.2093023255813957">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Fruc(1.6)diphosphat</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="0.9808862418118833" CI_START="0.7241902010951128" EFFECT_SIZE="0.8428215734716199" ESTIMABLE="YES" ESTIMATE="-0.171" LOG_CI_END="-0.008381356960626226" LOG_CI_START="-0.14014735585028593" LOG_EFFECT_SIZE="-0.07426435640545608" ORDER="5492" SE="0.0774" STUDY_ID="STD-Manani-1982" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Pantothen acid versus Placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.1699407179956567" CI_START="0.8513320153950648" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.9980019986673331" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.06" LOG_CI_END="0.06816385619091833" LOG_CI_START="-0.06990103411853131" LOG_DATA="YES" LOG_EFFECT_SIZE="-8.685889638064984E-4" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.980325432932296" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="45" WEIGHT="100.0" Z="0.02466091245376079">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Pantothen Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.1699407179956567" CI_START="0.8513320153950648" EFFECT_SIZE="0.9980019986673331" ESTIMABLE="YES" ESTIMATE="-0.0020" LOG_CI_END="0.06816385619091833" LOG_CI_START="-0.06990103411853131" LOG_EFFECT_SIZE="-8.685889638064984E-4" ORDER="1" SE="0.0811" STUDY_ID="STD-Mieny-1972" TOTAL_1="44" TOTAL_2="45" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Vasopressin versus Placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.5171032878467379" CI_START="0.860017290278746" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.1422499983308942" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="0.18101514955064363" LOG_CI_START="-0.06549281736437867" LOG_DATA="YES" LOG_EFFECT_SIZE="0.0577611660931325" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.358352832890826" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.9185082872928176">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Vasopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Means</EFFECT_MEASURE>
<IV_DATA CI_END="1.5171032878467379" CI_START="0.860017290278746" EFFECT_SIZE="1.1422499983308942" ESTIMABLE="YES" ESTIMATE="0.133" LOG_CI_END="0.18101514955064363" LOG_CI_START="-0.06549281736437867" LOG_EFFECT_SIZE="0.0577611660931325" ORDER="5494" SE="0.1448" STUDY_ID="STD-Hakansson-1985" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.1429258806297842" CI_START="0.45493918133234346" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.721083743026607" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="0.05801806707312775" LOG_CI_START="-0.3420466582378545" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.14201429558236334" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.16407708338436416" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.3914893617021278">
<NAME>Time to passage of first flatus</NAME>
<GROUP_LABEL_1>Vasopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of the Medians</EFFECT_MEASURE>
<IV_DATA CI_END="1.1429258806297842" CI_START="0.45493918133234346" EFFECT_SIZE="0.721083743026607" ESTIMABLE="YES" ESTIMATE="-0.327" LOG_CI_END="0.05801806707312775" LOG_CI_START="-0.3420466582378545" LOG_EFFECT_SIZE="-0.14201429558236334" ORDER="5495" SE="0.235" STUDY_ID="STD-Hakansson-1985" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-08-10 12:57:56 +0200" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-08-10 12:57:56 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-10 12:01:12 +0200" MODIFIED_BY="[Empty name]">Some information on evaluating clinical trials for the drug alvimopan (Entereg<SUP>®</SUP>) requires clarification</TITLE>
<DATE_SUBMITTED>
<DATE DAY="10" MONTH="8" YEAR="2009"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-08-10 12:57:56 +0200" MODIFIED_BY="[Empty name]">
<P>Thank you for the opportunity to present our feedback regarding the Cochrane review &#8220;Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus after abdominal surgery in adults&#8221; by Traut et al. in the forthcoming Cochrane Library. In this review, a considerable amount of text is devoted to evaluating clinical trials for the drug alvimopan (Entereg<SUP>®</SUP>); however, some of this information requires clarification.</P>
<P> 1. The alvimopan phase III clinical trials have been evaluated by the FDA, and the drug is now approved (May, 2008) for the acceleration of gastrointestinal recovery after partial large- or small-bowel resection (BR) with primary anastomosis.</P>
<P> 2. High methodological standards were implemented in all alvimopan clinical trials. All phase III trials were randomized, double-blind, placebo-controlled studies.<SUP>1-7</SUP> However, not all details of randomization and blinding were reported in the literature because of dissimilar journal guidelines. Additional details for each trial include</P>
<UL>
<LI>In all trials (except for Herzog 2006<SUP>8</SUP>) patients were randomized 1:1 as evidenced by the &#8220;n&#8221; values in the treatment and placebo arms</LI>
</UL>
<UL>
<LI>For all alvimopan phase III trials, an eligible patient was assigned to the first available randomization number for the stratum using the predetermined randomization schedules generated by the Adolor Biometrics Department before the start of the study. The study blind was to be broken only in situations where the safety of the patient was in jeopardy, and the treatment plan was dependent on the results of blind breaking.</LI>
</UL>
<UL>
<UL>
<LI>In Delaney et al, 2005<SUP>2</SUP> (Study 14CL302), 2 predetermined randomization schedules were generated by the Adolor Biometrics Department, one for each surgery type (BR vs rTAH/sTAH) at each site. Eligible patients were assigned the first available randomization number for the surgery type to which they were stratified.</LI>
</UL>
</UL>
<UL>
<UL>
<LI>In Ludwig et al, 2008<SUP>5</SUP> (Study 14CL314), at the time informed consent was obtained, the investigator or designee contacted an Interactive Voice Response System to obtain blister card assignment of either alvimopan or matching placebo. Sites received operation and instruction manuals for the Interactive Voice Response System.</LI>
</UL>
</UL>
<P> 3. The modified intent-to-treat (ITT) population in alvimopan phase III clinical trials was defined to exclude patients who did not receive the protocol specified surgery, had no surgical intervention due to cancellation, or received no study drug; thus, we feel this population is a reliable measure of the efficacy of alvimopan (a drug indicated for BR surgery) in the phase III trials. Moreover, prespecified ITT analyses yielded similar results for primary and key secondary endpoints. Additionally, the statistical analyses used in the alvimopan phase III trials were examined by an external, statistics and scientific advisory board, through which experts met, agreed, and supported the choice of using the Cox proportional hazards model as the primary means of statistical analysis.</P>
<P> 4. These protocols were posted on ClinicalTrials.gov and the results were published in peer-reviewed journals and full disclosure of involvement (financial or otherwise) was disclosed per journal guidelines. Moreover, whereas concern has been raised that industry-sponsored clinical trials are more likely to be positive compared with non-sponsored studies, a recent meta-analysis of high-quality industry-sponsored trials for acute pain and migraine using an analytical method based on potential conflict of interest within industry-sponsored trials indicated no evidence of bias.<SUP>9</SUP> Because the alvimopan trials were conducted with the highest methodological standards and all industry involvement was disclosed, this assumption is certainly not warranted in this case.</P>
<P> 5. Additional points of clarification:</P>
<UL>
<LI>Alvimopan is not a prokinetic agent.</LI>
</UL>
<UL>
<LI>&#8220;Sigma-opioid&#8221; receptors should be delta-opioid receptors (page 3).</LI>
</UL>
<UL>
<LI>Alvimopan acts as an antagonist of the inhibitory effects of endogenous and exogenous opioids <U>on gastrointestinal motility</U> (page 3).</LI>
</UL>
<UL>
<LI>In the review it was stated that, &#8220;Physicians were allowed to administer comedication to treat postoperative ileus in 5 trials (Delaney 2005; Hallerback 1987(2); Herzog 2006; Sadek 1988; Smith 2000)&#8221; (page 7).</LI>
</UL>
<UL>
<UL>
<LI>However, in all alvimopan trials, if medically necessary, any drug was permitted to treat an adverse event and prophylactic use of laxatives or prokinetic agents was prohibited.</LI>
</UL>
</UL>
<UL>
<LI>Six trials reported on the effect of alvimopan (Delaney 2005; Herzog 2006; Ludwig 2006; Taguchi 2001; Viscusi 2006; Wolff 2004) (page 8).</LI>
</UL>
<UL>
<UL>
<LI>The Results section (pages 8-9) describing the 6 alvimopan clinical trials makes no distinction between surgical subpopulations (ie, BR vs TAH) when comparing clinical outcomes.</LI>
</UL>
</UL>
<UL>
<LI>The Ludwig poster presented at ACS in 2006 presented GI-2 as the primary endpoint.<SUP>10 </SUP>GI-3 was a supportive endpoint.<SUP>10</SUP> Furthermore, this trial has now been published as a manuscript in 2008,<SUP>5</SUP> making the poster reference out of date (page 8).</LI>
</UL>
<UL>
<LI>Alvimopan has been approved by the US FDA for the acceleration of upper and lower GI recovery following large or small BR with primary anastomosis (May, 2008).<SUP>11</SUP> Moreover, the clinical hold because of safety concerns regarding the long-term use of alvimopan in patients with chronic pain and opioid-induced bowel dysfunction was recently lifted (July, 2008)<SUP>12</SUP> (page 14).</LI>
</UL>
<UL>
<LI>The article for Delaney 2005 states that the age range of patients was 29-93, not &#8220;18-80&#8221; (page 28).</LI>
</UL>
<UL>
<LI>Exclusion criteria listed for Delaney 2005 is incomplete. Additional exclusions were also included in Delaney 2005: patients scheduled to receive total colectomy, colostomy, or ileostomy, or expected to receive epidural opioids, local anaesthetics, or nonsteroidal anti-inflammatory drugs for postoperative pain management (page 28).</LI>
</UL>
<UL>
<LI>Outcomes section for Delaney 2005 (page 28), Herzog 2006 (page 36), Viscusi 2006 (page 49), and Wolff 2004 (page 51) lists length of hospital stay. The articles indicated that time of discharge order (DCO) written was an endpoint, not length of stay per se.</LI>
</UL>
<UL>
<LI>Start of drug treatment for Herzog 2006 is listed as: &#8220;Start 1. POD&#8221; (page 36). However, the drug was administered at least 2 hours before surgery, then twice daily postoperatively.</LI>
</UL>
<UL>
<LI>Outcomes section for Herzog 2006 does not list safety and tolerability of alvimopan (page 36).</LI>
</UL>
<UL>
<UL>
<LI>Safety and tolerability were the primary endpoints of Herzog 2006, and these are reported in the manuscript on page 448</LI>
</UL>
</UL>
<UL>
<LI>Methods section for Ludwig 2006 states: Randomization: No details available and Blinding: Double blind, no details given (page 39).</LI>
</UL>
<UL>
<UL>
<LI>This study has been published; therefore, information used from the poster presentation in 2006 is outdated.<SUP>5,10</SUP> The Ludwig manuscript states that after informed consent was obtained, an Interactive Voice Response System was used to obtain blister card assignment of alvimopan or placebo.<SUP>5</SUP> Blister cards contained identically packaged alvimopan or placebo with labels blackened for blinding.<SUP>5</SUP>
</LI>
</UL>
</UL>
<P>
<B>REFERENCES</B>
</P>
<P>1.             Delaney C, Wolff B, Viscusi E, Techner L, Du W, Wallin B. Alvimopan, a novel, peripherally active mu opioid receptor antagonist, in postoperative ileus: a pooled analysis of patients undergoing laparotomy [abstract]. <I>Colorectal Dis. </I>2005;7(suppl 1):93. Poster P147.</P>
<P>2.             Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. <I>Dis Colon Rectum. </I>2005;48(6):1114-1125; discussion 1125-1126; author reply 1127-1129.</P>
<P>3.             Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. <I>Surg Endosc. </I>2006;20(1):64-70.</P>
<P>4.             Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. <I>Ann Surg. </I>2004;240(4):728-734; discussion 734-725.</P>
<P>5.             Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. <I>Arch Surg. </I>2008;143(11):1098-1105.</P>
<P>6.             Adolor Corporation. Entereg<SUP>®</SUP> (alvimopan) capsules for postoperative ileus [US FDA Advisory Committee briefing document]. <A HREF="http://www.fda.gov/ohrms/DOCKETS/ac/08/briefing/2008-4336b1-02-Adolor.pdf">http://www.fda.gov/ohrms/DOCKETS/ac/08/briefing/2008-4336b1-02-Adolor.pdf</A>. Accessed June 5, 2008.</P>
<P>7.             US Food and Drug Administration. Gastrointestinal Drugs Advisory Committee supportive slides.  <A HREF="http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4336s1-06-Adolor-supportive-slides.pdf">http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4336s1-06-Adolor-supportive-slides.pdf</A>. Accessed June 5, 2008.</P>
<P>8.             Herzog TJ, Coleman RL, Guerrieri JP Jr, et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. <I>Am J Obstet Gynecol. </I>2006;195(2):445-453.</P>
<P>9.             Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. <I>Pain. </I>2006;121(3):207-218.</P>
<P>10.           Ludwig KA, Enker WE, Delaney CP, Wolff BG, Du W, Techner L. Accelerated gastrointestinal recovery and reduced length of stay following modified preoperative dose timing with alvimopan: results of a large, randomized, placebo-controlled study in partial bowel resection. Presented at: 92nd Annual Clinical Congress of the American College of Surgeons; October 8-12, 2006; Chicago, IL. Poster SE120.</P>
<P>11.           Adolor Corporation. Entereg<SUP>®</SUP> (alvimopan) capsules [prescribing information]. <A HREF="http://www.entereg.com/pdf/prescribing-information.pdf">http://www.entereg.com/pdf/prescribing-information.pdf</A>. Accessed September 9, 2008.</P>
<P>12.           Adolor provides update on Entereg® (alvimopan) OBD program. <A HREF="http://phx.corporate-ir.net/phoenix.zhtml?c=120919&amp;p=irol-newsArticle&amp;ID=1171802&amp;highlight=">http://phx.corporate-ir.net/phoenix.zhtml?c=120919&amp;p=irol-newsArticle&amp;ID=1171802&amp;highlight=</A>. Accessed September 9, 2008.</P>
<P/>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-08-10 12:04:17 +0200" MODIFIED_BY="[Empty name]">
<P>Lee Techner, DPM, Vice President, Medical Affairs and Medical Director, Adolor Corporation</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>